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ABSTRACT 
 
Three experiments were designed to explore the measurement of muscle fatigue in people with 
cerebral palsy (CP). The four aims were to 1) develop a feasible and reliable isokinetic protocol 
to assess muscle fatigue of the knee flexors and extensors in this population, 2) determine if 
muscle fatigue of the knee flexors and extensors in people with CP differs from subjects without 
a motor disorder, 3) determine whether muscle fatigue is related to functional measures of 
activity and participation, and 4) investigate possible contributing factors of muscle fatigue. 
Results show that muscle fatigue can be reliably assessed through an isokinetic protocol 
consisting of 35 consecutive knee extension and flexion repetitions at 60 degrees/second by 
calculation of a fatigue index (FI) and the slope of the decline in peak torque. When compared to 
a control group of age-matched peers without motor disorder, the knee flexors and extensors in 
subjects with CP were observed to be less fatigable. Furthermore, muscle fatigue of the knee 
extensors and flexors in the group with CP was positively correlated with transfers and basic 
mobility. Muscle fatigue of the knee extensors was also positively correlated with overall global 
functioning, participation in sports and physical function, and fast walking velocity. Lower Gross 
Motor Function Classification System Levels (GMFCS) (i.e. less involved subjects) were also 
associated with higher levels of muscle fatigability. Strength was directly related to muscle 
fatigability, where weaker subjects had lower levels of fatigue, regardless of muscle. 
Cocontraction and quadriceps stiffness, on the other hand, were inversely related to muscle 
fatigability. The strongest predictors of hamstring fatigability were hamstrings strength and 
quadriceps stiffness, whereas the strongest predictor of quadriceps fatigability was hamstring 
cocontraction. The presence of spasticity, regardless of muscle group, was associated with lower 
fatigability compared to control subjects. In summary, the results indicate that the knee flexors 
and extensors of people with CP are less fatigable than age-matched peers without motor 
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disability. In addition, lower levels of muscle fatigability are associated with lower levels of 
function and participation. Furthermore, weakness, spasticity, stiffness, and cocontraction are 
possible contributing factors to the observed fatigue resistance. 
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CHAPTER 1: INTRODUCTION 
 
Cerebral palsy (CP) describes a collection of disorders “of the development of movement 
and posture, causing activity limitation, that are attributed to non-progressive disturbances that 
occurred in the developing fetal or infant brain” (Bax et al., 2005). CP is not a disease, per se, but 
rather, a descriptive term that describes a heterogeneous group of children who often manifest 
with chronic motor impairment. Although variability exists with respect to the degree of 
impairments individuals with CP may exhibit, common impairments include loss of selective 
motor control, spasticity, muscle weakness, co-contraction, and contractures. In turn, these 
impairments can lead to activity restrictions such as difficulty in walking and other activities of 
daily living, with many patients experiencing worsening disability throughout the lifespan.  
Studies over the last 10 to 15 years have documented a gradual onset of newly recognized 
problems in adults with CP, such as fatigue, musculoskeletal pain, and deterioration of functional 
skills (Andersson & Mattsson, 2001; Bottos, Feliciangeli, Sciuto, Gericke, & Vianello, 2001; 
Cathels & Reddihough, 1993; Gajdosik & Cicirello, 2001; Jahnsen, Villien, Egeland, Stanghelle, 
& Holm, 2004; Jahnsen, Villien, Stanghelle, & Holm, 2003; Murphy, Molnar, & Lankasky, 
1995; Pimm, 1992). These problems manifest in adolescence and early adulthood and have 
consequences for activities and participation in work and social situations. Furthermore, these 
studies provide evidence of the progression of secondary impairments in CP and the need for 
targeted interventions throughout the life span, despite the non-progressive brain lesion 
Physical fatigue, in particular, has been identified as a significant impairment in adults 
with CP compared with the general population and has been significantly associated with 
deterioration of functional skills, bodily pain, limitations in physical and emotion role function, 
and low life satisfaction (Jahnsen et al., 2003). In fact, adults with CP report fatigue as a main 
cause of the deterioration or cessation of their walking ability (Bottos et al., 2001; Jahnsen et al., 
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2004; Murphy et al., 1995). Murphy et al. (1995) reported that 75% of subjects ceased to walk by 
the age of 25 due to fatigue and inefficiency of ambulation. Jahnsen et al. (2004) reported that 
44% of subjects had deterioration of walking due to fatigue, pain, and lack of adapted physical 
activity. However, fatigue was assessed subjectively in these studies through the use of 
questionnaires and interviews and did not attempt to differentiate among cardiorespiratory 
fatigue (e.g. heart beating too fast or person feeling out of breath), neural or psychological 
fatigue (increased sense of effort or feeling as if muscles are going to ‘give out’) or local muscle 
fatigue (muscles cannot produce as much or any force as they could at onset of task).  
Fatigue may be studied as a subjective symptom or the state of being fatigued. 
Conversely, fatigue can also be studied as an objective process with measurable signs, such as 
reduction in peak torque or work, and is often referred to as muscle fatigue (Bigland-Ritchie, 
Johansson, Lippold, & Woods, 1983). However, the two do not always correlate (Iriarte & de, 
1998; Sharma, Kent-Braun, Mynhier, Weiner, & Miller, 1995). The term “fatigue” as a 
subjective phenomenon has been used to describe a multitude of mental and physical symptoms 
and is often confused with other symptoms, such as weakness (Schwid, Covington, Segal, & 
Goodman, 2002). For example, a question in the Fatigue Questionnaire (Chalder et al., 1993) 
used in the Jahnsen et al. (2003) study reads “Do you have less strength in your muscles?” 
Another question reads “Do you feel weak?” Therefore, these self-report questionnaires are not 
adequate in the assessment of the objective or physical signs of fatigue (Schwid et al., 2002). 
Background Information 
Because of the broad use of the term fatigue, it is important to operationally define 
fatigue. Muscle fatigue, or fatigability, will be defined as a reduction in the force-generating 
capacity of the neuromuscular system, which occurs during sustained activity (Bigland-Ritchie et 
al., 1983). Muscle endurance, on the other hand, is resistance to fatigue or the ability to 
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withstand fatigue. These terms are often used interchangeably throughout the literature with 
muscle endurance tests often employed to assess muscle fatigue.   
The first published test of muscle fatigue in children with neuromuscular disease was 
measured as the length of time that the subject could hold the extended lower extremity 45 
degrees off of the ground while in a supine position (Hosking, Bhat, Dubowitz, & Edwards, 
1976). Although this test was able to discriminate between children with and without 
neuromuscular disease, it was very difficult to standardize and did not show sufficient 
reproducibility to be recommended for future testing.  
Other attempts to measure cardiorespiratory endurance in children with CP employed 
physiological measures of energy expenditure, such as oxygen consumption, heart rate, 
perceived exertion, and other measures of cardiorespiratory function (Hoofwijk, Unnithan, & 
Bar-Or, 1995; Rose, Haskell, & Gamble, 1993; Unnithan, Dowling, Frost, & Bar-Or, 1996). It 
has been well documented that children and adolescents with CP have lower VO2max than able-
bodied peers as assessed during tasks, such as lower extremity cycling (Lundberg, 1978) and 
treadmill ambulation (Hoofwijk et al., 1995; Rose et al., 1993). However, these authors 
independently suggested that additional factors other than cardiorespiratory were responsible for 
the limitations in the respective activities. Lundberg (1978) and Hoofwijk et al. (1995) suggested 
that spasticity may have decreased venous return and inhibited muscle lactate clearance during 
exercise, thereby increasing local muscle fatigue and leading to a decrease in VO2max values. 
Furthermore, because some believe that movement in children with CP is often accomplished 
through discrete bursts of activity, it has been suggested that aerobic function is unlikely to be a 
limiting factor in the ability of a child with CP to perform activities (Unnithan, Clifford, & Bar-
Or, 1998). Rather, anaerobic power has been considered to be the better measure of functional 
capacity in people with neuromuscular diseases, including CP (Unnithan et al., 1998).  
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Several investigators have studied muscle endurance from an anaerobic perspective in 
children and adolescents with CP by means of the Wingate Anaerobic Cycling Test (WAnT). 
The WAnT is a widely used, validated measure of anaerobic performance (Bar-Or, Dotan, & 
Inbar, 1977). It is reliable in both adults and children (Bar-Or, 1987) as well as in children with 
neuromuscular diseases, including those with CP (Tirosh, Bar-Or, & Rosenbaum, 1990). It is a 
30-second test, during which the subject pedals at maximal speed against a predetermined 
constant resistance based on body weight. From this test, peak power and mean power are 
calculated. Peak power is a measure of explosiveness and is moderately correlated with the 
percentage of fast twitch fibers in the vastus lateralis muscle (Bar-Or et al., 1980). Peak power is 
calculated as the product of flywheel resistance x number of revolutions x distance per revolution 
divided by time (usually 3 second sampling period). Proponents of anaerobic testing purport to 
measure muscle endurance by measuring mean power of the lower extremities during the WAnT. 
Mean power is the average of all power values measured at each sampling period. Results from 
these studies indicate that peak muscle power and mean power, as a measure of muscle 
endurance, are markedly deficient in people with CP (Parker, Carriere, Hebestreit, & Bar-Or, 
1992; Parker, Carriere, Hebestreit, Salsberg, & Bar-Or, 1993; Tirosh et al., 1990). However, this 
test cannot differentiate between right and left extremities nor can it differentiate among muscle 
groups; therefore, it is a non-specific, gross physiologic measurement of endurance. 
Furthermore, the measurement of mean power does not reflect the decline in force during 
sustained activity. Rather, it is an absolute measure that reflects the average level of 
explosiveness or power. Mean power has been directly correlated (r = 0.75) to relative fast twitch 
fiber size, where higher mean power equals higher endurance and preponderance of fast twitch 
fibers (Bar-Or et al., 1980). It is well established that fast twitch fibers are more fatigable; 
therefore, if mean power is a measure of muscle endurance, it does not correlate with our current 
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understanding of muscle physiology. We propose that this measurement does not reflect the 
decline in the force-generating capacity of the muscle, but rather reflects average power 
production throughout the test.  
Isokinetic dynamometry, on the other hand, has the ability to isolate a single muscle 
group under controlled conditions with stabilization of other joints, thus providing a measure of 
localized muscle fatigue. Reliable isokinetic fatigue protocols have been established for children 
(De Ste Croix, Armstrong, & Welsman, 2003), adults (Pincivero, Lephart, & Karunakara, 1997), 
and the neurologically impaired (Lambert, Archer, & Evans, 2001). However, to date, there are 
no studies that have quantitatively assessed localized muscle fatigue via isokinetic or isometric 
means in individuals with CP. The most commonly assessed muscle groups in these studies are 
the knee flexors and extensors. Clinically, it is important to study lower extremity muscles, 
particularly of the knee flexors and extensors, because they have been shown to be correlated to 
motor function in people with CP (Damiano & Abel, 1998; Damiano, Martellotta, Sullivan, 
Granata, & Abel, 2000; MacPhail & Kramer, 1995). Furthermore, it is important to study more 
than one muscle group because muscle characteristics such as size, fiber type distribution, fiber 
arrangement, recruitment and rate coding strategies differ considerably across muscle groups. 
These differences may become even more exaggerated in persons with CP because factors like 
spasticity, weakness, and selective motor control may affect different muscle groups to varying 
degrees.   
Experiments 
The World Health Organization’s International Classification of Functioning, Disability 
and Health (ICF) model was used as a framework in the investigation of muscle fatigue within 
the population of CP (World Health Organization, 2001). The ICF is a classification of health 
related domains that describe body functions and structures, activities, and participation in an 
 6 
effort to understand and measure health outcomes. Three levels of human functioning are 
classified by ICF: functioning at the level of body or body part (body functions and structures), 
the whole person (activities), and the whole person in a social context (participation). The formal 
definitions of the components of the ICF are provided in Table 1.1. 
 
Table 1.1. Definitions of the components of the World Health Organization’s ICF model (2001) 
Terms Definition 
Body functions Physiological functions of body systems (including psychological 
components) 
Body structures Anatomical parts of the body such as organs, limbs, and their 
components 
    Impairments Problems in body function or structure such as a significant 
deviation or loss 
Activity Execution of a task or action by an individual 
 
   Activity Limitations Difficulties an individual may have in executing activities 
 
Participation Involvement in a life situation 
 
   Participation Limitations Problems an individual may experience in involvement in life 
situations 
 
Based on this model, three experiments have been designed to further explore the 
measurement of muscle fatigue of the knee flexors and extensors; possible contributing factors to 
muscle fatigue at the body function level; activity limitations and participation restrictions 
associated with muscle fatigue; and the relationship of muscle fatigue to aspects of psychosocial 
well-being. Figure 1.1 illustrates the experiments within the context of the ICF model. 
Despite the evidence that fatigue is a problem in this population, there are no studies that 
have quantitatively assessed muscle fatigue. Therefore, the feasibility of an isokinetic muscle 
fatigue protocol for the knee flexors and extensors in ambulatory children with CP was 
investigated in Chapter 2 (experiment 1). In addition, the reliability of 3 fatigue measurement 
parameters was reported. 
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Figure 1.1. Illustration of the WHO ICF (2001) framework for the investigation of muscle 
fatigue within the health condition of CP; possible contributing factors to fatigue at the body 
function level, which are spasticity, stiffness, weakness, and cocontraction; activity limitations; 
participation restrictions; and the relationship of muscle fatigue to aspects of psychosocial well-
being. It should be noted that psychosocial well-being is not a part of the ICF model. 
 
 
In Chapter 3 (experiment 2), the protocol established in Chapter 1 was utilized to 
investigate whether muscle fatigue of the knee flexors and extensors was greater in individuals 
with CP compared to those without disability. Furthermore, as illustrated in Figure 1.1, the 
relationship of muscle fatigue (body functions) in individuals with CP (health condition) to 
activities (walking velocity); participation in sports and physical function; transfers and basic 
mobility; and aspects of psychosocial well-being such as happiness, satisfaction, and 
pain/comfort, was investigated.  
 
 
Health condition
Cerebral Palsy 
Body structures 
and functions
Activity Participation
FATIGUE Sports & Physical 
Function 
 
Transfers & Mobility Spasticity 
Weakness 
Stiffness 
Cocontraction 
Walking velocity 
Happiness 
Pain/Comfort 
Satisfaction 
“Psychosocial well-being” 
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In Chapter 4 (experiment 3) the relationship of muscle fatigue (body functions) to other 
impairments at the body function level were investigated to determine whether these factors 
contributed significantly to the level of muscle fatigue observed in our subjects with CP. CP is a 
multifaceted disorder and as such, complex interrelationships exist among upper motor neuron 
lesion impairments. The relationships among muscle fatigue and other impairments at the body 
function level are important in the understanding of fatigue, as these impairments may, in fact, 
contribute directly or indirectly to the level of muscle fatigability. As a result, four possible 
contributors to the level of muscle fatigability at the impairment/body function level were 
investigated and are presented in Figure 1.1: spasticity, weakness, co-contraction, and stiffness. 
Finally, synthesis of the conclusions presented in these chapters is presented in Chapter 5. 
 
Reference List 
 
Andersson, C. & Mattsson, E. (2001). Adults with cerebral palsy: a survey describing problems, 
needs, and resources, with special emphasis on locomotion. Dev.Med.Child Neurol., 43, 
76-82. 
Bar-Or, O. (1987). The Wingate Anaerobic Test - An Update on Methodology, Reliability and 
Validity. Sports Medicine, 4, 381-394. 
Bar-Or, O., Dotan, R., & Inbar, O. (1977). 30-Sec All-Out Ergometric Test - Its Reliability and 
Validity for Anaerobic Capacity. Israel Journal of Medical Sciences, 13, 326-327. 
Bar-Or, O., Dotan, R., Inbar, O., Rothstein, A., Karlsson, J., & Tesch, P. (1980). Anaerobic 
Capacity and Muscle Fiber Type Distribution in Man. Int.J.Sports Med., 1, 82-85. 
Bax, M., Goldstein, M., Rosenbaum, P., Leviton, A., Paneth, N., Dan, B. et al. (2005). Proposed 
definition and classification of cerebral palsy, April 2005. Dev.Med.Child Neurol., 47, 
571-576. 
Bigland-Ritchie, B., Johansson, R., Lippold, O. C., & Woods, J. J. (1983). Contractile speed and 
EMG changes during fatigue of sustained maximal voluntary contractions. 
J.Neurophysiol., 50, 313-324. 
Bottos, M., Feliciangeli, A., Sciuto, L., Gericke, C., & Vianello, A. (2001). Functional status of 
adults with cerebral palsy and implications for treatment of children. Dev.Med.Child 
Neurol., 43, 516-528. 
 9 
Cathels, B. A. & Reddihough, D. S. (1993). The health care of young adults with cerebral palsy. 
Med.J.Aust., 159, 444-446. 
Chalder, T., Berelowitz, G., Pawlikowska, T., Watts, L., Wessely, S., Wright, D. et al. (1993). 
Development of a fatigue scale. J.Psychosom.Res., 37, 147-153. 
Damiano, D. L. & Abel, M. F. (1998). Functional outcomes of strength training in spastic 
cerebral palsy. Arch.Phys.Med.Rehabil., 79, 119-125. 
Damiano, D. L., Martellotta, T. L., Sullivan, D. J., Granata, K. P., & Abel, M. F. (2000). Muscle 
force production and functional performance in spastic cerebral palsy: relationship of 
cocontraction. Arch.Phys.Med.Rehabil., 81, 895-900. 
De Ste Croix, M. B. A., Armstrong, N., & Welsman, J. R. (2003). The reliability of an isokinetic 
knee muscle endurance test in young children. Pediatric Exercise Science, 15, 313-323. 
Gajdosik, C. G. & Cicirello, N. (2001). Secondary conditions of the musculoskeletal system in 
adolescents and adults with cerebral palsy. Phys.Occup.Ther.Pediatr., 21, 49-68. 
Hoofwijk, M., Unnithan, V., & Bar-Or, O. (1995). Maximal treadmill performance of children 
with cerebral palsy. Pediatric Exercise Science, 7, 305-313. 
Hosking, J. P., Bhat, U. S., Dubowitz, V., & Edwards, R. H. (1976). Measurements of muscle 
strength and performance in children with normal and diseased muscle. Arch.Dis.Child, 
51, 957-963. 
Iriarte, J. & de, C. P. (1998). Correlation between symptom fatigue and muscular fatigue in 
multiple sclerosis. Eur.J Neurol., 5, 579-585. 
Jahnsen, R., Villien, L., Egeland, T., Stanghelle, J. K., & Holm, I. (2004). Locomotion skills in 
adults with cerebral palsy. Clin.Rehabil., 18, 309-316. 
Jahnsen, R., Villien, L., Stanghelle, J. K., & Holm, I. (2003). Fatigue in adults with cerebral 
palsy in Norway compared with the general population. Dev.Med.Child Neurol., 45, 296-
303. 
Lambert, C. P., Archer, R. L., & Evans, W. J. (2001). Muscle strength and fatigue during 
isokinetic exercise in individuals with multiple sclerosis. Med.Sci.Sports Exerc., 33, 
1613-1619. 
Lundberg, A. (1978). Maximal aerobic capacity of young people with spastic cerebral palsy. 
Dev.Med.Child Neurol., 20, 205-210. 
MacPhail, H. E. & Kramer, J. F. (1995). Effect of isokinetic strength-training on functional 
ability and walking efficiency in adolescents with cerebral palsy. Dev.Med.Child Neurol., 
37, 763-775. 
Murphy, K. P., Molnar, G. E., & Lankasky, K. (1995). Medical and functional status of adults 
with cerebral palsy. Dev.Med.Child Neurol., 37, 1075-1084. 
 10 
Parker, D. F., Carriere, L., Hebestreit, H., & Bar-Or, O. (1992). Anaerobic endurance and peak 
muscle power in children with spastic cerebral palsy. Am.J.Dis.Child, 146, 1069-1073. 
Parker, D. F., Carriere, L., Hebestreit, H., Salsberg, A., & Bar-Or, O. (1993). Muscle 
performance and gross motor function of children with spastic cerebral palsy. 
Dev.Med.Child Neurol., 35, 17-23. 
Pimm, P. (1992). Cerebral palsy; a non progressive disorder? Educational and Child Psychology, 
9, 27-33. 
Pincivero, D. M., Lephart, S. M., & Karunakara, R. A. (1997). Reliability and precision of 
isokinetic strength and muscular endurance for the quadriceps and hamstrings. 
Int.J.Sports Med., 18, 113-117. 
Rose, J., Haskell, W. L., & Gamble, J. G. (1993). A comparison of oxygen pulse and respiratory 
exchange ratio in cerebral palsied and nondisabled children. Arch.Phys.Med.Rehabil., 74, 
702-705. 
Schwid, S. R., Covington, M., Segal, B. M., & Goodman, A. D. (2002). Fatigue in multiple 
sclerosis: current understanding and future directions. J.Rehabil.Res.Dev., 39, 211-224. 
Sharma, K. R., Kent-Braun, J., Mynhier, M. A., Weiner, M. W., & Miller, R. G. (1995). 
Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. 
Muscle Nerve, 18, 1403-1411. 
Tirosh, E., Bar-Or, O., & Rosenbaum, P. (1990). New muscle power test in neuromuscular 
disease. Feasibility and reliability. Am.J.Dis.Child, 144, 1083-1087. 
Unnithan, V. B., Clifford, C., & Bar-Or, O. (1998). Evaluation by exercise testing of the child 
with cerebral palsy. Sports Med., 26, 239-251. 
Unnithan, V. B., Dowling, J. J., Frost, G., & Bar-Or, O. (1996). Role of cocontraction in the O2 
cost of walking in children with cerebral palsy. Med.Sci.Sports Exerc., 28, 1498-1504. 
World Health Organization (2001). International Classification of Functioning, Disability and 
Health. Geneva: World Health Organization. 
 11 
CHAPTER 2: A FEASIBLE AND RELIABLE MUSCLE FATIGUE ASSESSMENT 
PROTOCOL FOR INDIVIDUALS WITH CEREBRAL PALSY 
 
Introduction 
 
Lower extremity muscle strength, particularly of the knee flexors and extensors, has been 
shown to be correlated to motor function in cerebral palsy (CP) (Damiano & Abel, 1998; 
Damiano, Martellotta, Sullivan, Granata, & Abel, 2000; MacPhail & Kramer, 1995). As a result, 
routine isokinetic and isometric measurements of strength are becoming increasingly common in 
this population. While the importance of maintaining muscle strength is being increasingly 
recognized for those with chronic motor disabilities such as CP, recent studies have indicated 
that ‘fatigue’ is an even more frequent complaint of adults with CP and has been cited as a major 
limiting factor in diminished ambulatory capacity in early to middle adulthood (Jahnsen, Villien, 
Egeland, Stanghelle, & Holm, 2004). Corroborating this subjective complaint is objective 
evidence that cardiorespiratory endurance is reduced in individuals with CP (Lundberg, 1976; 
Lundberg, 1978). However, while muscle endurance, or resistance to fatigue, is known to be an 
important component of normal muscle performance, a search of the medical literature to date 
revealed no investigations of fatigue at the muscle level in CP. Muscle fatigue is defined as a 
reduction in the force-generating capacity of the neuromuscular system, which occurs during 
sustained activity (Bigland-Ritchie, Johansson, Lippold, & Woods, 1983). Muscle endurance is 
defined as the ability to withstand fatigue. The term muscle endurance is often used in the 
literature as the antonym, or positive, of muscle fatigue, similar to the use of strength vs. 
weakness.  
The first reported test of muscle fatigue in children with neuromuscular diseases was by 
Hosking, Bhat, Dubowitz, and Edwards (1976). In their protocol, the length of time the lower leg 
could be held out straight with the hip flexed to 45 degrees and the head at 45 degrees above the 
horizontal were recorded with the subject in the supine position. Although this test was able to 
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discriminate between children with and without neuromuscular disease, it did not show sufficient 
reproducibility to be recommended for future testing.  
Reported measures of cardiorespiratory endurance in children with CP have included 
physiological assessments of energy expenditure, oxygen consumption, heart rate, and subjective 
reports of perceived exertion among other measures of cardiorespiratory function (Lundberg, 
1976; Rose, Haskell, & Gamble, 1993). Others have studied endurance from an aerobic 
(Lundberg, 1978) versus anaerobic perspective (Parker, Carriere, Hebestreit, & Bar-Or, 1992). 
However, these cardiorespiratory assessments are distinctly different both physiologically and 
methodologically from tests of endurance at the muscle level.  
With respect to the latter, isokinetic dynamometry has the ability to isolate a group of 
muscles about a specific joint under controlled conditions with stabilization of other joints, thus 
providing a measure of muscle fatigue. It also provides a controlled, safe environment where no 
resistance (load) is applied once the movement has ceased, since it accommodates to the amount 
of muscle force that is applied (Jones & Stratton, 2000). Isokinetic muscle fatigue protocols for 
the knee have been extensively developed in the healthy adult population. The most widely used 
protocol consists of performance of a predetermined number of maximal repetitions, usually 
between 25 and 50, at 180 degrees/second (Burdett & Van Swearingen, 1987; Pincivero, Gear, & 
Sterner, 2001; Thorstensson & Karlsson, 1976). Another common protocol involves the 
performance of consecutive repetitions until the peak torque or work decreases to 50% of the 
maximum (Emery, Sitler, & Ryan, 1994). Calculation of a fatigue index (FI), which represents 
the percentage decline in work or torque from the beginning to the end of the protocol, is the 
most frequently reported parameter (Burdett & Van Swearingen, 1987; Pincivero et al., 2001; 
Thorstensson & Karlsson, 1976), despite the fact that some have questioned its reliability 
(Burdett & Van Swearingen, 1987). Alternatively, some authors have calculated the slope of the 
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regression line as a measurement of the decline in force and have found it to be more reliable 
than the FI (Pincivero et al., 2001).  
Existing isokinetic fatigue protocols have been modified for use with children (De Ste 
Croix, Armstrong, & Welsman, 2003) and with other neurological populations, such as multiple 
sclerosis (Lambert, Archer, & Evans, 2001). For example, slower testing speeds less than 100 
degrees/second have been recommended for normally developing children due to difficulty 
producing force at higher speeds (De Ste Croix et al., 2003; Gaul, 1996). Although no studies 
were identified that have examined isokinetic muscle fatigue in individuals with CP, speeds of 
30 (Van den Berg-Emons RJ, Van Baak, de, Speth, & Saris, 1996) and 90 (Ayalon, Ben-Sira, 
Hutzler, & Gilad, 2000) degrees/second have been shown to be reliable in children with CP for 
isokinetic strength assessment. In addition, isokinetic strength testing at 60 degrees/second has 
been observed to be reliable in adults with CP (Holland, McCubbin, Nelson, & Steinman, 1994).  
Reliable isokinetic fatigue protocols for the knee flexors and extensors have been 
established for healthy children (De Ste Croix et al., 2003), adults (Emery et al., 1994; 
Thorstensson & Karlsson., 1976), and those with various neurological impairments (Lambert et 
al., 2001), with no studies found to date that have quantitatively assessed muscle fatigue via 
isokinetic means in individuals with CP. Therefore, the primary purpose of this study was to 
develop a feasible and reliable isokinetic fatigue protocol for use in CP, so that we could later 
pose the question as to whether this aspect of muscle performance is impaired in this population. 
The aim of the feasibility assessment was to determine if a group of mild to moderately impaired 
subjects with CP of varying ages would be able to complete a muscle fatigue protocol. The aim 
of the reliability assessment was to determine the repeatability of the fatigue parameters obtained 
from the protocol. In order to evaluate the feasibility and reliability of these protocols, we 
decided to study the knee flexors and extensors, since these are the most commonly studied 
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muscles in isokinetic protocols. In addition, we wanted to study more than one muscle group 
because muscle characteristics may vary considerably across muscle groups, yielding different 
results with respect to the determination of the presence or degree of muscle fatigability.  
Methods 
 
Subjects 
 
Twelve subjects with a diagnosis of CP ranging in age from 10 to 22 years were recruited 
for the feasibility assessment. Five of the 12 subjects were tested on two occasions, exactly one-
week apart at the same time of day, for the reliability analysis. All subjects were able to ambulate 
at least short a distance with or without assistance and thus fell within Gross Motor Function 
Classification System (GMFCS) levels I, II, and III (Table 2.1). Subjects were excluded if they 
underwent orthopedic surgery within 9 months prior to the testing, received Botulinum toxin 
injections to the quadriceps or hamstrings within 6 months prior to the testing, or suffered from 
knee pain. Passive range of motion of the knee was also assessed prior to testing to determine if 
the subject had sufficient range of motion to complete the test.  
The protocol was approved by the Institutional Review Board at our institution. Written 
permission from each participant over 18 years of age was obtained before beginning this study. 
Participants under 18 years of age were required to have a parental permission form signed by 
one parent or legal guardian. In addition, the minor was required to read and sign a child assent 
form. 
Procedures 
 
An isokinetic dynamometer (Biodex Medical Systems Incorporated, Shirley, NY, USA) 
was used to evaluate muscle fatigue and ‘strength’ by means of peak voluntary torque of the 
knee flexors and extensors. Following familiarization with the isokinetic equipment and 
explanation of procedures, the subject was positioned in the Biodex chair in a semireclining 
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sitting position with the angle of the hip joint at 70 degrees. The more involved lower extremity 
was tested for subjects with bilateral involvement if they had sufficient motion and mobility in 
that limb to perform the test. The involved lower extremity was tested for subjects with unilateral 
involvement. The subject’s knee joint center was aligned with the center of rotation of the 
isokinetic device. The leg was secured against the knee attachment pad and additional stabilizing 
straps around the waist, the trunk, and over the mid-thigh portion were used to restrain trunk and 
hip movement during testing. Following set-up, the passive range of motion designated as 
“comfortable” by the patient, given the restrictions imposed by the chair which limits flexion, 
was determined and used to set the limits of motion for the rest of testing session. Subjects were 
instructed to keep their arms folded across their chest for all trials.  
Table 2.1 
Subject Characteristics and Feasibility Data 
Subject Age, yr Gender GMFCS 
 level 
KE 
50% rep 
KF 
50% rep 
Reason for 
termination of test 
1   10.3* M I 27 16 + 
2 11.2 M I 24  self @ 35reps 
3 11.4 F I  15 self @ 35reps 
4 13.1 M II   100 reps 
5   13.3* F I 26 26 + 
6 14.4 F III  30 †  @ 50reps 
7 17.2 F I 30 21 + 
8 19.9 F I  30 100 reps 
9 20.6 F II 43 30 + 
10   20.8* F II  32 self @ 35reps 
11   22.5* F II 23 14 + 
12   23.3* M III 73 55 + 
KE50% rep = repetition where criteria for 50% decline were met for knee extension; KF50% rep 
= repetition where criteria for 50% decline were met for knee flexion; self = self-termination 
* = subjects tested twice, 1-week apart 
+ = Goal of 35 repetitions and 50% decline in maximum peak torque achieved 
† = unable to complete range of motion and reach target velocity  
 
 
Subjects performed 8-12 submaximal concentric, reciprocal knee flexion and extension 
repetitions to familiarize themselves with the procedure. After a 2 minute rest period, subjects 
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then performed 3 maximal concentric exertions for each muscle group at 60 degrees per second. 
Strength was measured as the peak voluntary torque of each muscle group. Subjects were 
instructed to “push” and “pull” their leg against the lever of the Biodex as hard and fast as 
possible. Verbal encouragement was given for each repetition. One minute of rest was given 
between repetitions and five minutes of rest was given prior to the muscle fatigue protocol to 
prevent the occurrence of muscle fatigue. 
During the protocol development phase prior to this study, it was determined that 60 
degrees/second was the most comfortable speed for the majority of subjects. Therefore, the 
fatigue protocol consisted of reciprocal, maximal concentric knee extension and flexion at 60 
degrees/second until at least 35 repetitions were performed and peak torque declined to 50% of 
maximum. This point was defined when the peak torque of 2-3 consecutive repetitions fell below 
50% of the maximum torque value obtained during the fatigue protocol. A maximum of 100 
repetitions was allowed to achieve the 50% decline in peak torque. In this manner, two isokinetic 
testing protocols (35 repetitions and 50% decline) were imbedded within one session. Again, the 
subjects were instructed to “push” and “pull” their leg against the lever as hard as possible. 
Strong verbal encouragement was given for every repetition to encourage maximal effort on all 
repetitions. The test was terminated if the subject could no longer move through their available 
ROM at the desired velocity of 60 degrees/second or if self-terminated. 
Data Analysis 
 
Feasibility 
During the fatigue protocol, the repetition in which the maximum torque occurred, as 
well as the repetition in which the criteria for the 50% decline in peak torque were met, was 
recorded. In addition, paired t-tests were used to test the difference between peak torques 
obtained during the strength assessment versus the fatigue test. 
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Test-Retest Reliability 
 Data were gravity corrected, and only the constant velocity portion was used. Two 
accepted measures of fatigue were computed for each of the two embedded protocols: 1) percent 
decline in peak torque, calculated as a Fatigue Index (FI) (Pincivero, Gandaio, & Ito, 2003): 






−= %100x
5
5100FI
repshighestPT
repslastPT
  
and 2) rate of decline in PT represented by the slope of the linear regression, beginning with the 
first value of the highest 5 consecutive repetitions and ending with the last repetition (Pincivero 
et al., 2001). The slope was also normalized by peak torque as a method for comparison across 
individuals (Felicetti, Zelaschi, & Di Patrizi, 1994) (Figure 2.1). Intraclass correlation 
coefficients (ICC) were calculated to determine test-retest reliability for the slope, normalized 
slope, and FI (Portney & Watkins, 2000). Alpha level was set at .05.  
(Shrout &Fleiss model from Portney & Watkins, 2000)  
BMS
EMSBMSICC −=  
where BMS is the between-subjects mean square, and EMS is the error mean square. 
 
Results 
 
Feasibility 
 
In half of the 12 subjects tested, peak torque failed to decline to 50% of maximum in 
either one or both directions during the fatigue protocol (Table 1). However, all subjects were 
able to complete 35 repetitions. Furthermore, when the criteria for the 50% decline in peak 
torque were met, it occurred before the 35th repetition in 82% of the trials. Reasons for 
termination of the fatigue testing session are listed in Table 2.1 for each subject. Peak torque 
obtained from the fatigue test for the knee extensors (55.6 ± 20.8) was significantly greater than 
the value obtained during the single repetition strength assessment (42.7 ± 15.7, p = 0.001). 
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However, there was no difference in peak torque for the knee flexors observed during the fatigue 
test (24.6 ± 12.7) versus the strength test (22.5 ± 14.8, p = 0.18). It was noted that the maximum 
torque during the fatigue test occurred between the 3rd and 27th repetition for the knee extensors 
(9.3 ± 7.8) and between the 1st and 20th repetition for the knee flexors (5.0 ± 6.5).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Exemplar peak torque data during knee extension (PTKE) over 35 repetitions from 
one subject represented by the diamond marker (♦). Slope of the linear regression and the 
fatigue index (FI) were calculated and presented with the raw data.  
 
Test-Retest Reliability 
 
 Because the 50% decline in peak torque did not occur in all subjects, fatigue 
parameters were calculated only for the 35 repetitions. In one subject, the starting value, or the 
first of the highest 5 consecutive repetitions, occurred later than the 15th repetition consistently 
for both muscle groups during both test sessions. As a result, the protocol was extended to 
achieve a sufficient number of repetitions beyond that point.  
The ICC values of the absolute slope for the knee flexors and extensors were 0.94 and 
0.97, while the ICC values of the normalized slope for the knee flexors and extensors were 0.83 
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and 0.99, respectively. The ICC values of the FI were 0.86 and 0.73 for the knee flexors and 
extensors, respectively. The ICC values of the peak torque from the strength test were 0.96 and 
0.95, and the ICC values of the peak torque from the fatigue test were 0.89 and 0.87 for the 
flexors and extensors, respectively (Table 2.2).  
 
Table 2.2  
  Intraclass Correlation Coefficients (ICC) for Test-retest Reliability Analysis 
                                              Knee Extension                                                  Knee Flexion 
 Test 1 Test 2 ICC Test 1 Test 2 ICC 
FI   22.36 (14.89) 32.77 (8.57) .73 42.44 (11.59) 50.92 (14.95) .86 
Slope 
(Abs) 0.613 (0.380) 0.479 (0.298) .97 0.198 (0.121) 0.246 (0.156) .94 
Slope/PT 0.013 (0.008) 0.010 (0.007) .99 0.012 (0.008) 0.011 (0.008) .83 
StrengthPT 39.24 (20.42) 37.42 (16.32) .95 18.18 (14.57) 18.21 (13.63) .96 
FatiguePT 49.54 (17.05) 49.48 (10.96) .87 18.21 (12.13) 22.09 (9.10) .89 
Peak torque (PT) given in N-m. All the ICC values were significant at p < 0.05 
FI = Fatigue Index; (Abs) = absolute value; Slope/PT = slope normalized by peak torque; 
StrengthPT = peak torque calculated from strength test; FatiguePT = peak torque calculated from 
fatigue test 
 
Discussion 
 
The results of this study demonstrate that muscle fatigue of the knee flexors and 
extensors can be feasibly and reliably assessed in children and young adults with mild to 
moderate CP over 35 repetitions at an isokinetic speed of 60 degrees/second. According to 
Portney and Watkins (2000), ICC coefficients from .050 to 0.75 designate moderate reliability, 
and values above 0.75 indicate good reliability. In addition, Shrout and Fleiss (Shrout & Fleiss, 
1979) define ICCs exceeding 0.75 as excellent. Based on these guidelines, both the absolute and 
normalized slope was observed to have good/excellent reliability for both the knee flexors and 
extensors, whereas the FI presented with good/excellent reliability for the knee flexors only. 
Moderate reliability (0.73) was observed for the FI of the knee extensors.  
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The 50% decline protocol was not appropriate for use in this sample of individuals with 
mild to moderate CP since only half of the subjects tested were able to achieve a 50% decline in 
peak torque with the imposed limitations of 100 repetitions, self-termination, or inability to 
complete the task. However, if the rate of decline is linear, it is possible that based on the slope, 
this point could be extrapolated. When the 50% decline in peak torque was met, it occurred prior 
to the 35th repetition in over 80% of the trials. Therefore, the protocol that required 35 repetitions 
was more feasible for most subjects. However, in some subjects, the protocol may need to be 
extended when the maximum torque occurs past the 15th repetition, as less than 20 repetitions 
was not adequate in capturing the decline in torque in this sample of subjects. Testing at speeds 
other than 60 degrees/second may produce different results than observed in this study. It is 
possible that fewer repetitions could have been completed at 30 degrees/second. Since CP 
encompasses such a wide range of motor disabilities, and subjects in this study tended to fall on 
the milder end of the spectrum, these protocols may be increasingly problematic for individuals 
with greater involvement (GMFCS levels IV and V) and may require further modification. It is 
anticipated that reliable assessment of fatigue in those with greater involvement may not even be 
possible.  
Although the FI has been questioned in terms of its reliability (Burdett & Van 
Swearingen, 1987), our results indicate that the FI has moderate to good reliability in the CP 
population. Our results are comparable with other studies that have showed moderate to good 
reliability of the FI for the non-dominant knee flexors and extensors (ICC = 0.84 and 0.74) in the 
healthy adult population (Pincivero, Lephart, & Karunakara, 1997). The good/excellent 
reliability of the slope calculations is also comparable to other studies in the healthy adult 
population for the same muscle groups (ICC = 0.78 to 0.86) (Felicetti et al., 1994; Pincivero et 
al., 2001).  
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 Assessment of peak voluntary torque at 60 degrees/second as a measure of strength 
presented with good/excellent reliability, with ICC values of 0.96 and 0.95 for the knee flexors 
and extensors, respectively. Very little information is available in the literature regarding the 
reliability of isokinetic testing speeds in CP. Based on Van den Berg-Emons et al. (1996) 
reliability study, clinicians and researchers have considered the isokinetic speed of 30 
degrees/second as the “gold standard” for strength assessment for people with CP. However, 
faster angular velocities are more typical of everyday activities and movement. Furthermore, 
recent research suggests that a faster speed of 90 degrees/second is also reliable for children and 
adolescents with mild to moderate CP for the knee flexors and extensors (ICC = 0.98) (Ayalon et 
al., 2000). Holland et al. (1994) also tested 14 adults (ages 17 to 38) at 60 degrees/second and 
reported generalizability coefficients (ρ2) of 0.91 and 0.80 for the flexors and extensors, 
respectively. The results of this study are comparable and provide further evidence to support the 
reliability of speeds greater than 30 degrees/second for isokinetic strength assessments.  
 It is of clinical importance that peak torque was observed to be greater for the knee 
extensors during the fatigue test as compared to the strength test. In non-disabled, healthy adults 
and children, maximum torque is achieved during the first 5 repetitions (Burdett & Van 
Swearingen, 1987; De Ste Croix et al., 2003; Pincivero et al., 2001; Pincivero et al., 1997). 
Therefore, it is customary to utilize 3 to 5 isokinetic repetitions for maximum strength 
assessments even in individuals with chronic motor disorders, such as CP (Ayalon et al., 2000; 
Damiano & Abel, 1998; Holland et al., 1994; Van den Berg-Emons RJ et al., 1996). However, 
according to our study, not only was peak torque greater for the knee extensors during the fatigue 
test, but it occurred on average during the 9th repetition. The results indicate that we may not be 
giving our subjects enough repetitions to achieve maximum torque during strength assessments 
and may, in fact, be under representing their strength. Another reason for this discrepancy may 
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be that the subjects initiated knee extension during the strength test from a static position, 
followed by knee flexion motion and a rest period before the next trial. Although the fatigue test 
is initiated in this same manner, repetitions are performed consecutively without rest or pause, 
where knee extension is not initiated from a static position on subsequent repetitions. Hence, 
knee extension is preceded by a pre-stretch of the muscle (active knee flexion) during subsequent 
trials, which may have a potentiation effect on the contractile machinery of the quadriceps. This 
same phenomenon has been observed in stroke subjects during stretch-shortening cycles 
compared to contractions from a static starting position (Svantesson, Grimby, & Thomee, 1994). 
Knee flexion, on the other hand, begins from a dynamic position of pre-stretch on all trials for 
both the strength and fatigue test, which may explain why a discrepancy did not exist. However, 
further research is needed in order to decipher the influence of dynamic versus contractions from 
a static position. Still other explanations, such as decreased neural activation, need to be 
explored, because the production of the maximal torque after more than a few repetitions is quite 
a deviation from normal muscle performance and may suggest that the effort cannot possibly be 
maximal in those cases. 
 In conclusion, performance of 35 repetitions at 60 degrees/second is a feasible and 
reliable isokinetic muscle fatigue protocol for both children and young adults with mild to 
moderate CP and has widespread clinical and research applications. In addition, the number of 
repetitions given and the type of contraction (dynamic/pre-stretch vs. static) may influence the 
assessment of peak voluntary torque in subjects with CP.  
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CHAPTER 3: ARE MUSCLES MORE FATIGABLE IN INDIVIDUALS WITH CEREBRAL 
PALSY? 
 
Introduction 
 
Measures of physiological capacity, such as lower extremity muscle strength, have been 
correlated with functional measures in people with cerebral palsy (CP) and other disabilities 
(Damiano & Abel, 1998; Damiano, Kelly, & Vaughn, 1995; Kramer & MacPhail, 1994). 
However, neither muscle strength nor measures of physical function have been shown to be 
related to psychosocial aspects of quality of life (QOL), such as comfort and happiness (Pirpiris 
et al., 2006). Self-reported physical fatigue, on the other hand, has been significantly associated 
with QOL measures of psychosocial well-being, such as bodily pain, limitations in physical and 
emotion role function, and low life satisfaction in adults with CP (Jahnsen, Villien, Stanghelle, & 
Holm, 2003). Furthermore, adults with CP report fatigue as a main cause of the deterioration or 
cessation of their walking ability (Bottos, Feliciangeli, Sciuto, Gericke, & Vianello, 2001; 
Jahnsen, Villien, Egeland, Stanghelle, & Holm, 2004; Murphy, Molnar, & Lankasky, 1995). 
However, these studies assessed fatigue using questionnaires and interviews and did not attempt 
to differentiate among objective measures of fatigue. 
There are different types of objective measures of fatigue, such as cardiorespiratory 
fatigue (e.g. heart beating too fast or person feeling out of breath), neural or psychological 
fatigue (increased sense of effort or feeling as if muscles are going to ‘give out’) or local muscle 
fatigue. Muscle fatigue, or fatigability, was defined as a reduction in force output that occurs 
during sustained activity (Bigland-Ritchie, Johansson, Lippold, & Woods, 1983). Fatigue 
resistance is also referred to as muscle endurance, which is the term most often used in the 
literature as the antonym, or opposite, of muscle fatigue, similar to the use of strength vs. 
weakness. 
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Previous objective clinical measures of fatigue in people with CP were focused primarily 
on the cardiorespiratory system. Although it has been well documented that children and 
adolescents with CP have lower VO2max than their typically developing peers, most authors 
agreed that local muscle factors, such as muscle fatigue, were responsible for the lower VO2max 
and limitations in activity (Hoofwijk, Unnithan, & Bar-Or, 1995; Lundberg, 1978; Rose, Haskell, 
& Gamble, 1993; Tobimatsu, Nakamura, Kusano, & Iwasaki, 1998; Unnithan, Dowling, Frost, & 
Bar-Or, 1996). Following this same argument, Lundberg (1978) and Hoofwijk et al. (1995) 
suggested that spastic muscles may have decreased venous return and inhibited muscle lactate 
clearance during exercise, thereby increasing local muscle fatigue and leading to a decrease in 
VO2max values.  
Several investigators have studied muscle endurance from an anaerobic perspective in 
children and adolescents with CP by means of the Wingate Anaerobic Cycling Test (WAnT). 
The WAnT is a widely used, validated measure of anaerobic performance during which the 
subject pedals at maximal speed against a predetermined constant resistance for 30 seconds (Bar-
Or, Dotan, & Inbar, 1977). Results from these studies indicate that mean muscle power, as a 
measure of muscle endurance, is markedly deficient in people with CP (Parker, Carriere, 
Hebestreit, & Bar-Or, 1992; Parker, Carriere, Hebestreit, Salsberg, & Bar-Or, 1993; Tirosh, Bar-
Or, & Rosenbaum, 1990). However, due to the focus on speed and the short duration of the test, 
the validity of this test as a measure of muscle endurance is debatable. Also, it cannot 
differentiate between right and left extremities nor can it differentiate among muscle groups. 
Therefore, it is at best a non-specific, gross physiologic measurement of endurance or, perhaps 
more appropriately, of muscle power.  
Because muscles adapt to the amount and type of neural stimulation being imposed upon 
them, secondary effects of spasticity on muscle tissue can also have a profound impact on the 
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ability to generate and maintain muscle force. Muscle abnormalities such as alterations in muscle 
fiber size and fiber type distribution, excessive collagen accumulation, and increased stiffness of 
spastic muscle cells have been extensively reported (Booth, Cortina-Borja, & Theologis, 2001; 
Castle, Reyman, & Schneider, 1979; Friden & Lieber, 2003; Ito et al., 1996; Marbini et al., 2002; 
Romanini, Villani, Meloni, & Calvisi, 1989; Rose et al., 1994). These alterations of muscle 
properties can have major implications for essential aspects of muscle performance, such as the 
ability to generate force and to sustain force output. In cerebral palsy and other motor disorders, 
different muscle groups can be affected to varying degrees; therefore, these changes may also be 
muscle-specific. 
Isokinetic muscle fatigue protocols for the knee have been extensively developed in the 
healthy adult population. (Burdett & Van Swearingen, 1987; Pincivero, Gear, & Sterner, 2001; 
Thorstensson & Karlsson, 1976) and have been modified for use with children (De Ste Croix, 
Armstrong, & Welsman, 2003) and with other neurological populations, such as multiple 
sclerosis (Lambert, Archer, & Evans, 2001). Isokinetic dynamometry has the ability to isolate a 
group of muscles about a specific joint under controlled conditions with stabilization of other 
joints, thus providing a device with which to measure muscle fatigue. It also provides a 
controlled, safe environment where no resistance (load) is applied once the movement has 
ceased, since it accommodates to the amount of muscle force that is applied (Jones & Stratton, 
2000). An isokinetic fatigue protocol was developed recently by our group for use in children 
and young adults with mild to moderate CP and was shown to be feasible and reliable for testing 
the knee flexors and extensors (Moreau, Li, & Damiano, 2006). 
The primary purpose of this study was to determine whether muscle fatigue in the knee 
flexors and extensors in individuals with CP differs from those without a motor disability. A 
secondary purpose of the study was to determine the relationship of fatigue to functional level, 
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walking velocity, and psychosocial well-being and activity / participation as measured by the 
Pediatric Outcomes Data Collection Instrument (PODCI). We hypothesized that individuals with 
CP would have greater levels of muscle fatigability compared to non-disabled peers, and that this 
aspect of muscle performance would be inversely related to functional level, walking velocity, 
activity and participation, and psychosocial well-being.  
Methods 
 
Subjects 
 
A group of 18 subjects with cerebral palsy (CP) and 16 control subjects without a motor 
disability between the ages of 10 and 25 were recruited for the study. Gender and age 
distribution was similar across groups. Physical demographics of the subjects are listed in Table 
3.1. All subjects were able to ambulate at least a short distance with or without assistive devices. 
Subjects were excluded if they had orthopedic surgery within 12 months prior to the testing, 
received Botulinum toxin injections to the quadriceps or hamstrings within 6 months prior to 
testing, or complained of existing knee pain. Passive range of motion of the knee was also 
assessed prior to testing to determine if the subject had sufficient range of motion to complete the 
test.  
The study was approved by the Institutional Review Board at our institution. Written 
informed consent from each participant over 18 years of age was obtained before beginning this 
study. Participants younger than 18 years of age were required to have a parental consent form 
signed by one parent or legal guardian. In addition, the minor was required to read and sign a 
child assent form. 
Gross Motor Function Classification System 
 
All subjects were assigned a Gross Motor Function Classification System (GMFCS) level 
and were restricted to levels I, II, and III, secondary to ambulation requirements of the study. The 
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GMFCS is a standardized evaluation that allows for the classification of children with CP into 
levels based on functional ability. Emphasis is on the child's usual performance in home, school, 
and community settings. The GMFCS has been suggested to have good to excellent interrater 
reliability for severity of gross motor function limitations in children with CP (Palisano et al., 
1997; Wood & Rosenbaum, 2000). In addition, it has been shown to be a valid instrument in 
both cross-sectional (Palisano et al., 1997) and longitudinal (Wood & Rosenbaum, 2000) studies. 
 
Table 3.1. 
Physical Demographics 
 
 
Gender Age range Age (yr) ± SD Height (m) ± SD Weight (kg) ± SD 
CP 13F/5M 10 – 25 17.49 ± 5.03 1.52 ± 0.08 47.57 ± 9.92 
Control 13F/3M 10 – 23 16.61 ± 4.45 1.59 ± 0.09* 53.97 ± 9.72 
M = male; F = female. *The control group was significantly taller than the CP group (P = 0.01)  
 
 
Pediatric Outcomes Data Collection Instrument (PODCI) 
 
The Pediatric Outcomes Data Collection Instrument (PODCI) questionnaire was 
completed separately by the parent and child or by the adult subject only (AAOS/POSNA, 
Version 2.0, (Daltroy, Liang, Fossel, & Goldberg, 1998). The PODCI was designed to assess 
self-reported physical function and psychosocial aspects of health status in children with mild to 
moderate musculoskeletal disability. The PODCI contains 108 short questions and takes about 
10-20 minutes to complete. Each scale is computed to generate a score from 0 to 100 (worst to 
best). The following scales generated from this instrument were analyzed:  
• Transfer and Basic Mobility Scale: Measures difficulty experienced in performing routine 
motion and motor activities in daily activities.  
• Sports/Physical Functioning Scale: Measures difficulty or limitations encountered in 
participating in more active activities or sports.  
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• Pain/Comfort Scale: Measures the level of pain experienced during the past week.  
• Global Functioning Scale: A general combined scale calculated from the first three scales 
listed above and the ‘Upper Extremity and Physical Function Scale’.  
• Happiness Scale: Measures overall satisfaction with personal looks and sense of 
similarity to friends and others of own age.  
• Satisfaction with Symptoms Scale: Measures the patient's acceptance of current 
limitations should this be a life long state.  
Gait Velocity 
 
Gait velocity was assessed over level ground prior to isokinetic testing. A 10-m distance 
was marked on the floor with tape. Subsequent marks were placed 2-m from the starting point 
and 2-m from the ending point, thus allowing a 6-m timed middle section for the test. Timing 
began when the subject crossed the initial 2-m mark and ended when the subject crossed the final 
2-m mark. Each subject was given 2-4 trials at a comfortable walking speed and at a fast walking 
speed. The instructions for comfortable walking speed were, “When I say ‘go’, walk all the way 
to the last piece of tape at your comfortable walking speed.” For the fast walking speed, the 
instructions were, “When I say ‘go’, walk all the way to the last piece of tape as fast as possible 
but without running”. Time was recorded by a stopwatch in seconds, and velocity was calculated 
as meters per second. Two representative trials at each speed were averaged (Brusse, Zimdars, 
Zalewski, & Steffen, 2005). 
Isokinetic Testing 
 
An isokinetic dynamometer (Biodex Medical Systems Incorporated, Shirley, NY, USA) 
was used to record torque of the knee flexors and extensors during maximum voluntary 
contraction throughout the available range of motion. Following familiarization with the 
isokinetic equipment and explanation of procedures, the subject was positioned in the Biodex 
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chair in a semireclining sitting position with the angle of the hip joint at 70 degrees (thigh 
horizontal and trunk 70 degrees above horizontal). The more involved lower extremity was 
tested for subjects with bilateral or unilateral involvement if they had sufficient motion and 
mobility in that limb to perform the test. The left lower extremity was tested for control subjects. 
The subject’s knee joint center was aligned with the center of rotation of the dynamometer. The 
leg was secured against the knee attachment pad, and additional stabilizing straps around the 
waist, the trunk, and over the mid-thigh portion were used to restrain trunk and hip movement 
during testing. Following set-up, the passive range of motion designated as “comfortable” by the 
patient, given the restrictions imposed by the chair itself which limits flexion, was determined 
and used to set the limits of motion for the rest of testing session. Subjects were instructed to 
keep their arms folded across their chest for all trials.  
Subjects performed 8-12 submaximal concentric, reciprocal knee flexion and extension 
repetitions to familiarize themselves with the procedure. After a 2-minute rest period, subjects 
then performed 3 maximal concentric exertions for each muscle group at 60 degrees per second. 
Five minutes of rest was given prior to the muscle fatigue protocol to prevent the occurrence of 
muscle fatigue. 
The fatigue protocol consisted of reciprocal, maximal concentric knee extension and 
flexion at 60 degrees/second for 35 repetitions. The subjects were instructed to “push” and “pull” 
their leg against the lever as hard as possible. Strong verbal encouragement was given for every 
repetition to encourage maximal effort on all repetitions (Moreau et al., 2006). 
 Data were gravity corrected, and only the constant velocity portion was used for the 
following calculations. Two accepted measures of fatigue were computed as illustrated in Figure 
3.1: 1) percent decline in peak torque (PT), calculated as a Fatigue Index (FI) (Pincivero, 
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Gandaio, & Ito, 2003): 
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and 2) rate of decline in PT represented by the slope of the linear regression, beginning with the 
first value of the highest 5 consecutive repetitions and ending with the last repetition (Pincivero 
et al., 2001):   
∆Reps
PTSlope ∆=  
This fatigue protocol was previously shown to be feasible and reliable in children and young 
adults with mild to moderate CP (Moreau et al., 2006). 
 
 
Figure 3.1. Exemplar peak torque data during knee extension (PTKE) over 35 repetitions from 
a.) one subject with CP classified as GMFCS level I and b.) one subject classified as GMFCS 
level III. Two age-matched subjects from the Control group are illustrated for comparison. Slope 
(b) of the linear regression and the fatigue index (FI) were calculated and presented with the raw 
data. For illustrative purposes, PT was normalized by the maximum torque to yield a scale of 0 
to 1. 
 
 
Statistical Analysis 
 
Factorial Repeated Measures Analysis of Variance (ANOVA) procedures, with muscle 
(extensors/flexors) as the repeated measure, were used to test for differences in fatigue 
parameters between groups. Within the group with CP, Pearson correlation procedures were used 
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to relate gait velocity and PODCI scores to fatigue parameters, and a Spearman rank procedure 
was used for comparisons with the ordinal GMFCS categorization (levels I, II, and III). ANOVA 
procedures were also used to compare fatigue parameters across GMFCS levels in the subjects 
with CP. Alpha level was set at 0.05. 
Results 
 
The demographics of the two groups were similar with the control group slightly taller 
than the group with CP (p = 0.01, Table 3.1). The peak absolute torque of the knee extensors 
obtained during the fatigue protocol for the group with CP and the control group were 54.2 ± 
20.8 and 108.4 ± 37.9 N-m, respectively. For the knee flexors, the peak absolute torque was 24.2 
± 11.3 and 57.7 ± 21.3 N-m for the group with CP and the control group, respectively. The slope 
of the knee extensors and flexors were significantly correlated with age only for the control 
group (Control: r = 0.71 and 0.82, p < 0.05; CP: r = 0.002 and -0.12, respectively). Gender did 
not have a significant effect on within group or between group comparisons for either the FI or 
the slope. Therefore, gender was excluded as a factor in the ANOVA procedures.  
Fatigue 
 
 PT occurred at the 22nd and 27th repetition during the fatigue protocol for knee extension 
in 2 subjects. Therefore, the protocol was extended to 50 repetitions, so that a sufficient number 
of data points were obtained to see a clear trend and to be able to make equal comparisons across 
subjects. Figure 3.2 illustrates the mean and standard error of the mean (SEM) of the slope for 
the knee flexors and extensors for both groups. Compared to the group with CP, the control 
group was associated with greater slope values for both the knee flexors and extensors, 
indicating greater fatigability of the control group (Group: F1,60 = 36.90, P < 0.0001). The knee 
extensors were associated with greater slope values than the knee flexors across both groups 
(Muscle: F1, 60 = 21.86, P < 0.0001). No significant group and muscle interaction was observed.  
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Figure 3.2. Mean and SEM of the slope for knee flexion and extension for the group with CP 
and the control group. Significant differences were observed among the different groups (P < 
0.0001) and different muscles (P < 0.0001). No significant interaction between Group and 
Muscle was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Mean and SEM of the Fatigue Index (FI) for knee flexion and extension for the 
group with CP and the control group. Significant differences were observed among the different 
groups (P = 0.009) and different muscles (P = 0.004). No significant interaction between Group 
and Muscle was observed. 
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GMFCS 
 
 Greater slope values were associated with lower GMFCS levels in the group with CP, 
regardless of muscle group (F2,27 = 5.25, P = 0.012).. Post-hoc analysis with Tukey adjustments 
revealed significant differences between GMFCS levels I and III and between levels II and III (P 
= 0.009 and 0.037, respectively). Figures 3.1a and 3.1b illustrate the FI and the slope of the 
decline in knee extensor PT for a subject within GMFCS level I and level III, respectively. A 
significant interaction between GMFCS and muscle group was not observed. Spearman rank 
correlations revealed a significant negative association between GMFCS level and the slope for 
knee extension only, as illustrated in Figure 3.4 (r = -0.47, P = 0.047). Thus, more proficient 
ambulators with CP, i.e. lower GMFCS levels, had greater levels of knee extensor fatigability. 
There were no significant main effects or interactions for the FI across GMFCS levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Spearman rank (r) correlation between the slope of the knee extensors (KE) and 
GMFCS levels I, II, and III (r = -0.474, P = 0.047). Mean and SEM are illustrated. 
 
 
PODCI 
 
 The Global Function scale of the PODCI was directly correlated with both the slope and 
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slope only. Transfers and basic mobility were directly correlated to the slope and FI of the knee 
extensors, as well as to the slope of the knee flexors. A positive correlation indicates that people 
with higher levels of functioning (i.e. higher scores on the PODCI) have increased levels of  
fatigability. None of the scales related to psychosocial well-being (Pain/comfort, happiness, 
satisfaction) were correlated with the fatigue parameters. Correlation coefficients are listed in 
Table 3.2.  
Velocity 
 
 Among the normalized and non-normalized self-selected and fast velocities, only non-
normalized fast velocity was significantly correlated to the slope of the knee extensors (r = 0.51, 
P = 0.03). Therefore, the capacity to walk faster is associated with greater levels of knee extensor 
fatigability among the subjects with CP. 
 
Table 3.2 
Pearson (r) correlations of PODCI subscales and velocity data with fatigue parameters 
 
PODCI = Pediatric Outcomes Data Collection Instrument; Slope KE = slope of peak torque for 
knee extension; Slope KF = slope of peak torque for knee flexion; FI = Fatigue Index 
 
 
 
Slope KE Slope KF FI KE FI KF 
PODCI Sports & 
Physical Function   0.50*  0.40   0.40 0.23 
PODCI Transfers 
& Basic Mobility   0.55*  0.49*   0.55* 0.37 
PODCI Global 
Functioning   0.47*  0.30   0.50* 0.29 
PODCI Happiness 
Scale   0.34  0.43   0.23         -0.09 
PODCI Pain & 
Comfort   0.01  0.02  -0.25 0.07 
PODCI 
Satisfaction   0.10  0.13  -0.18 0.14 
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Discussion 
 
Contrary to our hypotheses, the knee flexors and extensors in our sample of subjects with 
CP were actually less fatigable than in the age-matched control group, as indicated by both Slope 
and FI. Furthermore, higher levels of fatigability (Slope) were associated with higher functioning 
GMFCS levels, higher levels of function as measured by the PODCI Transfers and Basic 
Mobility scale and fast velocity, and greater levels of participation in sports and other activities 
for the CP group. Counterintuitively, it appears as though lower levels of fatigability of the knee 
flexors and extensors are characteristic of greater disability. 
This fatigue protocol was designed as a measure of volitional activity, which would be 
more representative of everyday function versus an electrically elicited fatigue test or an 
isometric test. Nevertheless, our results are similar to a study that utilized an electrically elicited 
fatigue test where the quadriceps were found to be less fatigable than a control group 
(Stackhouse, Binder-Macleod, & Lee, 2005). However, it should be noted that voluntary 
contractions, which form the basis of our study, were not part of the fatigue test. Because the 
muscles were electrically stimulated, only peripheral aspects of muscle fatigue distal to the 
peripheral motor nerve were assessed. Our study, on the other hand, encompassed both central 
and peripheral aspects of muscle fatigue, from the central nervous system command to the 
contractile apparatus of the muscle itself. Furthermore, electrically elicited fatigue tests differ 
from volitional fatigue tests in the order of activation of muscle fibers, as well as in the firing 
rate and synchrony of nerve depolarizations (Delitto & Snyder-Mackler, 1990). Therefore, 
similarities between the two studies should be interpreted within this context. 
Our results differ from anaerobic tests previously reported by Parker et al. (1992, 1993) 
and Tirosh et al. (1990). Results from these studies indicate that peak muscle power and mean 
power, as a measure of muscle endurance, are markedly deficient in people with CP (Parker et 
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al., 1992; Parker et al., 1993; Tirosh et al., 1990). However, these authors assessed muscle 
endurance, or fatigue resistance, in subjects with CP by means of the Wingate Anaerobic Cycling 
Test (WAnT). From this 30-second, maximal cycling test, mean power is calculated as a measure 
of endurance. However, mean power is an absolute measure that reflects the average level of 
explosiveness or power and does not reflect the decline in the force-generating capacity of the 
muscle. Therefore, the differences in measurement parameters between our study and the 
aforementioned explain the discrepancy in results.  
Several mechanisms can be suggested to explain the greater fatigue resistance of the CP 
group, the first of which are maximal torque level (strength) and muscle mass. It has been 
suggested that males are more fatigable than females (Hunter & Enoka, 2001; Pincivero et al., 
2003), and adults are more fatigable than children (Kanehisa, Okuyama, Ikegawa, & Fukunaga, 
1995) and older adults (Lanza, Russ, & Kent-Braun, 2004) due to greater strength and/or greater 
muscle mass. The muscle mass or strength hypothesis states that stronger subjects would have 
more blood flow occlusion than weaker subjects at the same relative load, particularly during 
isometric tasks (Barnes, 1980). While gender was not predictive of muscle fatigue in our sample 
of subjects with CP, the peak absolute torque of both muscle groups obtained during the fatigue 
test was 50% lower in the CP group compared to the control group and could partially explain 
the greater fatigue resistance. Perhaps, the lower capacity for force production in the subjects 
with CP prohibits the rapid decline in torque that was observed in the control group. However, it 
should be noted that gender and age differences in fatigability due to absolute strength 
differences have been refuted by some researchers (Hunter, Critchlow, Shin, & Enoka, 2004; 
Lindstrom, Lexell, Gerdle, & Downham, 1997). Some authors claim that weakness leads to 
disuse atrophy and increased levels of fatigability (Edgerton, Roy, Allen, & Monti, 2002). A 
secondary consequence of weakness and muscle atrophy is the recruitment of more motor units 
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or the greater frequency of excitation required to perform a given task. As a consequence of 
recruiting more motor units, the overall fatigability will likely increase because increased 
numbers of upper threshold units will be recruited, which include more fast fatiguing fibers. 
Although these are all plausible theories, the relationship between absolute strength and muscle 
fatigue is not fully understood and warrants further investigation. 
Second, predominance of a particular fiber type can influence fatigue, as Type I (slow 
twitch) fibers are more fatigue-resistant, while Type II (fast twitch) fibers are more fatigable 
(Burke, Levine, Tsairis, & Zajac, 1973; Thorstensson & Karlsson, 1976). Decreased muscle 
fatigue of children and the elderly as compared to adults has also been attributed to an increased 
proportion of Type I, fatigue resistant fibers (Jansson, 1996; Larsson, Sjodin, & Karlsson, 1978). 
Similarly, it has been postulated than a greater proportion of type II muscle fibers in men may 
account for the greater fatigability of men compared to women observed in certain studies 
(Bilodeau, Schindler-Ivens, Williams, Chandran, & Sharma, 2003). Although there are reports of 
increased type I fibers in CP, there has been no consensus on fiber type predominance (Castle et 
al., 1979; Ito et al., 1996; Marbini et al., 2002; Ponten, Friden, Thornell, & Lieber, 2005; 
Romanini et al., 1989; Rose et al., 1994). These studies sampled muscle fibers across numerous 
muscles and clinical presentations in addition to other methodological differences. Therefore, it 
is not surprising that there is no general consensus on fiber type predominance. However, the 
main results of this study could partially be explained if the disease process of CP does result in 
muscle adaptations, which include increased proportions of Type I fibers. Other muscle 
abnormalities in individuals with CP include collagen accumulation (Booth et al., 2001) and 
increased stiffness at both the cellular (Friden & Lieber, 2003) and whole muscle level 
(Hufschmidt & Mauritz, 1985). Perhaps, these muscle adaptations play a role in the development 
of fatigue resistance as well. 
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Third, the issue of voluntary muscle activation must be considered. Lower voluntary 
muscle activation in older adults has been postulated to contribute to differences in muscle 
fatigue between older and younger adults (Bilodeau, Erb, Nichols, Joiner, & Weeks, 2001; 
Stackhouse et al., 2001). Similarly, Stackhouse, Binder-Macleod, and Lee (2005) observed 
voluntary muscle activation ratios of approximately 0.45 of the quadriceps and triceps surae in 
children with CP ages 7 to 13 compared to 0.68 and 0.92, respectively, in age-matched typically 
developing children. Therefore, despite the fact that the subjects with CP were giving 100% 
effort, it is possible that they were not activating all of their motor units secondary to impaired 
motor pathways. As a result, type I fibers may be preferentially recruited with lower firing rates, 
contributing to the fatigue resistance. A limitation of the Stackhouse et al. (2005) study and 
others that have examined voluntary or central activation ratios by means of twitch interpolation 
is that voluntary activation is not assessed during the fatigue testing protocol. Therefore, it is 
difficult to determine the extent to which voluntary activation levels contribute to the decline in 
torque during the fatigue test. Further research is necessary to determine if there is a relationship 
between level of voluntary muscle activation and muscle fatigue, as evidence for this theory is 
lacking in the literature.  
Differences in fatigability of the hamstrings measured during knee flexion and the 
quadriceps measured during knee extension emerged across both groups. However, the 
differences were not consistent for both fatigue parameters. According to the FI, the hamstrings 
were more fatigable than the quadriceps. Conversely, the quadriceps were more fatigable than 
the hamstrings, as indicated by a greater slope. This discrepancy may be due to the manner in 
which the fatigue parameters are calculated.  
The formula for the FI (%) can be reorganized as ∆PT / maximum torque. Thus, FI is 
inversely influenced by the maximum PT values, where the slope is not, e.g. Slope = ∆PT / 
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∆Reps. The following theoretical discussion illustrates that extremely low PT could artificially 
inflate FI values. The following torque values are approximated to the actual values for ease of 
interpretation. For simplification, assume ∆ Reps equals 50 repetitions, and that the average of 
the PT of the last 5 repetitions is theoretically equivalent to the PT of the last rep and that the 
average of the highest consecutive 5 reps is equivalent to the first of the highest 5 reps. For the 
quadriceps, the average PT of the last repetition was approximately 50 N-m, and the average PT 
of the first of the highest 5 consecutive repetitions was 80 N-m, averaged across groups. This 
would result in a slope of 0.6 and a FI of 37.5%, with a max torque of 80 and ∆PT of 30 N-m. 
For the weaker hamstrings in this study, the average PT of the last repetition was 20 N-m, and 
the average PT of the first of the highest 5 consecutive repetitions was 40 N-m. This would result 
in a slope and FI of 0.4 and 66%, respectively, with a max torque of 40 and ∆PT of 20 N-m. It is 
clear that the much lower maximum torque inversely influenced the FI, e.g., FI ∝ ∆ PT / 
maximum torque. The slope, on the other hand, was only influenced by the magnitude of the 
difference between the lowest and highest PT value, where Slope ∝ ∆ PT. Therefore, the slope of 
the hamstrings was less than the quadriceps due to the smaller ∆ PT, but the FI was biased by the 
much lower maximum torque of the hamstrings, resulting in a higher FI value. The difference in 
the way the two parameters are calculated explains the discrepancy between the results of the FI 
and slope for the effect of muscle groups (hamstrings and quadriceps). The same trend was 
observed for the quadriceps and hamstrings when the fatigue parameters were calculated 
separately for the group with CP and the control group. This observation is similar to other 
studies that have shown the weaker hamstrings to be more fatigable than the quadriceps by 
calculation of a FI in a healthy adult population (Gleeson & Mercer, 1992). 
Most studies of muscle function in people with CP have focused on strength. However, 
muscle endurance, or resistance to fatigue, is an important component of muscle performance 
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and has been overlooked in people with CP. Similar to studies of muscle strength, muscle fatigue 
in this study was directly related to functional aspects, such as global functioning, transfers and 
mobility, and sports and participation, and unrelated to psychosocial aspects. However, the 
interpretation of these results is the converse (i.e., greater fatigue resistance, or endurance, is 
predictive of lower levels of function and participation, as measured by the PODCI and 
GMFCS). Until we understand the mechanisms behind the apparent fatigue resistance observed 
in subjects with CP, we cannot fully understand the relationship between fatigue and function. 
In summary, the results of our study indicate that the knee flexors and extensors of people 
with CP are less fatigable than age-matched peers without motor disability. In addition, lower 
levels of muscle fatigability are associated with lower levels of function and participation. These 
results suggest that a certain level of muscle fatigability is typical of a normally developed 
muscle. It is postulated that the fatigue resistance may be attributed to weakness or lower 
absolute torque levels, decreased voluntary activation, or muscle fiber type changes secondary to 
hypertonia. However, further research is needed in order to explore these mechanisms and the 
potential effect on muscle fatigability.  
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CHAPTER 4: MUSCLE FATIGUE IN CEREBRAL PALSY: RELATIONSHIP TO 
SPASTICITY, STRENGTH, STIFFNESS, AND COCONTRACTION 
  
Introduction 
 
Muscle fatigue, or fatigability, is defined as a reduction in force output that occurs during 
sustained activity (Bigland-Ritchie, Johansson, Lippold, & Woods, 1983). Debate over the 
mechanisms responsible for lower levels of muscle fatigue, known as fatigue resistance, in 
certain populations has been the topic of discussion for many years. For example, greater fatigue 
resistance has been observed in children and healthy older adults compared to young adults and 
females compared to males. Despite the fact that the results are equivocal, several mechanisms 
have been proposed to explain the fatigue resistance, primarily differences in the following: 
muscle mass, muscle morphology, voluntary activation, patterns of motor unit recruitment and 
rate modulation, and energy metabolism or substrate utilization (Lanza, Russ, & Kent-Braun, 
2004; Pincivero, Gandaio, & Ito, 2003; Ratel, Lazaar, Williams, Bedu, & Duche, 2003).  
We have shown in a previous study that the knee flexors and extensors in children and 
young adults with cerebral palsy (CP) are more fatigue resistant than those of typically 
developing peers (Moreau, Li, & Damiano, 2006b). In addition to the aforementioned factors, 
there are additional factors related to neurological injury that may play a significant role in the 
fatigue-resistance observed in our sample of subjects with CP. Factors that may contribute to 
muscle fatigue are weakness, cocontraction, spasticity, and stiffness. CP is a multifaceted 
disorder and as such, complex interrelationships exist among upper motor neuron lesion 
impairments. The relationships between muscle fatigue and other impairments are important in 
the understanding of fatigue, as these impairments may, in fact, contribute directly or indirectly 
to the level of muscle fatigability. 
It is well-recognized that many children with CP have spasticity, or a velocity-dependent 
increased resistance to movement due to hyperexcitable stretch reflexes (Lance, 1980). Although 
 48 
the primary lesion of CP is neural, it is important to discuss the properties of spastic muscle 
because muscles adapt to the amount and type of neural stimulation that is imposed upon them. 
In general, fiber type distribution and muscle fiber size are indicators of the amount and type of 
activity imposed upon a muscle and as such, are often investigated in spastic muscle in order to 
determine a muscle’s usage pattern (Lenman, Tulley, Vrbova, Dimitrijevic, & Towle, 1989; 
Miller, Green, Moussavi, Carson, & Weiner, 1990; Rose et al., 1994). Predominance of a 
particular fiber type can influence fatigue, as Type I (slow twitch) fibers are more fatigue-
resistant while Type II (fast twitch) fibers are more fatigable (Burke, Levine, Tsairis, & Zajac, 
1973; Thorstensson & Karlsson, 1976). Therefore, investigation of the muscle adaptations which 
may occur secondary to spasticity has provided insight into the effects of the disease process on 
muscle characteristics over an extended period of time (Lieber, Steinman, Barash, & Chambers, 
2004). Several authors have reported increased percentages of type I fibers in children with CP 
(Ito et al., 1996; Marbini et al., 2002; Rose et al., 1994). If greater loss or transformation of Type 
II to Type I fibers occurs as a secondary adaptation to spasticity, then this could contribute to 
lower levels of fatigability. However, the results are not conclusive as there have also been 
reports of no differences in fiber type (Castle, Reyman, & Schneider, 1979; Romanini, Villani, 
Meloni, & Calvisi, 1989). These studies sampled fibers across numerous muscles in addition to 
other methodological differences, so it is not surprising that there are discrepancies. Furthermore, 
spasticity may not affect certain muscles while affecting others to varying degrees within and 
between individuals, so it is important to document both the presence and magnitude of 
spasticity for the muscles under investigation.  
Other muscle abnormalities which may play a role in the development of fatigue 
resistance in individuals with CP include excessive collagen accumulation (Booth, Cortina-
Borja, & Theologis, 2001) and increased stiffness at both the cellular (Friden & Lieber, 2003) 
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and whole muscle level (Hufschmidt & Mauritz, 1985). Stiffness is defined as a length-
dependent resistance to movement and quantified as the slope of the torque/angle curve. It has 
been suggested that increased stiffness may be a compensation for weakness, thus allowing 
better utilization of elastic energy during functional activities, such as gait (Lamontagne, 
Malouin, & Richards, 2000; Svantesson & Sunnerhagen, 1997). Therefore, stiffness may also 
contribute to fatigue resistance through altered mechanical properties of muscle.  
Strength deficits as high as 50% or greater have been well documented in children with 
CP. The exact nature of the weakness is unclear and is thought to be a result of either decreased 
central drive to the agonist due to the lesion itself, spasticity, cocontraction, secondary changes 
in the properties of the muscles fibers, or some combination of the above (Damiano, Quinlivan, 
Owen, Shaffrey, & Abel, 2001). Cocontraction refers to the simultaneous activation of agonist 
and antagonist muscles during voluntary movement. Cocontraction, in particular, may impair the 
full activation of the agonist due to reciprocal inhibition, leading to weakness (Milner, Cloutier, 
Leger, & Franklin, 1995; Tyler & Hutton, 1986). Differences in strength have been postulated to 
explain the differences in fatigability observed between older and younger adults (Hunter & 
Enoka, 2001; Pincivero et al., 2003), children and young adults (Kanehisa, Okuyama, Ikegawa, 
& Fukunaga, 1995), and females and males (Hunter & Enoka, 2001; Pincivero et al., 2003). The 
muscle mass or strength hypothesis states that stronger subjects would have more blood flow 
occlusion than weaker subjects at the same relative load, particularly during isometric tasks, 
leading to higher levels of fatigability (Barnes, 1980). Still others feel that stronger individuals 
have a higher susceptibility to fatigue due to the ability to generate higher absolute torque levels 
(Pincivero et al., 2003). 
Although we have previously shown that the knee flexors and extensors in people with 
CP are less fatigable than typically developing peers, possible contributors to the fatigue 
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resistance have yet to be investigated. Therefore, the purpose of this study was to quantify 
spasticity, stiffness, cocontraction, and strength of the quadriceps and hamstrings in a group of 
subjects with mild to moderate CP in order to determine whether these variables are associated 
with fatigue-resistance of these muscle groups. We hypothesized that subjects with spasticity 
would have lower levels of muscle fatigability. In addition, we hypothesized that the magnitude 
of spasticity would be inversely related to the amount of muscle fatigue in the spastic muscle. 
For example, those with spasticity of the hamstrings would have lower levels of muscle fatigue 
of the hamstrings compared to those without hamstring spasticity. Furthermore, higher 
magnitudes of spasticity as measured by resistive torque would be associated with lower levels 
of muscle fatigue. Due to the interrelationships of muscle weakness with stiffness and 
cocontraction, we also hypothesized that higher levels of weakness, stiffness, and cocontraction 
would be associated with lower levels of muscle fatigue about the knee joint.  
Methods 
 
Participants 
 
Seventeen subjects with cerebral palsy (CP) between the ages of 10 and 25 were recruited 
for the study. Physical demographics of the subjects are listed in Table 4.1. All subjects were 
able to ambulate at least a short distance with or without assistive devices. Subjects were 
excluded if they underwent orthopedic surgery within 12 months prior to the testing, received 
Botulinum toxin injections to the quadriceps or hamstrings within 6 months prior to the testing, 
or suffered from knee pain. Passive range of motion of the knee was also assessed prior to testing 
to determine if the subject had sufficient range of motion to complete the test. A control group of 
14 subjects without motor disability (ages 10-24) was used for comparison and illustrative 
purposes. 
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Table 4.1 
Physical Demographics 
  Age   GMFCS 
 
 
Sex range mean/sd Height (m) Weight (kg) I II III 
CP 12F/5M 10 - 23 17.5 ± 5.0 1.5 ± 0.1 47.6 ± 9.9 9 5 3 
Control 11F/3M 10 - 23 16.6 ± 4.4 1.6 ± 0.1 54.0 ± 9.7 na Na na 
M = male; F = female; na = not applicable 
 
 
The study was approved by the Institutional Review Board at our institution. A written 
consent form was obtained from each participant over 18 years of age. A parental permission 
form signed by one parent or legal guardian was required for participants under 18 years of age. 
In addition, the minor was required to read and sign a child assent form (APPENDIX 2). 
Instruments 
 
Isokinetic Dynamometry 
 An isokinetic dynamometer (Biodex Medical Systems Incorporated, Shirley, NY, USA) 
was used to collect angular displacement, angular velocity, and torque data for both the passive 
and active trials. These were then used to calculate strength, spasticity, stiffness, and muscle 
fatigue of the knee flexors and extensors. Consistent throughout the paper, the terms knee 
extension and flexion will refer to the direction of motion, regardless of whether the trial was 
active or passive.  
Electromyography   
Surface electromyography (EMG) of the lateral hamstrings and quadriceps was collected 
with the MA-300 EMG system (Motion Lab Systems, Baton Rouge, LA, USA). The skin of the 
participant was cleansed and abraded with alcohol prep pads before placement of the electrodes. 
The Ag-AgCl bipolar electrode pair was positioned one-third of the distance between the ischial 
tuberosities and the popliteal crease on the muscle bellies of the biceps femoris and 
 52 
semitendinosus. The circular 1.0 cm diameter electrode pair was positioned 2.0 cm, center to 
center, from each other and longitudinally along the muscles. The MA-311 (Motion Lab 
Systems, Baton Rouge, LA, USA) surface EMG pre-amplifiers were placed on the muscle bellies 
of the rectus femoris and vastus medialis, on the proximal and distal one-third of the distance 
between the anterior iliac superior spine and the patella, respectively. A ground electrode was 
placed on the anterolateral surface of the participant’s upper thigh. Proper electrode placement 
was verified through use of the WinDaq Acquisition software (Dataq Instruments, Dayton, OH, 
USA) in conjunction with manual muscle testing of each muscle. The bandpass width used for 
collection was 0 – 500 Hz, and the signal was sampled at 1000 Hz per channel with an 
amplification of up to 20,000. The common mode rejection ratio (CMRR) was 100 dB. The 
EMG was collected using a 12 bit analog to digital conversion board via the EMG system and 
saved for future processing. Angular displacement, angular velocity, and torque data from the 
dynamometer were collected with the EMG data and internally synchronized using the WinDaq 
Acquisition software.  
Protocol 
 
Setup 
The electrodes were positioned as described above. The subject was positioned in the 
Biodex chair in a semireclining sitting position with the thigh horizontal and trunk 70 degrees 
above horizontal. The more involved lower extremity was tested for subjects with bilateral or 
unilateral involvement if they had sufficient motion and mobility in that limb to perform the test. 
The left lower extremity was tested for control subjects. The subject’s knee joint center was 
aligned with the center of rotation of the isokinetic device. The leg was secured against the knee 
attachment pad and additional stabilizing straps around the waist, the trunk, and over the mid-
thigh portion were used to restrain trunk and hip movement during testing. The passive range of 
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motion designated as “comfortable” by the patient was determined and used to set the limits of 
motion for the rest of testing sessions. Subjects were instructed to keep their arms folded across 
their chest for all trials.  
Isokinetic Passive Testing 
The passive testing consisted of repeated extension and flexion of the knee within the 
preset range of motion with a 1 second pause during the reversal of motion. The subjects were 
instructed to relax their muscles. Surface EMG of the quadriceps and hamstrings were monitored 
during the test to provide verification that the muscles were not active. Three passive repetitions 
were performed at 5, 10, 30, 60, 90, and 120 degrees/second. A 30 second rest period was 
provided between each velocity. Peak resistive torque (RT) was calculated for both knee flexion 
and extension motions (Damiano et al., 2002; Damiano et al., 2001).  
Isokinetic Strength Testing  
The subjects performed 5-10 submaximal concentric, reciprocal knee flexion and 
extension repetitions to familiarize themselves with the procedure. The subjects then performed 
3 maximal concentric exertions for each muscle group at 60 degrees per second. One minute of 
rest was given between repetitions to minimize muscle fatigue (Damiano et al., 2001). The 
subjects were instructed to “push” and “pull” their leg against the lever as hard as possible. 
Verbal encouragement and visual feedback of the torque value presented on the monitor was 
used to encourage maximum effort.  
Isokinetic Fatigue Testing  
Five minutes of rest was given prior to the muscle fatigue protocol. The fatigue protocol 
consisted of reciprocal, maximal concentric knee extension and flexion at 60 degrees/second for 
35 repetitions. This protocol was shown to be feasible in a group of subjects with mild to 
moderate CP (Moreau, Li, & Damiano, 2006a). The subjects were instructed to “push” and 
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“pull” their leg against the lever as hard as possible. Strong verbal encouragement was given for 
every repetition to encourage maximal effort on all repetitions. The subject was able to terminate 
the test at any time either verbally or through use of a safety switch.  
Data Analysis 
 
Spasticity 
 Table 4.2 lists all of the abbreviations used to identify variables by category in the data 
analysis. Only data in the constant velocity portion of the passive trials were analyzed, thereby 
negating the effects of inertia. Gravity correction calculation of the limb’s weight was taken 
between 30 and 45 degrees of knee flexion in order to remove the gravitational effects of the 
limb and attachment from each trial. The algorithm provided by the Biodex Advantage Software  
Operations Manual (Version 3.29/3.30) was utilized for the gravity correction. Spasticity was 
measured as the peak resistive torque (RT) during the isokinetic portion of the range at 60 and 
120 degrees/second, with EMG verification of a stretch response. 60 degrees/second was chosen 
because the voluntary tests of strength and muscle fatigue were tested at this speed. Due to the 
velocity dependent nature of spasticity, the fastest speed of 120 degrees/second was also chosen 
as a representative measure of spasticity. Spasticity of the hamstrings was measured as the peak 
RT during passive knee extension (RTH), and spasticity of the quadriceps was measured as the 
peak RT during passive knee flexion (RTQ).  
EMG data were used to verify the presence or absence of a stretch response, or spasticity, 
during each passive trial at 30, 60, 90, and 120 degrees/second separately for the hamstrings and 
quadriceps. Participants were categorized by whether or not they demonstrated hamstrings or 
quadriceps stretch responses. The speed at which the stretch response began, or the velocity 
threshold, was recorded for each subject (Damiano et al., 2002; Damiano et al., 2001).   
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Table 4.2 
List of abbreviations (by category) used to identify the various variables  
Variables (units) Description 
Universal  
KE Knee extension 
KF Knee flexion 
PT (N·m) Peak torque 
Fatigue variables  
Slope PTQ (N·m·rep-1) Slope of the decline in quadriceps PT (KE) over 35 reps 
Slope PTH (N·m·rep-1) Slope of the decline in hamstring PT (KF) over 35 reps 
FIQ (% decline) Fatigue index of quadriceps (% decline in PTKE) over 35 reps 
FIH (% decline) Fatigue index of hamstrings (% decline in PTKF) over 35 reps 
Strength variables  
PTQ (N·m) Strength (PT) of the quadriceps during active KE 
PTH (N·m Strength (PT) of the hamstrings during active KF 
FatPTQ (N·m) PT of quadriceps over all KE repetitions of the fatigue test 
FatPTH (N·m) PT of hamstrings over all KF repetitions of the fatigue test 
Spasticity  
RT (N·m) Resistive torque 
RTQ60 and RTQ120 (N·m) Peak RT of the quadriceps during passive KF at 60 and 120 
degrees/second, respectively 
RTH60 and RTH120 (N·m) Peak RT of the hamstrings during passive KE at 60 and 120 
degrees/second, respectively 
Stiffness  
StiffQ5, StiffQ30, StiffQ60, 
StiffQ90 (N·m·deg-1) 
Stiffness of quadriceps (slope of torque/angle curve) measured 
during passive KF at 5, 30, 60, & 90 deg/sec, respectively 
StiffH5, StiffH30, StiffH60, 
StiffH90  (N·m·deg-1) 
Stiffness of hamstrings (slope of torque/angle curve) measured 
during passive KE at 5, 30, 60, & 90 deg/sec, respectively 
Cocontraction  
CoconQ (%) Cocontraction of quads as % of activity working as an agonist 
CoconH (%) Cocontraction of hams as % of activity working as an agonist 
 
 
Stiffness 
 Gravity correction and removal of the acceleration and deceleration phases of the trials 
were performed as described above. Passive tissue properties can be characterized as viscoelastic 
(Lehmann, Price, deLateur, Hinderer, & Traynor, 1989). Passive elastic stiffness was measured 
by the slope of the resistance torque by angle curve during the constant velocity portion of the 5 
degree per second passive trial in the absence of EMG activity. Simultaneous collection of 
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surface EMG of the quadriceps and hamstrings provided verification that the muscles were not 
active during this slow, passive trial. The slow speed was used in order to minimize the effect of 
velocity and reflexive activity (Lee, Huang, Chen, & Hwang, 2002). In this manner, the 
resistance provided by the passive mechanical properties of the tissues, such as non-active 
muscle tissue, joint capsule, and surrounding connective tissue was measured. For simplification, 
stiffness measured during knee extension will be referred to as stiffness of the hamstrings 
(StiffH), and stiffness measured during knee flexion will be referred to as stiffness of the 
quadriceps (StiffQ). To provide a measure of velocity-dependency, stiffness was also calculated 
as the slope of the resistance torque by angle curve at 30, 60 and 90 degrees/second (Damiano et 
al., 2001). Both reflexive and elastic stiffness play a role in those with spastic responses at these 
higher velocities. We were unable to calculate stiffness at 120 degrees/second in the majority of 
subjects secondary to the truncated constant velocity range.  
Cocontraction 
The recorded EMG data from the strength assessment were full-wave rectified and 
smoothed with a low pass filter at 6 Hz using a fourth-order zero lag Butterworth filter. The 
filtered EMG was separated into a flexion and extension phase during the isokinetic portion and 
the mean absolute value (MAV) was calculated. Hamstring cocontraction (CoconH) during the 
maximal knee extension contraction was calculated as the ratio of the MAV of the biceps 
femoris EMG activity during the extension phase to the EMG activity during the flexion phase, 
multiplied by 100. Quadriceps cocontraction (CoconQ) during the maximal knee flexion 
contraction was calculated as the ratio of the MAV of the rectus femoris EMG activity during the 
flexion phase to the EMG activity during the extension phase, multiplied by 100 (Baratta et al., 
1988; Weir, Keefe, Eaton, Augustine, & Tobin, 1998). 
 
 57 
Strength 
 Torque data from the strength assessment were also gravity corrected and only the 
constant velocity portion was used. Voluntary peak torque (PT) was calculated for each of the 3 
repetitions of the strength test for both extension and flexion. The maximum of these values over 
the 3 repetitions was the measure of strength for each muscle group (Damiano et al., 2001). 
Strength of the quadriceps (StrPTQ) was measured as the voluntary PT during knee extension. 
Strength of the hamstrings (StrPTH) was measured as the voluntary PT during knee flexion. The 
maximum PT over the 35 repetitions of the fatigue protocol was also recorded as a measure of 
strength for the quadriceps (FatPTQ) and the hamstrings (FatPTH). 
Fatigue 
Two accepteded measures of fatigue were computed: 1.) percent decline in peak torque 
over the 35 repetitions, calculated as a Fatigue Index (FI) (Pincivero et al., 2003):   
   





−= %100x
5
5100FI
repshighestPT
repslastPT
 
2.) rate of decline in PT represented by the slope of the linear regression, beginning with the first 
value of the highest 5 consecutive repetitions and ending with the last repetition (Pincivero, 
Gear, & Sterner, 2001). Because FI and slope calculations began with the first value of the 
highest 5 consecutive repetitions, the protocol was extended to 50 repetitions in subjects when 
the initial highest torque value occurred later than the 15th repetition. Torque data from the 
fatigue protocol were gravity corrected and only the constant velocity portion was used as 
described previously. Fatigue of the quadriceps muscle group was measured as the FI (FIQ) and 
slope (SlopePTQ) calculated during knee extension, and fatigue of the hamstrings was measured 
as the FI (FIH) and (SlopePTH) during knee flexion. This fatigue protocol was previously shown 
to be reliable in children and young adults with mild to moderate CP (Moreau et al., 2006a). 
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Statistical Analyses 
Linear regression was used to determine the relationships between the fatigue parameters 
(slope and FI) and stiffness, spasticity, strength, and cocontraction for both knee extension and 
flexion. Stepwise multiple regression analyses were performed in order to identify which of these 
factors or combination of factors best explained the variations in fatigability. The dependent 
variables were the FI and slope for the knee extensors and flexors. Measures of stiffness, 
spasticity, strength, and co-contraction were entered as independent variables. The criterion for 
entry into the regression equation and removal was p < 0.05. An R-Square selection option was 
also run to see if other combinations of variables predicted similar amounts of variance as the 
resulting step-wise regression models. For example, if a two factor model was predicted by the 
step-wise multiple regression analysis, then other two factor models were compared to see if a 
similar amount of variance could be explained with a different combination of variables. One-
way ANOVA was used to test for differences in fatigability between subjects with and without 
hamstring and quadriceps spasticity and control subjects. Tukey’s HSD was used for post-hoc 
analysis. Finally, t-tests were used to test for differences in the peak torque obtained from the 
strength test versus the fatigue protocol for both muscle groups.  
Results 
 
The maximum torque during the fatigue test occurred between the 3rd and 27th repetition 
for the knee extensors (9.3 ± 7.2) and between the 1st and 20th repetition for the knee flexors (5.0 
± 6.1) for the group with CP.  In the control group, the maximum torque during the fatigue test 
occurred on average during the 3rd repetition for both knee extension (3.4 ± 2.1) and knee flexion 
(3.4 ± 3.7). As illustrated in Table 4.3, maximum peak torque of the quadriceps obtained during 
the strength test (PTQ) was significantly less than the maximum torque obtained during the 
fatigue test (FatPTQ) for the group with CP. However, values from the two tests for the 
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hamstrings were similar. No significant differences between the PT values of the strength and 
fatigue tests were observed in the control group for either muscle (Table 4.3). Because strength 
of the quadriceps in the group with CP was underestimated by PTQ in this study and a previous 
study (Moreau et al., 2006a), the PT values obtained during the fatigue test were used in 
subsequent analyses as the measure of strength. After normalizing strength by body weight, the 
subjects with CP were on average 40% and 60% weaker than the age-matched control group for 
the quadriceps and hamstrings, respectively. 
Table 4.3 
Comparison of voluntary peak torque obtained    
during the strength versus the fatigue test 
  
Strength 
test 
Fatigue 
test 
CP    
 Quad 41.2 ± 3.9 55.0 ± 5.1* 
 nQuad 89.9 ± 8.9 120.9 ± 12.0* 
 Hams 22.8 ± 3.2 23.9 ± 2.8 
 nHams 49.8 ± 6.8 52.3 ± 6.2 
Control    
 Quad 110.2 ± 8.8 113.0 ± 9.5 
 nQuad 197.4 ± 10.9 200.9 ± 11.9 
 Hams 63.0 ± 6.4 60.2 ± 5.5 
 nHams 111.7 ± 8.5 107.0 ± 6.9 
         Peak torque (PT) given in N-m ; * = p < .0001;  
         Quad = PT obtained during knee extension; Hams = PT  
         obtained during knee flexion; nQuad = Quad normalized by 
         body weight; nHams = Hams normalized by body weight 
 
Regression Analyses 
Figures 4.1 and 4.2 illustrate the means and SEM of the stiffness and RT values, 
respectively, for the quadriceps and hamstrings. Figure 4.3 illustrates the means and SEM of the 
cocontraction values of the quadriceps (CoconQ) and hamstrings (CoconH). The results of both 
the linear and stepwise multiple regression analyses for the slope of the quadriceps (SlopePTQ) 
as a measure of fatigue are presented in Table 4.4. Strength of the hamstrings and quadriceps  
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Figure 4.1. Mean and SEM of a.) hamstring stiffness and b.) quadriceps stiffness at 5, 30, 60, 
and 90 degrees/second for the group with CP and the control group.  
 
 
 
 
 
 
Figure 4.2. Mean and SEM of a.) resistance torque (RT) of the hamstrings and b.) RT of the 
quadriceps at 60 and 120 degrees/second as a measure of spasticity for the group with CP and the 
control group. 
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Figure 4.3. Cocontraction of the hamstrings (CoconH) and quadriceps (CoconQ) for the group 
with CP and the control group. 
 
Table 4.4 
Linear and stepwise multiple regression analysis of variables potentially related to muscle fatigue 
of the knee extensors as represented by the slope of the decline in peak torque across repetitions 
(SlopePTQ). 
Variables Linear regression 
coefficient (r) p 
Multiple linear 
regression 
parameter est. 
Partial  
R-square 
Model 
R-square p 
FatPTQ  0.69 0.002 - - - - 
FatPTH  0.74 0.001 - - - - 
StiffH5  0.31 0.22 - - - - 
StiffH30  0.20 0.44 - - - - 
StiffH60  0.16 0.53 - - - - 
StiffH90  0.15 0.58 - - - - 
StiffQ5 -0.49 0.04 - - - - 
StiffQ30 -0.43 0.08 - - - - 
StiffQ60 -0.36 0.15 - - - - 
StiffQ90 -0.64 0.02 - - - - 
RTH60  0.20 0.45 - - - - 
RTH120 -0.06 0.83 - - - - 
RTQ60 -0.17 0.53 - - - - 
RTQ120 -0.13 0.64 - - - - 
CoconH -0.57 0.02 -0.004 0.43 0.43 0.03 
CoconQ -0.54 0.03 - - - - 
est. = estimate 
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(FatPTH and FatPTQ) were positively correlated to the SlopePTQ, where those who were 
weaker had lower levels of muscle fatigue of the quadriceps. CoconH and CoconQ were 
inversely correlated to the SlopePTQ, where higher cocontraction was related to lower levels of 
quadriceps fatigability. Stiffness of the quadriceps at both 5 (StiffQ5) and 90 (StiffQ90) 
degrees/second were also inversely correlated to SlopePTQ, such that increased stiffness of the 
quadriceps was related to lower levels fatigability of the quadriceps. Although strength, stiffness,  
and cocontraction of both muscle groups were related to fatigability of the quadriceps in the 
univariate analysis, CoconH was the only significant predictor of SlopePTQ in the multiple 
regression analysis, explaining 43% of the variance. Both univariate linear regression 
coefficients and parameter estimates indicate that increased levels of cocontraction of the 
antagonistic hamstrings muscle group are associated with lower levels of quadriceps fatigability. 
No other single factor models predicted a similar amount of variance in SlopePTQ.  
Table 4.5 illustrates the results of both the linear and stepwise multiple regression 
analyses for the slope as a measure of fatigue of the hamstrings (SlopePTH). Similarly, FatPTH 
and FatPTQ were positively correlated to the SlopePTH, where weaker individuals had lower 
levels of hamstring fatigability. Likewise, StiffQ5, StiffQ90, and CoconH were inversely related 
to fatigability of the hamstrings. Multiple regression analysis revealed that FatPTH and StiffQ5 
were significant predictors of hamstring fatigability as measured by SlopePTH, explaining a total 
of 72% of the variance. Univariate linear regression coefficients and parameter estimates indicate 
that weaker hamstrings and stiffer quadriceps are associated with lower levels of hamstring 
fatigability. No other two factor models predicted a similar amount of variance in SlopePTH.  
None of the variables in the univariate linear regression analysis were significantly 
correlated with the FI of the quadriceps (FIQ), although CoconH approached significance (r = -
0.49, p = 0.056). Only StiffQ90 displayed a significant inverse relationship to FI of the 
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hamstrings (FIH: r = -0.68, p = 0.01). Because only one variable was correlated with FIH and 
none with FIQ, multiple regression analyses were not performed for these variables, and 
subsequent analyses were only performed on the fatigue slope values.  
 
Table 4.5 
Linear and stepwise multiple regression analysis of variables potentially related to muscle fatigue 
of the knee flexors as represented by the slope of the decline in peak torque across repetitions 
(SlopePTH). 
Variables Linear regression 
coefficient (r) p 
Multiple linear 
regression 
parameter est. 
Partial  
R-square 
Model 
R-square p 
FatPTQ  0.54 0.02 - - - - 
FatPTH  0.78 0.001 0.01 0.27 0.27 0.02 
StiffH5  0.27 0.30 - - - - 
StiffH30  0.06 0.81 - - - - 
StiffH60  0.15 0.56 - - - - 
StiffH90  0.13 0.62 - - - - 
StiffQ5 -0.49 0.04 -5.60 0.45 0.72 0.02 
StiffQ30 -0.24 0.36 - - - - 
StiffQ60 -0.22 0.40 - - - - 
StiffQ90 -0.72 0.01 - - - - 
RTH60  0.10 0.70 - - - - 
RTH120 -0.11 0.68 - - - - 
RTQ60 -0.30 0.27 - - - - 
RTQ120 -0.15 0.59 - - - - 
CoconH -0.52 0.04 - - - - 
CoconQ -0.42 0.11 - - - - 
est. = estimate 
 
 
Presence of Spasticity 
 
Out of the 17 subjects with CP, 10 had hamstring spasticity only, none had quadriceps 
spasticity only, 4 had quadriceps and hamstrings spasticity, and 3 had no spasticity of either 
muscle group. Spastic or reflexive stretch responses were detected at 30 degrees/second in 13 of 
the18 muscles with spasticity. In the remaining 5 muscle groups, stretch responses were detected 
at 60 degrees/second in 4 and at 120 degrees/second in 1. All subjects who demonstrated a 
spastic response at a lower velocity also demonstrated a response at the higher velocities. A 
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significant difference was observed between groups for both quadriceps (F3,27 = 13.04, p < 
0.0001) and hamstring (F3,27 = 10.09, p < 0.0001) fatigability as measured by the slope.  Post hoc 
analyses reveal significant differences between the control group without disability and the two 
groups with spasticity for SlopePTQ and Slope PTH as illustrated in Figures 4.4a and 4.4b, 
respectively. The control group was more fatigable than the two groups with spasticity. 
However, there were no significant differences between the control group and the group without 
spasticity for both SlopePTQ and SlopePTH, nor were there any differences between the 3 
groups with CP. 
Discussion 
 
Results of this study indicate that strength, spasticity, stiffness, and cocontraction are 
related to muscle fatigability of the quadriceps and hamstrings, as measured by the slope. More 
specifically, strength was directly related to muscle fatigability, where weaker subjects had lower 
levels of fatigability, regardless of muscle. Cocontraction and quadriceps stiffness, on the other 
hand, were inversely related to muscle fatigability, where higher cocontraction and quadriceps 
stiffness yielded lower levels of hamstrings and quadriceps fatigue. When controlling for 
confounding variables in the multiple regression analysis, the strongest predictors of hamstring 
fatigability were hamstrings strength and quadriceps stiffness (StiffQ5). A positive relationship 
of hamstrings strength and an inverse relationship of quadriceps stiffness (StiffQ5) to hamstring 
yielded lower levels of hamstring fatigability. When controlling for confounding variables in the 
multiple regression analysis, the strongest predictor of quadriceps fatigability was hamstring 
cocontraction. An inverse antagonistic relationship of hamstring cocontraction to quadriceps 
fatigability was observed, where increased cocontraction of the hamstrings was related to lower 
levels of quadriceps fatigability. Furthermore, the presence of spasticity was also able to  
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Figure 4.4. Differences in a.) hamstring fatigability (SlopePTH) and b.) quadriceps fatigability 
(SlopePTQ) as represented by the slope among groups characterized by presence of spasticity: 
control group, none, hamstring spasticity only (Hams), and hamstring and quadriceps spasticity 
(Hams & Quads). * indicates p < 0.01 for post-hoc Tukey HSD pairwise comparisons 
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distinguish between the fatigability of the subjects with CP and the control group, regardless of 
muscle group.   
The direct relationship of strength and muscle fatigue has been observed in other studies 
(Hunter, Critchlow, Shin, & Enoka, 2004; Pincivero, Gear, Sterner, & Karunakara, 2000); 
however, the relationship of muscle stiffness and cocontraction to fatigability has not been 
previously investigated. An antagonistic relationship of fatigability with cocontraction and 
stiffness emerged in the results of the multiple regression analyses. Perhaps this antagonistic 
relationship was due to the mechanical effect of cocontraction and stiffness on the net torque 
measured by the dynamometer. Cocontraction, as well as stiffness of an antagonistic muscle, 
generates opposing joint torque .throughout the range of motion of the agonist. The mechanical 
effect of the opposing torque would be a decrease in the net agonist torque. Hamstring 
cocontraction, in particular, has been previously shown to cause a significant decrease in the net 
moment during knee extension in children with CP (Ikeda, Abel, Granata, & Damiano, 1998). 
Therefore, the lower absolute torque level, or weakness, may predispose the smaller decline in 
quadriceps PT, and thus, a lesser slope value.  
 The presence of spasticity was an important factor that explained the differences in 
fatigability between the control group and the group with CP. Although there were only 3 
subjects without a spastic response in either muscle, there was no significant difference in 
SlopePTQ or SlopePTH between this group and the control group. However, there were 
significant differences between the control group and the 2 groups with spasticity. The effect was 
robust and appeared to be independent of whether spasticity was present in the hamstrings only 
or the hamstrings and quadriceps for both SlopePTQ and SlopePTH. Differences between the 
spasticity groups were not detected probably due to the fact that we had a group with mixed 
quadriceps and hamstrings spasticity rather than a group with isolated quadriceps spasticity. 
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Nevertheless, subjects without spasticity in the group with CP had similar fatigue values as the 
control group for both muscle groups.  
Surprisingly, the magnitude of spasticity of both the hamstrings (RTH) and quadriceps 
(RTQ) was not correlated with either the SlopePTQ or SlopePTH. Perhaps, the small sample size 
and range of RT data were not sufficient to achieve a significant correlation. Our data were 
comparable to a previous study where RT was calculated at 60 and 120 degrees/second for both 
the hamstrings and quadriceps; however, a direct comparison cannot be made between the 2 
studies because the RT was normalized by body weight in the previous study (Damiano et al., 
2001). Stiffness values for both the hamstrings and quadriceps in this study were also 
comparable to the previous study. 
Although the two extremes of stiffness values (Stiff5 and Stiff90) were inversely 
correlated with SlopePTQ and SlopePTH, StiffQ30 and StiffQ60 were not correlated with either 
fatigue measure. StiffQ5 represents the elastic or intrinsic stiffness of the muscle in the absence 
of reflexive activity, whereas stiffness measured at higher velocities is influenced by reflexive 
activity for those with spasticity. Because the onset of stretch reflex activity occurred at either 30 
or 60 degrees/second in the majority of subjects, we would expect greater variability in StiffQ30 
and StiffQ60 in regards to the representation of reflexive stiffness. Furthermore, because of the 
velocity dependent nature of reflexive activity, we would expect StiffQ90 to be a more 
representative measure of elastic plus reflexive stiffness and StiffQ5 to be more representative of 
intrinsic elastic stiffness.  
We observed a significant difference in the PT of the quadriceps measured during the 
strength test (PTQ) versus the fatigue test (FatPTQ) for the group with CP only. This same 
phenomenon was observed in a previous study (Moreau et al., 2006a) and is believed to be of 
great clinical importance. During the strength assessment, knee extension always begins from a 
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static position with a 1 minute rest between trials. However, during the fatigue test knee 
extension is preceded by a pre-stretch of the muscle (active knee flexion) during subsequent 
trials, which may have a potentiation effect on the contractile machinery of the quadriceps. This 
enhancement of force production due to pre-stretch has been observed to be significantly greater 
in subjects post-stroke compared to healthy subjects during stretch-shortening cycles 
(Svantesson, Grimby, & Thomee, 1994). Perhaps force was enhanced in our group of subjects 
with CP due to heightened stretch reflex responses or spasticity during pre-stretch of the 
quadriceps. For the hamstrings, knee flexion is preceded by pre-stretch (active knee extension) 
during all trials of both the strength and fatigue test. The fact that no difference was observed for 
the hamstrings between the two measures provides further support for this hypothesis.  
Low correlations were observed between the FI and other tested parameters with only 
significant correlation between FIH and FIQ observed. Although there was consistency of results 
between the FI and the slope, there were more significant correlations for the slope versus the FI. 
Despite its popularity of use, the high degree of variability of the FI has been a common finding 
(Burdett & Van Swearingen, 1987; Sinacore, Bander, & Delitto, 1994). Greater variability makes 
it difficult to detect changes or relationships between variables and could explain the lack of 
significance. Furthermore, we have previously shown that the FI is influenced greatly by the 
maximum torque value, FI ∝ (∆PT/Max PT)*100% (Moreau et al., 2006b). Therefore, it appears 
that the slope is a more sensitive measure of muscle fatigability than the FI. 
It is important to note that other factors, beyond the scope of this study, such as energy 
metabolism, morphological differences, patterns of motor unit recruitment, and voluntary 
activation may play a role in the differences in fatigability between the two groups. Future 
studies are needed to decipher the influence of these variables on the level of fatigability. Lastly, 
caution should be used in extrapolating the results of this study to muscle groups other than the 
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knee flexors and extensors, as muscle characteristics such as size, fiber type distribution, fiber 
arrangement, recruitment, and rate coding strategies differ considerably across muscle groups. 
In conclusion, the results of this study suggest that the maximum absolute torque level 
played a significant role in the fatigue resistance observed in the group with CP. The opposing 
torque created by cocontraction of the hamstrings, which was inversely related to quadriceps 
fatigability, and the opposing torque generated by intrinsic stiffness of the quadriceps, which was 
inversely related to hamstring fatigability, possibly contributed to the lower net agonist torque 
level. Furthermore, the presence of spasticity, regardless of muscle group, was related to lower 
levels of fatigability compared to control subjects without motor disability.  
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CHAPTER 5: GENERAL DISCUSSION 
 
Summary of Results 
 
 Fatigue is a frequent subjective complaint in individuals with cerebral palsy (CP) and has 
been cited as a cause of worsening disability in adulthood (Bottos, Feliciangeli, Sciuto, Gericke, 
& Vianello, 2001; Jahnsen, Villien, Egeland, Stanghelle, & Holm, 2004). Previous work on 
fatigue in people with CP has focused primarily on the cardiorespiratory system. This approach 
has led to limited success as most authors agree that local muscle factors, such as muscle fatigue 
are responsible for the lower VO2max and limitations in activity (Hoofwijk, Unnithan, & Bar-Or, 
1995; Rose, Haskell, & Gamble, 1993; Unnithan, Dowling, Frost, & Bar-Or, 1996). Therefore, 
the purpose of the experiments presented in Chapters 2, 3, and 4 was to further the measurement 
and understanding of muscle fatigue in the CP population utilizing the WHO ICF (2001) model 
as a conceptual framework. Based on this model, the measurement of muscle fatigue at the body 
function level, the relationship of fatigue to activities and participation, and the possible 
contributing factors to fatigue at the body function level were investigated. 
In Chapter 2, an isokinetic muscle fatigue protocol consisting of the performance of 35 
consecutive knee flexion and extension repetitions at 60 degrees/second was determined to be 
feasible for mild to moderately impaired subjects with CP over a wide age range. Furthermore, 
two established measures of muscle fatigability (fatigue index and rate of decline in peak torque) 
were reliably measured from the muscle fatigue protocol. In Chapter 3, the muscle fatigability of 
the hamstrings and quadriceps in individuals with CP were compared to a control group of age-
matched peers without CP. Contrary to our original hypothesis, the hamstrings and quadriceps in 
individuals with CP were observed to be less fatigable than in age-matched peers without motor 
disability. Furthermore, lower levels of function, participation, and walking velocity were 
associated with lower levels of muscle fatigability in the group with CP. In Chapter 4, it was 
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hypothesized that other impairments at the body function level, such as weakness, spasticity, 
stiffness, and cocontraction, may contribute to the fatigue resistance observed in the subjects 
with CP. Results indicate that hamstring strength and antagonistic quadriceps stiffness were the 
strongest predictors of hamstring fatigability, while cocontraction of the hamstrings was the 
strongest predictor of quadriceps fatigability. Furthermore, the level of fatigability in subjects 
with CP who did not have spasticity did not differ from the control subjects, indicating that 
spasticity may play a role in the fatigue resistance observed in this population. 
Discussion of Results and Future Studies 
 
 The 3 main findings from these experiments are the following 1.) Muscle fatigue of the 
hamstrings and quadriceps can be reliably measured in mild to moderately involved individuals 
with CP utilizing an isokinetic protocol; 2.) The hamstrings and quadriceps of individuals with 
CP are less fatigable than those of age-matched peers without motor disability, and the lower 
levels of fatigability are inversely related to measures of function and participation; and 3.) The 
fatigue resistance observed in the hamstrings and quadriceps of individuals with CP is related to 
weakness, spasticity, stiffness, and cocontraction of the muscles in question.  
 Muscle fatigue has been investigated in healthy adults as well as in other neurological 
populations, such as multiple sclerosis, stroke, and spinal cord injury that present with spasticity 
and other similar impairments to those seen in CP. Although subjective complaints of fatigue 
have been documented in people with CP, muscle fatigue has been overlooked in the assessment 
of muscle performance. Therefore, it was critical to establish a feasible and reliable assessment 
of muscle fatigue in this population. First, it was necessary to define muscle fatigue before 
establishing a measurement protocol. Muscle fatigue, or fatigability, was defined as a reduction 
in the force-generating capacity of the neuromuscular system that occurs during sustained 
activity (Bigland-Ritchie, Johansson, Lippold, & Woods, 1983). Based on this definition, an 
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isokinetic muscle fatigue protocol was tested in people with CP over 10 years of age. This 
protocol was observed to be reliable in mild to moderately impaired children and young adults.  
 Based on this protocol, the results of the 2nd and 3rd experiments indicate that stronger, 
more functional people with and without CP have higher levels of muscle fatigability of the 
hamstrings and quadriceps compared to those with CP who are weaker and less functional. These 
results do not imply that the muscles of people with CP are somehow superior to those without 
disability due to the observed fatigue-resistance. Rather, the results suggest that a certain level of 
muscle fatigability, as measured by the slope and FI, is typical of a normally developed muscle. 
So how do we explain that the knee muscles of people with CP are less fatigable that those 
without motor disability? Results suggest a discernable relationship of agonist and antagonistic 
forces with muscle fatigability. An agonist relationship of hamstring strength and an antagonistic 
relationship of quadriceps stiffness to hamstring fatigability were observed. Similarly, an 
antagonistic relationship of hamstrings cocontraction with quadriceps fatigability was observed. 
The positive relationship between the strength of an agonist muscle and the fatigability of that 
muscle has shown by others and is thought to be the result of muscle mass differences. 
According to the muscle mass or strength hypothesis, stronger subjects have more blood flow 
occlusion than weaker subjects at the same relative load, resulting in greater fatigability (Barnes, 
1980). Others believe that the higher absolute torque level predisposes the muscle to a greater 
rate of decline (Pincivero, Gandaio, & Ito, 2003).  This may be due to a greater proportion of 
type II, fast, fatigable fibers, which are typical of stronger muscles (Miller, MacDougall, 
Tarnopolsky, & Sale, 1993). The inverse relationship between antagonistic stiffness and 
cocontraction with fatigability, however, has not been investigated previously. We have 
proposed a mechanical hypothesis to explain this relationship. According to this hypothesis, 
antagonistic stiffness and cocontraction would generate opposing torque throughout the range of 
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motion of the agonist. Because cocontraction and stiffness are inherently higher in this 
population, the amount of agonist torque negated by these opposing forces would be substantial. 
This would result in a lower measured (net) torque level, hence weakness. Weakness would 
further predispose the muscle to be less fatigable.  
Theoretically, to assess the effect of strength on the level of fatigability, we would need 
to match subjects with and without CP for strength for comparison between groups (Hunter, 
Critchlow, Shin, & Enoka, 2004). Realistically, this would not be feasible, as in our study alone 
we found strength differences as high as 60% between groups. Perhaps, an alternative would be 
to investigate the differences between the groups with a measure of fatigue that is not dependent 
on the maximum torque level. The FI and the slope are both proportional to the difference 
between the highest and lowest torque, which can be influenced by the maximum torque. The FI 
is further inversely proportional to the maximum torque level, as observed in Chapter 4. 
However, Sinacore, Bander, and Delitto (1994) showed that recovery of peak torque of the 
quadriceps after completion of a fatigue protocol is a reliable measure that is not dependent on 
the maximum torque level. Furthermore, the measure was responsive to 12 weeks of endurance 
training, whereas the percentage decline in peak torque (FI) was not altered as a result of 
training. Future studies should investigate the differences in recovery of peak torque between 
subjects with and without CP after completion of the fatigue protocol described in Chapter 2 to 
see if the differences in fatigability persist. The results of this study should provide further 
insight into the influence of maximum torque level, or strength, on the level of muscle 
fatigability.  
In order to further explore the relationship between cocontraction and fatigability, future 
studies should investigate the relative contribution of antagonist muscle activity to the net 
moment measured throughout the fatigue protocol. For example, if both agonist and antagonist 
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force production decline at similar rates during the fatigue protocol for subjects with CP, then the 
torque output should remain relatively constant throughout the protocol due to the reduced 
contribution of the antagonist. This would result in a small rate of decline in PT and hence, a low 
rate of fatigability as measured by the slope. The results of this study would provide direct 
evidence of the contribution of antagonist cocontraction to the rate of decline in peak torque of 
the agonist muscle. Figure 5.1 illustrates a hypothetical situation where the rate of decline (slope) 
of agonist torque is identical for the groups with and without CP, but the magnitude of torque 
output is substantially lower for the group with CP secondary to weakness. The contribution of 
antagonist force production to the net torque remains constant for the control group, as has been 
observed by Kellis (2003) in healthy subjects. In contrast, the magnitude of antagonist force 
production and rate of decline is much greater for the group with CP. Therefore, the result is a 
substantially lower net torque output and a lower rate of decline for the group with CP, similar to 
the results of our experiments. 
The presence of spasticity, regardless of muscle group, was also a contributing factor to 
the lower muscle fatigability observed in the subjects with CP. The fatigability of the subjects in 
the CP group without spasticity did not differ from the control subjects. Only those subjects with 
spasticity of either muscle group had lower levels of fatigability compared to controls. This 
result provides indirect support that spasticity results in alterations of muscle properties that may 
include fiber type changes that would predispose the muscles to a lower rate of fatigue. 
Future studies are needed in order to address the effects of spasticity on fiber type 
composition and the resultant effect on the level of muscle fatigability observed in this 
population. An issue that has not been addressed in these biopsy studies of spastic muscle is the 
presence and amount of spasticity, if any, in the muscles sampled. Both clinically and 
experimentally, it is common to have spasticity in certain muscle groups and not in others  
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(Damiano et al., 2002; Katz, Rovai, Brait, & Rymer, 1992). For example, it is more common to 
have spasticity of the hamstrings than in the quadriceps. However, the relationship of fiber type 
to the amount of spasticity has not been explored. Therefore, if spasticity is believed to result in 
secondary myopathic changes, the presence and degree of spasticity should be documented for 
the muscles in question. Until this is documented and investigated experimentally, we cannot 
accurately say that these findings are representative of “spastic” muscle. Future studies should 
include biopsies of identical muscles across individuals with EMG verification of the presence of 
spasticity of each muscle. Fiber type compositions could then be compared to investigate 
whether or not the relationship exists. The results of this study would shed considerable light on 
the effect of spasticity on muscle fiber type composition and the resulting effect on muscle 
performance.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Hypothetical example of agonist and antagonist contributions to the net joint torque, 
represented by a straight line, over 10 consecutive repetitions for a control group and a group 
with CP. The effect on the rate of the decline in peak torque is represented by the absolute value 
of the slope (b). 
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Clinical Significance 
 
Although previous research has focused on the amelioration of spasticity as a primary 
goal of treatment, current research has shown that other aspects of muscle performance, such as 
strength, have higher correlations with gross motor function and walking velocity, and are 
amenable to treatment. Therefore, most studies of muscle function in people with CP have 
focused on lower extremity strength, thereby overlooking muscle fatigue as an important 
component of muscle function. A search of the medical literature revealed there are no 
established muscle fatigue protocols for people with CP. Therefore, this is the first investigation 
of localized muscle fatigue in this population by means of voluntary contraction in conjunction 
with measures of strength, hypertonia, and function. The establishment of a feasible and reliable 
muscle fatigue protocol in this population has widespread applications for future research as well 
as for clinical assessment. 
The WHO ICF model was developed as a framework to assist in the understanding and 
measurement of health outcomes. By investigating muscle fatigue at the body function level, as 
well as the level of functioning of the individual (activities) and the whole person in a social 
context (participation), we have provided a more comprehensive view of muscle fatigue. For 
example, this series of experiments has provided unique insight into the muscle fatigue 
characteristics of this population and the relationship to function. For example, based on the 
results of our study, a clinician would expect muscle fatigue to increase, not decrease, as walking 
velocity and strength improved as the result of an intervention program in a person with CP. This 
runs counter-intuitive to the view that increased muscle fatigue is a negative symptom that would 
occur in lower functioning patients. Based on our definition and measurement of fatigue, the 
results of our study challenge the notion that less fatigable is better in this population. It raises 
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the question of whether the fatigue resistance observed in this population is the product of 
disordered motor control and possibly, muscle property alterations.   
Traditionally, muscle fatigue was thought to occur exclusively either in the central 
nervous system or the peripheral nervous system. However, since muscle activity depends on the 
integrity of the entire chain of events, muscle fatigue may occur at central and peripheral sites 
simultaneously (McComas, Miller, & Gandevia, 1995). Thus, muscle fatigue should be viewed 
as the result of the interaction of several different processes in both the central and peripheral 
nervous system. This series of experiments provides a unique contribution to the literature, 
thereby supporting the interaction of the central and peripheral nervous system in the process of 
muscle fatigue induced by voluntary muscle contractions in people with CP.  
Lastly, these results provide a better understanding of the possible contributing factors to 
fatigue resistance, improving our understanding of muscle fatigue in this population. In addition, 
the results have increased our understanding of the complex interrelationships among 
impairments in CP, such as strength, cocontraction, spasticity, and stiffness. The results of this 
study open the door for further exploration into this area of study and the possible muscle 
adaptations that may occur secondary to CP. 
Reference List 
 
Barnes, W. S. (1980). The relationship between maximum isometric strength and intramuscular 
circulatory occlusion. Ergonomics, 23, 351-357. 
Bigland-Ritchie, B., Johansson, R., Lippold, O. C., & Woods, J. J. (1983). Contractile speed and 
EMG changes during fatigue of sustained maximal voluntary contractions. 
J.Neurophysiol., 50, 313-324. 
Bottos, M., Feliciangeli, A., Sciuto, L., Gericke, C., & Vianello, A. (2001). Functional status of 
adults with cerebral palsy and implications for treatment of children. Dev.Med.Child 
Neurol., 43, 516-528. 
Damiano, D. L., Quinlivan, J. M., Owen, B. F., Payne, P., Nelson, K. C., & Abel, M. F. (2002). 
What does the Ashworth scale really measure and are instrumented measures more valid 
and precise? Dev.Med.Child Neurol., 44, 112-118. 
 81 
Hoofwijk, M., Unnithan, V., & Bar-Or, O. (1995). Maximal treadmill performance of children 
with cerebral palsy. Pediatric Exercise Science, 7, 305-313. 
Hunter, S. K., Critchlow, A., Shin, I. S., & Enoka, R. M. (2004). Fatigability of the elbow flexor 
muscles for a sustained submaximal contraction is similar in men and women matched 
for strength. J Appl.Physiol, 96, 195-202. 
Jahnsen, R., Villien, L., Egeland, T., Stanghelle, J. K., & Holm, I. (2004). Locomotion skills in 
adults with cerebral palsy. Clin.Rehabil., 18, 309-316. 
Katz, R. T., Rovai, G. P., Brait, C., & Rymer, W. Z. (1992). Objective quantification of spastic 
hypertonia: correlation with clinical findings. Arch.Phys.Med.Rehabil., 73, 339-347. 
Kellis, E. (2003). Antagonist moment of force during maximal knee extension in pubertal boys: 
effects of quadriceps fatigue. European Journal of Applied Physiology, 89, 271-280. 
McComas, A. J., Miller, R. G., & Gandevia, S. C. (1995). Fatigue brought on by malfunction of 
the central and peripheral nervous systems. Adv.Exp.Med.Biol., 384, 495-512. 
Miller, A. E., MacDougall, J. D., Tarnopolsky, M. A., & Sale, D. G. (1993). Gender differences 
in strength and muscle fiber characteristics. Eur.J Appl.Physiol Occup.Physiol, 66, 254-
262. 
Pincivero, D. M., Gandaio, C. M., & Ito, Y. (2003). Gender-specific knee extensor torque, flexor 
torque, and muscle fatigue responses during maximal effort contractions. 
Eur.J.Appl.Physiol, 89, 134-141. 
Rose, J., Haskell, W. L., & Gamble, J. G. (1993). A comparison of oxygen pulse and respiratory 
exchange ratio in cerebral palsied and nondisabled children. Arch.Phys.Med.Rehabil., 74, 
702-705. 
Sinacore, D. R., Bander, B. L., & Delitto, A. (1994). Recovery from a 1-minute bout of fatiguing 
exercise: characteristics, reliability, and responsiveness. Phys.Ther., 74, 234-241. 
Unnithan, V. B., Dowling, J. J., Frost, G., & Bar-Or, O. (1996). Role of cocontraction in the O2 
cost of walking in children with cerebral palsy. Med.Sci.Sports Exerc., 28, 1498-1504. 
 
 
 
 82 
APPENDIX 1: EXPANDED LITERATURE REVIEW  
 
Introduction 
 
This review is designed to build a foundation for understanding muscle fatigue in 
Cerebral Palsy (CP) and its potential role in the disablement process. The relationships between 
muscle fatigue and other impairments will be explored, as well as how fatigue, in general, has 
been shown to impact activity, participation, and quality of life. The World Health 
Organization’s International Classification of Functioning, Disability and Health (ICF) will be 
used as a framework to illustrate this process (Figure A.1) (World Health Organization, 2001). 
The formal definitions of the ICF are provided in Table A.1. 
 
Table A.1 
WHO ICF Model Definitions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Body Functions are physiological functions of body systems (including  
psychological functions).  
  
Body Structures are anatomical parts of the body such as organs, limbs and  
their components.   
  
Impairments are problems in body function or structure such as a 
significant deviation or loss.   
  
  
Activity is the execution of a task or action by an individual.
  
  
Participation is involvement in a life situation.
  
  
Activity Limitations are dif ficulties an individual may have in executing 
  
activities.
  
  Participation Restrictions are problems an individual may experience in 
  involvement in life situations.
  
  Environmental Factors  
  environment in which people live and conduct their lives 
.  
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Figure A.1. The World Health Organization’s International Classification of 
Functioning, Disability and Health (ICF, 2001) 
 
CP describes a collection of disorders “of the development of movement and posture, 
causing activity limitation, that are attributed to non-progressive disturbances that occurred in the 
developing fetal or infant brain” (Bax et al., 2005). CP is not a disease, per se, but rather, a 
descriptive term that describes a heterogeneous group of children who often manifest with 
chronic motor impairment. Although variability exists with respect to the degree of impairments 
individuals with CP may exhibit, common impairments include loss of selective motor control, 
spasticity, muscle weakness, co-contraction, and contractures. In turn, these impairments can 
lead to activity restrictions such as difficulty in walking and other activities of daily living, often 
leading to worsening disability throughout the lifespan.  
Studies over the last fifteen years have documented a gradual onset of newly recognized 
problems in adults with CP, such as fatigue, musculoskeletal pain, and deterioration of functional 
skills (Andersson & Mattsson, 2001; Bottos, Feliciangeli, Sciuto, Gericke, & Vianello, 2001; 
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Cathels & Reddihough, 1993; Gajdosik & Cicirello, 2001; Jahnsen, Villien, Aamodt, Stanghelle, 
& Holm, 2004; Jahnsen, Villien, Egeland, Stanghelle, & Holm, 2004; Jahnsen, Villien, 
Stanghelle, & Holm, 2003; Murphy, Molnar, & Lankasky, 1995; Pimm, 1992). These problems 
manifest in adolescence and early adulthood and have consequences for activities and 
participation in work and social situations. Furthermore, these studies provide evidence of the 
progression of certain impairments in CP and the need for targeted interventions throughout the 
life span, despite the non-progressive brain lesion (Figure A.2). 
Physical fatigue, in particular, has been identified as a significant impairment in adults 
with CP compared with the general population and has been significantly associated with 
deterioration of functional skills, bodily pain, limitations in physical and emotion role function, 
and low life satisfaction (Jahnsen et al., 2003) (Figure A.2). In fact, adults with CP report fatigue 
as a main cause of the deterioration or cessation of their walking ability (Bottos et al., 2001; 
Jahnsen et al., 2004; Murphy et al., 1995). Murphy et al. (1995) reported that 75% of subjects 
ceased to walk by the age of 25 due to fatigue and inefficiency of ambulation. Jahnsen et al. 
(2004) reported that 44% of subjects had deterioration of walking due to fatigue, pain, and lack 
of adapted physical activity. However, fatigue was assessed subjectively in these studies through 
the use of questionnaires and interviews. 
The term “fatigue” has been subjectively used to describe a multitude of mental and 
physical symptoms and is often confused with other symptoms, such as weakness (Schwid, 
Covington, Segal, & Goodman, 2002). Therefore, these self-report questionnaires may not be 
adequate in the assessment of fatigue. Jahnsen et al. (2003) was the only study to divide the 
questionnaire into mental and physical fatigue components for separate analysis. Compared to 
the general population, adults with CP report significantly more physical, but not more mental 
fatigue. Despite the overwhelming evidence that physical fatigue is a significant impairment in 
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this population, there are no studies to date that have quantitatively assessed physical fatigue in 
this population.  
 
Figure A.2. The World Health Organization’s International Classification of Functioning, 
Disability and Health (ICF, 2001) illustration of the relationships between fatigue (body 
function) and activity limitations and participation. The relationship between fatigue and low life 
satisfaction is also illustrated.  
 
 
Further support for the existence of muscle fatigue in individuals with CP comes from 
studies of energy expenditure. Because of the frequent clinical observation of fatigue in children 
with CP, previous studies have investigated cardiovascular endurance (Lundberg, 1978; Rose, 
Haskell, & Gamble, 1993; Unnithan, Dowling, Frost, & Bar-Or, 1996). Rose et al. (1993) 
demonstrated that the cardiorespiratory response to walking at submaximal level of work was not 
significantly different for children with cerebral palsy as compared to a healthy control group. In 
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addition, Dahlback and Norlin (1985) reported that children with CP became fatigued while 
working at levels less than 50-60% of maximal oxygen uptake during treadmill walking, 
indicating that local muscle fatigue was responsible for the exhaustion. Furthermore, McNevin, 
Coraci, and Schafer (2000) observed a significant increase in perceived exertion without a 
concomitant increase in heart rate during an incremental gait speed test. The authors suggest this 
was possibly due to fatigue. Similar results have been observed in the upper extremities of 
children with CP. In one study, cardiorespiratory endurance during an arm ergometer test did not 
differ between subjects with CP and controls at 75% VO2 and maximum heart rate (Tobimatsu, 
Nakamura, Kusano, & Iwasaki, 1998). Subjects with CP also stopped the ergometer test 
prematurely at 75% VO2 max because of arm muscle fatigue. Collectively, this evidence 
provides support that local muscle fatigue rather than cardiorespiratory factors may be 
responsible for the exhaustion observed in submaximal states.  
Fatigue has also been studied extensively in other neurological populations with upper 
motor neuron lesions that present with spasticity and other similar impairments to those seen in 
CP. Although there are similar documented complaints of fatigue in other neurological 
populations via questionnaires and fatigue scales (Sharma, Kent-Braun, Mynhier, Weiner, & 
Miller, 1995; Staub & Bogousslavsky, 2001), objective assessments of fatigue have been 
measured. Muscle fatigue, in particular, has been quantitatively assessed in MS and spinal cord 
injury (SCI) (de Haan A., de Ruiter, van der Woude, & Jongen, 2000; Lambert, Archer, & 
Evans, 2001; Lenman, Tulley, Vrbova, Dimitrijevic, & Towle, 1989; Miller, Green, Moussavi, 
Carson, & Weiner, 1990). Muscle fatigue as used here is defined as a decline in the force-
generating capacity of the neuromuscular system, which occurs during sustained activity 
(Bigland-Ritchie, Johansson, Lippold, & Woods, 1983). The commonality among these studies is 
that muscles of individuals with MS and SCI are more fatigable than those without pathology. 
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 Perhaps the most extensive evidence of muscle fatigue in neurological populations is 
from studies of MS, as fatigue is one of the most common and disabling symptoms in this 
disease (Schwid et al., 2002). However, unlike CP, MS is a progressive neurological disorder 
with differing pathology. The most similar upper motor lesion to CP would be cerebrovascular 
accident (CVA), characterized by unilateral damage to the cerebral cortex. However, studies on 
this population are limited, and results are equivocal. When comparing the involved to the 
uninvolved contralateral side, decreased levels of fatigue (Riley & Bilodeau, 2002; Toffola, 
Sparpaglione, Pistorio, & Buonocore, 2001) and no significant differences (Sunnerhagen, 
Svantesson, Lonn, Krotkiewski, & Grimby, 1999; Svantesson, Osterberg, Grimby, & 
Sunnerhagen, 1998; Svantesson, Sunnerhagen, Carlsson, & Grimby, 1999) were observed. The 
discrepancy among studies may be explained by differing methodology, muscles studied, and 
subject characteristics. Methodological differences include the use of electrical stimulation 
techniques (Riley et al., 2002; Toffola et al., 2001), isokinetic dynamometry (Sunnerhagen et al., 
1999; Svantesson et al., 1999), and the standing heel-rise test (Svantesson et al., 1998), which 
may partially explain the different results. In fact, the heel-rise has not been validated as a 
measure of fatigability. Riley and Bilodeau (2002) studied the upper extremity, where the others 
studied different lower extremity muscles. Among the studies where no differences were 
observed, the subjects were ambulatory with only minor motor impairment. In fact, two of the 
three studies reported that spasticity was absent (0 on the Ashworth Scale) in the studied 
plantarflexors of all subjects (Svantesson et al., 1998; 1999). The mild impairment level of these 
subjects may explain why there were no observed differences between the paretic, non-paretic, 
and control sides. Regardless of the measurement technique utilized, considering that we know 
the ipsilateral “uninvolved” extremity is often affected in CVA (Baskett, Marshall, Broad, Owen, 
& Green, 1996), it may not be valid to compare the two sides without a control group. In 
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summary, CP is a lifelong disorder, which distinguishes it further from these other neurological 
disorders and as such, these results cannot be extrapolated to CP without further investigation. 
Purpose and Clinical Significance 
 
The purpose of this paper is to review the evidence implicating muscle fatigue as a 
significant impairment in people with CP and to discuss potential contributors of fatigue in this 
population. Although previous research has focused on the amelioration of spasticity as a 
primary goal of treatment, current research has shown that other aspects of muscle performance, 
such as strength, have higher correlations with gross motor function and walking velocity, and 
are amenable to treatment (Damiano & Abel, 1998; Damiano, Kelly, & Vaughn, 1995; MacPhail 
& Kramer, 1995). A critical aspect of muscle performance is endurance, or resistance to fatigue, 
and this area of performance has not been substantiated in individuals with CP. Therefore, a 
better understanding of muscle fatigue or endurance in this population and its relationship to 
other impairments and activity limitations will lead to improved treatment programs. Improved 
treatment aimed at addressing fatigue may ultimately improve the health related quality of life in 
these individuals, thereby delaying the onset of worsening disability with age. 
Muscle Fatigue 
 
Definition 
 
Because of the broad use of the term fatigue, it is important to operationally define 
fatigue. For purposes of this review, muscle fatigue will be defined as a reduction in the force-
generating capacity of the neuromuscular system, which occurs during sustained activity 
(Bigland-Ritchie et al., 1983). Muscle endurance, on the other hand, is resistance to fatigue or the 
ability to withstand fatigue. These terms are often used interchangeably throughout the literature 
with muscle endurance tests often employed to assess muscle fatigue (Jones & Stratton, 2000).  
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Mechanisms 
 
Fatigue is a common occurrence in the everyday life of individuals with neurological 
disorders as well as in able-bodied individuals (Sharma et al., 1995; Staub & Bogousslavsky, 
2001). The perception of fatigue is very subjective, with complaints such as feelings of 
weakness, lack of energy, and lassitude. Objectively, however, fatigue has been defined as a 
reduced capacity to maintain a required physical or mental output (Staub & Bogousslavsky, 
2001). Although not the focus of this paper, it is important to mention that fatigue can occur in 
several different central and peripheral sites, such as the following: 1.) primary motor cortex 
activation, 2.) central nervous system drive to motor neurons, 3.) muscles and motor units that 
are activated, 4.) neuromuscular propagation, 5.) excitation-contraction coupling, 6.) the 
availability of metabolic substrates, 7.) intracellular mechanisms, 8.) contractile apparatus, and 
9.) muscle blood flow (Bigland-Ritchie, 1981). Traditionally, fatigue was thought to occur 
exclusively either in the central nervous system or the peripheral nervous system. However, 
since muscle activity depends on the integrity of the entire chain of events, fatigue may occur at 
many sites simultaneously (McComas, Miller, & Gandevia, 1995). Thus, fatigue should be 
viewed as the result of the interaction of several different processes in both the central and 
peripheral nervous system. 
Contributors to Muscle Fatigue in Individuals with CP 
 
Introduction 
 
 Central nervous system lesions may cause impaired central drive to the motoneurons, or 
central fatigue. However, it is not specific to the underlying disorder. In other words, upper 
motor neuron lesions do not exclusively induce central fatigue as a consequence of the lesion 
site. Rather, individuals with upper motor neuron disorders generally demonstrate both central 
and peripheral fatigue factors (de Haan A. et al., 2000; Lenman et al., 1989; Miller et al., 1990). 
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The relationships among these factors are usually quite complex and vary among disorders 
(Figure A.3).  
In addition to these factors, CP is a multifaceted disorder and as such, complex 
interrelationships exist among upper motor neuron lesion impairments. The relationships among 
muscle fatigue and other impairments are important in the understanding of fatigue, as these 
impairments may, in fact, contribute directly or indirectly to muscle fatigue. As a result, four 
contributors to fatigue at the impairment/body function level have been identified and will be 
discussed: weakness, co-contraction, spasticity, and stiffness. Muscle adaptations in spastic 
disorders will be also be highlighted, as these factors may play an important role in the process 
of fatigue (Figure A.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.3. Diagram illustrating the relationships between central and peripheral factors of 
muscle fatigue in upper motoneuron (UMN) lesions. (LMN = lower motoneuron). Modified 
from McComas et al., 1995. 
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Muscle Adaptation in Spastic Disorders 
 
Definitions 
 Lesions to the central nervous system, also known as upper motor neuron lesions, result 
in hypertonia or an increased resistance to passive muscle elongation (Stolov, 1966). 
Unfortunately, the term “spasticity”, a component of hypertonia, is frequently and non-
specifically used to describe all aspects of hypertonia in addition to other upper motor neuron 
signs, such as clonus and spasms. Hypertonia is associated with an increased sensitivity of the 
stretch reflex (reflex component) and with changes in muscle and connective tissue properties 
(non-reflexive component) (Malouin, Bonneau, Pichard, & Corriveau, 1997). The reflexive 
component, also know as spasticity, is defined as a velocity-dependent increased resistance to 
movement due to hyperexcitable stretch reflexes (Lance, 1980). Passive stiffness, on the other 
hand, denotes the non-reflexive components, such as changes in muscle tissue, joint capsules, 
and surrounding connective tissue, which are not velocity-dependent (Singer, Dunne, & Allison, 
2001). Rather, stiffness is a length-dependent resistance to movement. It should be noted that 
there is also a non-reflexive, velocity dependent component known as viscosity. However, 
viscosity has been observed to contribute insignificantly to passive resistance in CP (Damiano, 
Quinlivan, Owen, Shaffrey, & Abel, 2001). For clarity, the terms spasticity (reflexive) and 
stiffness (non-reflexive) will be used throughout the review paper as described above.  
Introduction 
 
Although the primary lesion of CP is neural, it is important to discuss the properties of 
spastic muscle. It has been well established that muscle properties adapt to the amount and type 
of neural stimulation that is imposed upon them. Therefore, investigation of the muscle changes 
which occur secondary to CP can provide insight into the effects of the disease process on 
muscle characteristics over an extended period of time (Lieber, Steinman, Barash, & Chambers, 
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2004). In general, fiber type distribution and muscle fiber size are indicators of the amount and 
type of activity imposed upon a muscle and as such, are often investigated in spastic muscle in 
order to determine a muscle’s usage pattern (Lenman et al., 1989; Miller et al., 1990; Rose et al., 
1994). Predominance of a particular fiber type can influence fatigue, as Type I (slow twitch) 
fibers are more fatigue-resistant, while Type II (fast twitch) fibers are more fatigable (Burke, 
Levine, Tsairis, & Zajac, 1973; Thorstensson & Karlsson, 1976). Therefore, the investigation of 
fiber type predominance in individuals with CP will provide insight into muscle fatigue in this 
population. 
Increased/Decreased Use Models 
 
Two models of muscle usage have been extensively described in the literature and serve 
as templates to describe the changes that occur in skeletal muscle with either increased or 
decreased use. Increased use models, such as chronic electrical stimulation or endurance 
exercise, result in muscle fiber hypertrophy and an increased percentage of type I, slow and 
oxidative, fibers due to transformation of fast to slow twitch fibers (Eisenberg & Salmons, 1981; 
Lieber, 1986; Roy, Meadows, Baldwin, & Edgerton, 1982). On the other hand, decreased use 
models, such as reduced activity, immobilization, and spinal cord isolation or injury, result in 
muscle fiber atrophy and transformation to a greater proportion of type II, fast and glycolytic, 
fibers (Booth & Kelso, 1973; Grossman, Roy, Talmadge, Zhong, & Edgerton, 1998; Lieber, 
Friden, Hargens, & Feringa, 1986a; Lieber, Johansson, Vahlsing, Hargens, & Feringa, 1986b). 
Two schools of thought have emerged regarding the effect of spasticity on muscle properties. 
One is that spasticity leads to muscle disuse, while the other purports that spasticity results in 
chronic muscle overactivity as seen in increased use models (Lieber et al., 2004). Although it 
appears likely that spasticity represents an increased use model due to chronic over-activity, 
there has been no consensus on fiber type predominance in spastic disorders. There are biopsy 
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reports of increased percentages of Type I fibers (Dietz, Ketelsen, Berger, & Quintern, 1986; Ito 
et al., 1996; Marbini et al., 2002; Rose et al., 1994), increased percentages of Type II fibers 
(Carroll, Gallagher, Seidle, & Trappe, 2005; Kent-Braun et al., 1997; Ponten, Friden, Thornell, 
& Lieber, 2005; Sjostrom, Fugl-Meyer, Nordin, & Wahlby, 1980), or no change in fiber type 
distribution (Booth, Cortina-Borja, & Theologis, 2001; Castle, Reyman, & Schneider, 1979; 
Romanini, Villani, Meloni, & Calvisi, 1989). As a result, it appears that spastic muscle may not 
be adequately represented by either model. These conclusions in the literature regarding the 
effect of spasticity on muscle properties are deduced across a wide range of diagnoses with 
spasticity (Lieber et al., 2004). Therefore, it is important to discuss the muscle properties in 
individuals with CP alone, as these other diagnoses (MS and SCI) may present confounding 
issues, such as adult versus pediatric onset of spasticity. 
Muscle Properties in Individuals with CP 
 
Specific to individuals with CP, literature suggests that there may be significant 
secondary effects of CP on muscle tissue itself. Muscle abnormalities such as changes in muscle 
fiber size and fiber type distribution, collagen accumulation, and increased stiffness of spastic 
muscle cells have been extensively reported (Booth et al., 2001; Castle et al., 1979; Friden & 
Lieber, 2003; Ito et al., 1996; Marbini et al., 2002; Romanini et al., 1989; Rose et al., 1994). A 
common finding among these studies, however, is an increase in fiber size variability, which is 
representative of a pathological but non-specific skeletal muscle abnormality (Lieber et al., 
2004). 
However, there is also no general consensus as to whether spastic muscles in individuals 
with CP represent an increased or decreased use model. For example, Ito et al., Marbini et al., 
and Rose et al. identified a predominance of Type I fibers, while Castle et al. and Romanini et al. 
showed no change. Methodological issues regarding biopsy studies include the number of fibers 
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sampled, the variability in fiber type and fiber size between muscles, whether different muscles 
are being used to compare control subjects to those with pathology, and the variability in severity 
of disease or clinical presentation (Lieber et al., 2004). These studies sampled muscle fibers 
across numerous different muscles and in a wide range of ages (Castle et al., 1979; Ito et al., 
1996; Marbini et al., 2002; Romanini et al., 1989; Rose et al., 1994). In addition, only 200 to 300 
fibers per biopsy were sampled (Castle et al., 1979; Ito et al., 1996; Marbini et al., 2002; 
Romanini et al., 1989; Rose et al., 1994) or no specifics were reported (Marbini et al., 2002; 
Romanini et al., 1989). Only one study had a control group but examined historical pathological 
specimens from different muscles (Rose et al., 1994). Therefore, it is not surprising that there is 
no general consensus as to whether muscles in individuals with CP represent an increased or 
decreased use model.  
An issue that has not been addressed in these biopsy studies of “spastic” muscle is the 
degree of spasticity present, if any, in the muscles sampled. Both clinically and experimentally, it 
is common to be unable to detect spasticity in certain muscle groups while detecting it in others 
(Damiano et al., 2002; Damiano et al., 2001; Katz, Rovai, Brait, & Rymer, 1992). Therefore, if 
spasticity is believed to result in secondary myopathic changes, the presence and degree of 
spasticity should be documented for the muscles in question. Until this is documented and 
investigated experimentally, we cannot accurately say that these findings are representative of 
“spastic” muscle. Rather, these histopathological results are representative of muscles involved 
in upper motor neuron lesions. With this in mind, Ponten et al. (2005) indirectly provided insight 
into the preferential affect of spasticity on muscle properties in CP. The aim of this study was to 
determine whether different muscle groups in the same individuals with CP are affected 
differentially by the disease process. Therefore, biopsies of the wrist flexors and extensors were 
sampled in the same individuals with CP. Furthermore, Ponten et al. addressed some of the 
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earlier methodological concerns by testing a smaller age range of five years and sampling over a 
thousand fibers per biopsy. Results revealed increased fiber type variation and decreased fiber 
size for the wrist flexors as compared to the extensors. More importantly, there was a 
significantly greater percentage of type IIb, fast fatigable, fibers in the flexors as compared with 
the extensors. It is well known that spasticity affects the upper extremity flexors greater than the 
extensors and for this reason, the wrist flexors are often the site of tendon transfers (Friden & 
Lieber, 2003; Katz et al., 1992). Although spasticity was not measured in this study, all subjects 
were undergoing tendon transfers or flexor tendon lengthenings. Therefore, we can infer with 
some degree of confidence that the wrist flexors were spastic and had greater levels of spasticity 
than the extensors. The authors concluded that the increased percentages of Type IIb fibers and 
decreased fiber size in the wrist flexors as compared to the extensors provides the most sound 
evidence that spasticity in CP may represent a decreased-use model. However, further research is 
needed to verify this assumption.  
Weakness 
 
The presence of weakness in muscles of individuals with CP as compared to age-matched 
controls has been well documented (Damiano, Vaughan, & Abel, 1995; Wiley & Damiano, 
1998). The exact nature of the weakness is unclear and is thought to be a result of either 
decreased central drive to the agonist due to the lesion itself, spasticity, co-contraction, 
secondary changes in the properties of the muscles fibers, or some combination of the above 
(Damiano et al., 2001). In fact, leg strength has been observed to be correlated to self-selected 
walking speed and to the Gross Motor Function Measure (GMFM) in children and adolescents 
with CP (Damiano & Abel, 1998; Kramer & MacPhail, 1994). As a consequence, weakness is 
considered one of the primary contributors to motor dysfunction in individuals with CP. 
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Weakness in upper motor neuron disorders is often accompanied by disuse, as the 
individual tries to conserve strength by resting or by ceasing to perform tasks that are tiring. 
Disuse can reduce the ability of the higher motor centers to recruit motoneurons maximally, 
leading to fatigue (McComas et al., 1995). As discussed previously, muscles respond to the 
amount and type of activity that is imposed upon them. Disuse, or decreased use models, result 
in muscle fiber atrophy and transformation to a greater proportion of type II, fast and glycolytic, 
fibers (Booth & Kelso, 1973; Grossman et al., 1998; Lieber et al., 1986a; Lieber et al., 1986b). 
Therefore, weakness can also lead to increased numbers of type II fibers, which are more 
fatigable. As a result, weaker muscles may demonstrate greater levels of fatigability.  
A secondary consequence of weakness and muscle atrophy is the recruitment of more 
motor units or the greater frequency of excitation required to perform a given task (Edgerton, 
Roy, Allen, & Monti, 2002). Normally, the force of a muscular contraction is determined by both 
firing rate or rate modulation and the recruitment of additional motor units (Deluca & Erim, 
1994). In addition, smaller motor units are recruited first, followed by larger motor units. This 
regulation serves to decrease the occurrence of fatigue by ensuring that the larger, more fatigable 
units are recruited later in the contraction (Calcancie & Bawa, 1990). Recruitment and rate 
modulation have been shown to be impaired in stroke patients with hemiparesis (Gemperline, 
Allen, Walk, & Rymer, 1995; Jakobsson, Grimby, & Edstrom, 1992; Rosenfalck & Andreassen, 
1980). In particular, Gemperline et al. studied the upper extremity muscles of six subjects with 
hemiparesis and showed that motor units were recruited at lower thresholds and failed to increase 
firing rates with increased muscle activation. As a result, additional force was generated 
primarily through increased recruitment rather than rate modulation. They concluded that the 
inability to increase firing rates may alter the precise match between the properties of the 
motoneuron and the mechanical properties of the muscle fibers, leading to fatigue and weakness. 
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As a consequence of recruiting more motor units, the overall fatigability will increase because 
increased numbers of upper threshold units will be recruited.  
Working at a higher capacity during everyday tasks secondary to weakness was first 
described by Pimm (1992) as “physiological burn-out” in adults with CP. In other words, 
working at a greater load relative to maximum on a daily basis can cause the system to become 
overburdened and physical function to deteriorate (de Haan A. et al., 2000; Pimm, 1992). 
Deterioration of function leads to disuse. Disuse exacerbates weakness, and a vicious cycle 
develops. Combined with an increase in perceived effort, fatigue is sure to develop.  
Co-contraction 
 
 Co-contraction refers to the simultaneous activation of agonist and antagonist muscles 
during voluntary movement. Although co-contraction occurs normally in everyday activities, it is 
excessive in individuals with CP. Co-contraction in persons with upper motor neuron lesions is 
thought to be caused by reciprocal facilitation/excitation of the agonist and antagonist 
(Myklebust, Gottlieb, Penn, & Agarwal, 1982) or decreased disynaptic or presynaptic reciprocal 
inhibition of the antagonist muscle during agonist activation (Morita, Crone, Christenhuis, 
Petersen, & Nielsen, 2001). Co-contraction has been suggested to generate opposing torque 
throughout the range of motion (Baratta et al., 1988). In addition, it may impair the full 
activation of the agonist due to reciprocal inhibition (Milner, Cloutier, Leger, & Franklin, 1995; 
Tyler & Hutton, 1986). Therefore, co-contraction could reduce the efficiency of force output, 
leading to fatigue. It is of importance to note that neither the antagonistic moment (Kellis, 2003) 
nor the electromyography (EMG) activity (Kellis & Kellis, 2001) has been shown to change 
during an isokinetic fatigue task in pubescent boys. Therefore, the contribution of the antagonist 
co-contraction to the force output should remain constant throughout a fatigue task. 
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Further support for this hypothesis comes from studies of energy expenditure during gait 
in children with CP. It has been established that children with CP have a lower maximal oxygen 
uptake (VO2 max) as compared with able bodied peers during tests of cycling and treadmill 
walking (Hoofwijk, Unnithan, & Bar-Or, 1995; Lundberg, 1978). On average they also have a 
three-fold increase in submaximal walking energy expenditure (Campbell & Ball, 1978). 
Dahlback and Norlin (1985) reported that children with CP became fatigued while working at 
submaximal levels less than 50-60% of maximal oxygen uptake during treadmill walking. They 
concluded that local muscle factors rather than cardiopulmonary factors were responsible for the 
exhaustion. Furthermore, Unnithan et al. (1996) reported a positive relationship between co-
contraction of lower extremity muscles in children with CP and the elevated energy cost of 
treadmill walking at submaximal speeds. Children with CP also complain of fatigue at these 
submaximal walking intensities considered slow for able-bodied peers (Berg, 1970; Dahlback & 
Norlin, 1985; Unnithan et al., 1996). Therefore, high levels of co-contraction may be responsible 
for the early fatigue of muscles, thereby contributing to the reduction in VO2 max at maximal 
exercise intensity.  
Spasticity 
 
It is well-recognized that many children with CP have spasticity, or a velocity-dependent 
increased resistance to movement due to hyperexcitable stretch reflexes (Lance, 1980). Although 
spasticity was once considered the primary cause of motor dysfunction in individuals with CP, it 
is now believed that other impairments, such as weakness, are more detrimental to function 
(Damiano & Abel, 1998; Sahrmann & Norton, 1977). Furthermore, spasticity has been observed 
to have a weak to absent relationship to strength (Damiano et al., 2001; Ross & Engsberg, 2002) 
and only a weak to moderate relationship to function (Damiano et al., 2001). Since muscle 
endurance, like strength, is also a component of muscle performance, perhaps spasticity will 
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have a weaker or no relationship to muscle endurance as well. Nevertheless, spasticity is an 
important component of the upper motor neuron syndrome. Therefore, the potential long-term 
and short-term effects of spasticity on muscle fatigability are worth investigating.  
In regards to long-term muscle adaptation to spasticity in CP, there is no consensus on 
whether spasticity represents an increased or decreased use model (Booth et al., 2001; Castle et 
al., 1979; Ito et al., 1996; Marbini et al., 2002; Ponten et al., 2005; Romanini et al., 1989; Rose et 
al., 1994). If spasticity leads to disuse, then spastic muscles should be more fatigable due to 
increased numbers of Type II fibers as seen in decreased use models. In turn, if spasticity leads 
to muscle overactivity, then spastic muscles should be more fatigue-resistant due to increased 
numbers of Type I fibers as observed in increased use models. Perhaps, fiber type predominance 
may be dependent upon the muscle studied and the amount of spasticity in that particular muscle. 
It is well established that different muscles have different fiber type distributions (Edstrom & 
Nystrom, 1969); however, the relationship of fiber type to the amount of spasticity has not been 
explored. The first histopathological study in CP reported a variety of patterns of Type I/II 
atrophy and hypertrophy depending on the muscle biopsied and the degree of spasticity or 
severity of each subject (Castle et al., 1979). However, a definitive relationship could not be 
ascertained. Further support for this hypothesis stems from the original work of Ponten et al. 
(2005). In this study, the presumed spastic wrist flexors were found to have increased amounts of 
type II, fast fatigable fibers as compared to the less spastic wrist extensors. If the degree of 
spasticity does indeed play a part in fiber type predominance, then the amount of spasticity 
should influence the development of fatigue accordingly. Future muscle-specific biopsy studies 
in conjunction with spasticity assessment are needed to explore this hypothesis. 
It is important to note that these muscle fiber changes are the result of long-term 
spasticity. However, fatigue is not solely determined by muscle fiber type. From a short-term 
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perspective, spasticity could impair the maximum force output of the agonist, secondary to the 
hyperexcitable stretch reflex. Therefore, independent of fiber type changes, spasticity could also 
result in an immediate reduction in the efficiency of force output, which would lead to fatigue.  
Stiffness 
  
Literature suggests that the properties of muscles in individuals with CP are very 
different from normally developed muscles, including collagen accumulation (Booth et al., 2001) 
and increased stiffness at both the cellular (Friden & Lieber, 2003) and whole muscle level 
(Hufschmidt & Mauritz, 1985). This is of no surprise, considering the subjective complaints of 
tightness and stiffness by individuals with CP and the resistance felt upon passive movement of 
the extremities.  
Dietz, Quintern, and Berger (1981) first suggested that that muscle hypertonia is mainly 
due to secondary changes in spastic muscles and that these altered mechanical properties 
contribute to muscle stiffness during gait. They observed increased EMG activity of the anterior 
tibialis without a concomitant increase in ankle dorsiflexion during the swing phase compared to 
controls. Furthermore, there was no excessive EMG activity of the gastroc/soleus and no 
evidence of contracture. They concluded that the altered mechanical properties of the 
gastroc/soleus muscle fibers themselves were responsible for the limited ankle dorsiflexion. This 
hallmark study spurred numerous investigations into this phenomenon.  
It has also been suggested that increased stiffness may be a compensation for weakness, 
thus allowing better utilization of elastic energy during functional activities, such as gait 
(Lamontagne, Malouin, & Richards, 2000; Svantesson & Sunnerhagen, 1997). Lamontagne et al. 
reported that the passive stiffness contribution to the total plantarflexor moment in individuals 
with CVA was greater on the weaker, affected side as compared to controls during gait. Thus, 
the affected plantarflexors in subjects with CVA appeared to utilize passive stiffness to 
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compensate for weakness as compared to the healthy controls. Svantesson & Sunnerhagen 
(1997) reported a similar observation during controlled stretch-shortening cycles of the 
plantarflexors in individuals with CVA. Furthermore, in a follow-up study in healthy adults, 
fatigue, measured as the number of heel-rises performed to exhaustion, was negatively correlated 
to the amount of stiffness (Svantesson, Carlsson, Takahashi, Thomee, & Grimby, 1998). 
Increased stiffness was thus suggested to enhance the development of fatigue. Therefore, 
stiffness, as a compensation for weakness, may be directly related to muscle fatigue. 
Furthermore, stiffness (quantified as the slope of the torque/angle curve) has been observed to 
have a stronger relationship to both strength and function as compared to quantitative measures 
of spasticity (Damiano et al., 2002; Damiano et al., 2001). In accordance, perhaps stiffness will 
have a stronger relationship to muscle fatigue than spasticity.  
Methods of Measurement 
 
Introduction 
 
 Muscle fatigue, or muscle endurance, has been studied using a wide variety of exercise 
protocols and assessment methods. Based on the definition of muscle fatigue as a reduction in 
the force-generating capacity of the neuromuscular system during sustained activity, the different 
methods to measure muscle fatigue are discussed. The focus of this review is on voluntary 
assessment techniques of muscular fatigue rather than electrical stimulation procedures, such as 
tetanic stimulation and twitch interpolation. These electrical stimulation techniques are used to 
differentiate between central and peripheral fatigue factors. The reliable assessment of muscle 
fatigue is highly dependent upon the measurement of maximum force generation and as such, 
maximal voluntary contraction force is considered the “gold standard” for the assessment of 
fatigue (Vollestad, 1997). The advantage of using maximal voluntary force is that the output is 
the result of the total chain of events, including both central and peripheral fatigue factors. 
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Therefore, voluntary contraction should serve as the first choice of methods before additional 
methods are employed to examine the possible sites within the central and peripheral systems 
(Vollestad, 1997). 
Fatigue Assessment in Children 
 
Isometric and isokinetic techniques are most commonly employed in the assessment of 
muscle performance in children. However, the limitations of isometric techniques are that the 
strength measurements are limited to a fixed joint angle and optimal angles for individual muscle 
groups in children have not been identified (Gaul, 1996). Despite the expense and complexity of 
testing, isokinetic dynamometry is currently considered the most valid tool for muscle 
performance assessment (Jones & Stratton, 2000). It provides a controlled, safe environment 
where no resistance is applied once the movement has ceased. Although isokinetic testing in 
children has typically been performed in the range of 0-240 degrees/second, an optimal 
movement velocity for reliable measurement has not been established (Gaul, 1996; Jones & 
Stratton, 2000). 
Limited information regarding isokinetic muscle endurance testing in children is 
available in the literature. To the author’s knowledge, there is only one study that has utilized 
isokinetic dynamometry to assess the reliability of muscle fatigue testing in the knee flexors and 
extensors of children. De Ste Croix, Armstrong, and Welsman (2003) studied 30, 12-year old 
children on two test sessions separated by 1 week. The subjects performed 50 concentric, 
reciprocal knee flexions and extensions at 90 degrees/second. A fatigue index was calculated by 
using the average torque and average work of the first 3 and last 3 repetitions. The percentage 
difference between these values was used to represent the decline in torque and work. Intra-class 
correlation coefficients (ICCs) for knee extension torque fatigue and work fatigue were higher 
(.90 and .85, respectively) than for flexion torque and work fatigue (.36 and .54, respectively). In 
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addition, all fatigue indices except for knee flexion torque fatigue index (.36), were deemed 
reliable by high ICC values. After a sufficient recovery period, a second test of endurance was 
performed consisting of reciprocal knee flexion and extension until the torque fell below 50% of 
the maximal torque or the subjects reached 80 repetitions. Interestingly, none of the subject’s 
extension or flexion torque fell below 50% of maximum after 80 repetitions. This testing 
protocol has been frequently used in adults. Therefore, it is unclear as to why the subjects’ torque 
did not fall below the 50% of maximum in the allotted number of repetitions. The authors 
suggested that it may be a function of the lower initial maximal torque values as compared to 
adults. This idea is in agreement with Pincivero, Gear, Sterner, and Karunakara (2000) who 
demonstrated that a faster rate of fatigue was significantly related to the ability to generate a high 
initial level of torque. Kellis and Kellis (2001) utilized a similar protocol with reciprocal knee 
flexion and extension at 60 degrees/second for approximately 60 seconds or 22 repetitions. 
However, intersession reliability was not assessed for this protocol.  
Fatigue Assessment in Cerebral Palsy 
 
The first reported test of endurance in children with neuromuscular diseases was 
published by Hosking, Bhat, Dubowitz, and Edwards (1976). For this test, the length of time the 
leg could be held straight with the hip flexed to 45 degrees and the head at 45 degrees above the 
horizontal were recorded with the subject in the supine position. Although this test was able to 
discriminate between children with and without neuromuscular disease, it did not show sufficient 
reproducibility to be recommended for future testing.  
Other attempts to measure overall endurance in children with CP employed physiological 
measures of energy expenditure, such as oxygen consumption, heart rate, perceived exertion, and 
measures of cardiorespiratory function (Dahlback & Norlin, 1985; Hoofwijk et al., 1995; 
Lundberg, 1976; Rose, Gamble, Burgos, Medeiros, & Haskell, 1990; Rose et al., 1993; Unnithan 
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et al., 1996). Others have studied endurance from an aerobic (Lundberg, 1978; Tobimatsu et al., 
1998) versus anaerobic perspective (Parker, Carriere, Hebestreit, & Bar-Or, 1992; Tirosh, Bar-
Or, & Rosenbaum, 1990). However, these are physiological measures of the overall individual 
and are different from tests of muscle endurance. Proponents of anaerobic testing via the 
Wingate anaerobic test purport to measure muscle endurance by measuring mean power of the 
lower extremities (Parker et al., 1992). However, this test cannot differentiate between right and 
left limb measurements or among muscle groups; therefore, it is a non-specific, gross 
physiologic measurement of endurance. Isokinetic dynamometry, on the other hand, has the 
ability to isolate a single muscle group under controlled conditions with stabilization of other 
joints, thus providing a measure of localized muscle fatigue.  
To date, there are no studies that have quantitatively assessed localized muscle fatigue via 
isokinetic or isometric means in individuals with CP. However, because the basis of fatigue or 
endurance testing is maximal voluntary contraction (Vollestad, 1997), it is important to discuss 
the reliability of isokinetic strength testing in children with and without CP.  
Isokinetic Strength Testing in Children With and Without CP 
 
Two studies have examined the reliability of isokinetic strength assessments in children 
and adolescents with CP (Ayalon, Ben-Sira, Hutzler, & Gilad, 2000; Van den Berg-Emons RJ, 
Van Baak, de, Speth, & Saris, 1996). Both examined isokinetic concentric knee extension and 
flexion but at different velocities of movement. Van den Berg-Emons et al. (1996) examined the 
reliability of strength assessments in 12 children with CP (ages 6-12) on two separate tests 
during the same day. Peak torque of the knee flexors and extensors was assessed over 5 
maximum trials at 30, 60, and 120 degrees/second. Results revealed that the only reliable 
measurement of peak torque for both the knee flexors and extensors was at 30 degrees/second 
(Spearman rank correlation = rs= .71 - .84). However, it should be noted that knee flexion peak 
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torque was reliable at 60 and 120 degrees/second as well (rs =.75 and .65, respectively). These 
results are questionable, considering that the two test sessions were performed on the same test 
day with only an hour and a half break between tests. In addition, only two familiarization trials 
were given. Therefore, the reliability at 60 and 120 degrees/second may have been significant 
with a greater number of familiarization trials and increased time between tests. 
A more recent study by Ayalon et al. (2000) investigated the reliability of strength 
measurements in 12 children with CP (ages 9-15) on two separate occasions one week apart. 
However, Ayalon et al provided 15 to 20 submaximal familiarization trials and utilized only one 
velocity (90 degrees/second), which was determined to be the most comfortable for the 
participants during a pilot study. Mean absolute peak torque and mean relative peak torque 
normalized by body weight were the dependent measures. Results revealed both absolute and 
relative peak torque measurements to be equally reliable with intrasession ICCs of .90 to .99 and 
intersession ICCs of .95 to .99. In contrast with the Van den Berg-Emons et al study, knee 
extension and knee flexion tests were both reliable at the faster speed of 90 degrees/second (ICC 
intersession = .95-.98 and .96-.98, respectively). These results support the use of isokinetic 
concentric testing at 90 degrees/second in children and adolescents.  
Holland, McCubbin, Nelson, and Steadward (1994) were the first to investigate the 
reliability of isokinetic concentric and eccentric strength testing in adults (ages 17-38) with CP. 
Reliability of knee flexion and extension at 60 degrees/second was assessed over 3 test sessions 
conducted every other day. All average torque and peak torque values were reliable except for 
eccentric knee extension average torque, as determined by generalizability coefficients (p2 =.20). 
In general, concentric tests were more reliable than eccentric tests (.69-.91 and .20-.90, 
respectively). Furthermore, the concentric knee flexion test was more reliable than the knee 
extension test (.80-.90 and .69-.91, respectively). Further support for the use of isokinetic 
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velocities greater than 30 degrees/second comes from strength testing in individuals with CVA, 
during which reliability was established in normalized and non-normalized peak torque measures 
at 90 and 60 degrees, respectively (Hsu, Tang, & Jan, 2002; Pohl, Startzell, Duncan, & Wallace, 
2000). Collectively, these studies provide support for the use of higher speeds (60 – 90 
degree/second), which have been speculated to mimic more functional speeds encountered in 
everyday activities (Ayalon et al., 2000). 
Studies of reliable strength assessment are more prevalent in healthy children than in 
children with either neuromuscular or neurological disorders. Nevertheless, an optimal 
movement velocity for isokinetic strength testing in children has not been established (Gaul, 
1996; Jones & Stratton, 2000). However, reliability of strength measurements has been 
demonstrated at 30, 60, 90, 100, 120, and 180 degrees/second for the knee flexors and extensors 
in children and adolescents (De Ste Croix, Armstrong, & Welsman, 2003; Deighan, De Ste 
Croix, & Armstrong, 2003; Kellis, Kellis, Gerodimos, & Manou, 1999; Merlini, Dell'Accio, & 
Granata, 1995). In general, reliability for able-bodied children is higher for the knee extensors 
compared to the knee flexors and for concentric versus eccentric testing.  
Isokinetic Muscle Fatigue / Endurance Protocols 
 
Adults 
 
No single, reliable test of muscle endurance exists in children with or without CP. 
Therefore, it is important to discuss endurance protocols in adults. The most widely used 
protocol consists of a predetermined number of maximal repetitions. The number of maximal 
repetitions in adults usually varies from 25 to 50 repetitions and is usually performed at 180 
degrees/second (Burdett & Van Swearingen, 1987; Gleeson & Mercer, 1992; Manou, Arseniou, 
Gerodimos, & Kellis, 2002; Pincivero, Gear, & Sterner, 2001; Pincivero, Lephart, & Karunakara, 
1997; Thorstensson & Karlsson, 1976). Another common protocol involves the performance of 
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consecutive repetitions or maximum isometric contractions until the torque, work, or power 
decreases to 50% of the maximum torque (Emery, Sitler, & Ryan, 1994; Schwendner, Mikesky, 
Wigglesworth, & Burr, 1995). Other protocols require the subject to perform as many repetitions 
as possible in a predetermined period of time (Felicetti, Zelaschi, & Di Patrizi, 1994; 
Montgomery, Douglass, & Deuster, 1989) or repeated contractions until exhaustion (Patton, 
Hinson, Arnold, Jr., & Lessard, 1978).  
The most commonly used measurement parameter is the calculation of the fatigue index 
(FI) as an indicator of muscle endurance. This idea was first proposed by Thorstensson and 
Karlsson (1976), where the decline in torque output of the quadriceps after 50 contractions was 
expressed as a percentage of the highest of the first 3 peak torques to the last 3 peak torques. 
Although there is no standardized definition for FI, it usually represents the percentage decline in 
work or torque from the beginning to the end of a predetermined number of repetitions or a 
certain period of time. Thorstensson and Karlsson also reported a positive correlation between 
the percentage of Type II fibers and the FI.  
Although the most common technique, the FI has been questioned in terms of its 
reliability (Burdett & Van Swearingen, 1987; Pincivero et al., 2001; Pincivero et al., 1997). With 
similar protocols of 25 to 30 repetitions at 180 degrees/second, ICC’s have been reported from 
.26 to .82 for knee extension and .52 to .84 for knee flexion. The disadvantages of the FI are that 
it represents only the initial and final values. Furthermore, the division of one value with error 
associated with it by another value with error associated with it results in a ratio with even more 
error (Burdett & Van Swearingen, 1987). Because reductions in torque output over short periods 
of time (30-60 seconds) have been observed to be linear (Bigland-Ritchie et al., 1983; 
Lindstrom, Karlsson, & Gerdle, 1995), researchers have suggested the linear slope as an 
alternative measure of the rate of decrease in work or torque over the testing session (Pincivero, 
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Gandaio, & Ito, 2003; Pincivero et al., 2001). The slope was found to be more reliable than the 
FI with ICC’s of .78 to .82 (Pincivero et al., 2001). An advantage of using the slope is that it 
captures the rate of decline over the entire test. However, the data must be linear in order to use 
this measure of fatigue. 
Emery, Sitler, and Ryan (1994) developed another alternative to the FI, in which fatigue 
was measured by counting the number of repetitions completed in which three consecutive 
repetitions met the 50% of peak torque deficit. They discovered that the number of repetitions 
needed at 60 and 150 degrees/second, respectively, was 30 and 46 for knee extension and 36 and 
41 for knee flexion. Burdett and Van Swearingen (1987) also calculated the number of 
contractions until torque fell below 50% of maximum as well as a type of FI in which the ratio of 
work done during the last 5 repetitions to the first five was measured. They determined that the 
number of repetitions was more reliable (r = .85) than the FI/work ratio (r = .48). Similarly, 
Manou et al. (2002) determined that the number of repetitions was very reliable for the knee 
extensors and flexors (r = .82 and .90, respectively). Another measure of fatigability is endurance 
time, or the time to reach either 50% of maximum or exhaustion (Manou et al., 2002; Patton et 
al., 1978). The advantage of these two parameters is that they are simple and easy to calculate. 
On the other hand, they do not provide a measure of the rate of decline. Furthermore, it has been 
documented that endurance time is not closely related to fatigue (Vollestad, 1997).  
Total work, or area under the isokinetic torque curve for all repetitions, is another 
common measurement in endurance testing that has been determined to be highly reliable 
(Burdett & Van Swearingen, 1987; Gleeson & Mercer, 1992; Manou et al., 2002). Again, with 
similar protocols for the knee extensors and knee flexors, ICC’s were between .92 and .98 and 
between .88 and .97, respectively. In fact, Gleeson and Mercer (1992) have proposed that total 
work should be the recommended index of isokinetic leg muscular endurance. It has also been 
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suggested that the reliability of total work over all repetitions is a better indicator of similar effort 
across all repetitions during repeated trials (De Ste Croix et al., 2003). 
Neurological Populations 
 
Isokinetic protocols that are similar to those used in adult populations have been 
employed in studies of individuals with neurological impairments. The majority are studies of 
fatigue in MS in which either isokinetic concentric (Armstrong et al., 1983; Lambert et al., 2001) 
or isometric (Surakka et al., 2004) contractions of the knee extensors and flexors were 
investigated in comparison with a control population. Lambert et al. (2001) measured total work 
and a FI for three sets of 30 repetitions at 180 degrees/second. Total work was determined to be 
reliable for the knee flexors and extensors (.80 and .94, respectively) while the FI had low 
reliability (.51 and .36, respectively). Armstrong et al. (1983) and Sunnerhagen et al. (1999) 
examined FI in individuals with MS and CVA, respectively, with 50 concentric repetitions at 180 
degrees/second; however, reliability was not measured. It is of interest to note that even though 
higher speeds were employed, the subjects were able to effectively complete the testing, despite 
the inherent motor control issues associated with upper motor neuron lesions. 
Conclusions 
 
Although no single standardized protocol exists for the assessment of muscle endurance 
in either adult, pediatric, or neurological populations, some conclusions can be drawn from the 
available literature (See Table A.2 for a list of fatigue protocols). First, utilizing a set number of 
repetitions between 25 and 50 appears to be most reliable. Secondly, although 180 
degrees/second is the most common speed utilized in the adult population, speeds of 100 
degrees/second or less may be more reliable in children with and without CP. However, the 
previous limitation of 30 degrees/second in CP, proposed by Van den Berg-Emons et al. (1996), 
appears to be unsupported by recent research. For example, the only study to test muscle  
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Author Popu-lation Age N Protocol 
Velocity 
(deg/s) 
Action 
Type 
Limb 
tested Measurement Reliability 
          
De Ste Croix et 
al., 2003 
Children 12.2 
(+0.3) 
30 Reciprocal KF 
and KE;  
50 maximal reps 
 
 
90 Isokinetic 
Concentric 
DOM  
-FI (MPT)  
-FI (Avg. Work) 
-Total Work 
 
(ICC Test-retest -1wk) 
KE / KF = .90 / .36 
KE / KF = .85 / .54 
KE / KF = .95 / .86 
 
Kellis & Kellis, 
2001 
Adol-
escents 
13.8 
(+0.8) 
15 Reciprocal KF 
and KE; 
30 maximal reps 
 
60 Isokinetic 
Concentric 
NR -Joint moment 
-EMG 
NR 
Burdett & Van 
Swearingen, 
1987 
Adults NR 36 Reciprocal KF 
and KE;  
25 max reps & 
the decline of KE 
torque to 50% of  
maximum 
 
180 
240 
Isokinetic 
Concentric 
DOM  
-Total Work 
 
-Work Ratio 
 
-# of reps 
 
(ICC Test-retest) 
KE(180/240) = .98/.87 
KF(180/240) = .91/.83 
KE(180/240) = .48/.55 
KF(180/240) = .60/.73 
KE only        = .84/.71 
Emery et al., 
1994 
Adults 21 12 Reciprocal KF 
and KE; 
torque decline to 
50% of 
maximum 
 
60 
150 
Isokinetic 
Concentric
& 
Eccentric 
NR -# of contractions NR 
Felicetti et al., 
1994 
Adults 20-30 50 Reciprocal KF 
and KE for 
60seconds 
 
180 Isokinetic 
Concentric 
Both  
-# of reps until 20% 
decline in PT 
-# of reps until 30% 
decline in PT 
-# of reps until 50% 
decline in PT 
-Slope 
-Total Work 
(ICC 3 test sessions) 
KE / KF = .74 / .70 
 
KE / KF = .70 / .69 
 
KE / KF = .77 / .75  
 
KE /KF  = .86 / .83 
KE / KF = .85 / .82 
 
Table A.2: Isokinetic Endurance Protocols 
(table continued) 
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Author Popu-lation Age N Protocol 
Velocity 
(deg/s) 
Action 
Type 
Limb 
tested Measurement Reliability 
          
Gleeson & 
Mercer, 1992 
Adults 28.4 
(+3.9) 
10 Reciprocal KF 
and KE; 
30 maximal reps 
 
180 Isokinetic 
Concentric 
DOM  
 
-FI (work) 
-Total Work 
(ICC 3 test sessions x 5 
days) 
KE / KF = .84 / .49 
KE / KF = .93 / .88 
 
Manou et al., 
2002 
Adults 27 
(+3.8) 
12 Reciprocal KF 
and KE; 
40 maximal reps 
 
120 Isokinetic 
Concentric 
DOM  
 
-FI (work) 
-Total Work 
-50% fatigue work 
-50% fatigue time 
-50% fatigue reps 
 
(Reliability coefficient 
test-retest - 5days) 
KE / KF = .90 / .49 
KE / KF = .92 / .97 
KE / KF = .89 / .96 
KE / KF = .88 / .84 
KE / KF = .82 / .90 
 
Montgomery et 
al., 1989 
Adults 20-49 32 # of reciprocal 
KF and KE 
contractions 
performed in 
45seconds 
180 Isokinetic 
Concentric 
R  
-Total Work 
-# of reps 
-FI #1: (reps 1-5 / 
reps 21-25) 
-FI #2: (1st 5 reps / 
last 5) 
(ICC) 
KE = .92 
KE = .55 
Work = .67  
MPT = .60 
Work = .72 
MPT = .74 
 
Patton et al., 
1978 
Adults 18-24 32 Elbow flexion to 
exhaustion 
60 Isokinetic 
Concentric 
 
NR -# of contractions NR 
Pincivero et al., 
1997 
Adults 22 
(+2.2) 
21 Reciprocal KF 
and KE; 
30 maximal reps 
 
180 Isokinetic 
Concentric 
DOM 
& 
NDOM 
 
-FI (Work) 
 
-Total Work 
(ICC Test-retest -1wk) 
KE = .62-.74 
KF = .52-.84 
KE = .88-.90 
KF = .91-.95 
 
 
 
(table continued) 
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Author Popu-lation Age N Protocol 
Velocity 
(deg/s) 
Action 
Type 
Limb 
tested Measurement Reliability 
          
Pincivero et al., 
2001 
Adults 22 
(+1.9) 
16 Reciprocal KF 
and KE; 
30 maximal reps 
 
180 Isokinetic 
Concentric 
DOM 
& 
NDOM 
 
-FI (Work) 
-Slope 
(ICC Test-retest;1-2wk)  
KE = .26-.82 
KE = .78-.82 
 
Pincivero et al., 
2003 
Adults 22 
(+3.8) 
19 Reciprocal KF & 
KE; 30 max reps 
180 Isokinetic 
Concentric 
DOM -FI (Work) 
-Slope 
 
NR 
Schwendner et 
al., 1995 
Adults 20-40 17 Reciprocal KF & 
KE until torque 
declined to 50% 
of maximum 
 
90 Isokinetic 
Concentric 
DOM 
& 
NDOM 
-Decline in force 
output 
NR 
Thorstensson & 
Karlsson, 1976 
Adults 30 
(+2.0) 
10 Consecutive KE; 
50 max reps 
 
180 Isokinetic 
Concentric 
L -FI (MPT) ME = 1.4% 
Armstrong et al., 
1983 
Multiple 
Sclerosis 
MS: 
~27-57 
C:  
~29-58 
10 
 
20 
Consecutive KE; 
50 max reps 
190 Isokinetic 
Concentric 
R -FI (PT) NR 
 
 
 
 
Lambert et al., 
2001 
 
 
 
Multiple 
Sclerosis 
MS: 39 
(+1.0) 
C: 33 
(+7.6) 
15 
 
15 
Reciprocal KE 
and KF; 3 x 30 
max reps 
180 Isokinetic 
Concentric 
DOM MS 
-FI (Work) 
-Total Work 
 
Control 
-FI (Work) 
-Total Work 
 
MS (ICC): 
KE / KF = .36 / .51 
KE / KF = .94 / .80 
 
C (ICC): 
KE / KF = .58 / .38 
KE / KF = .92 / .81 
 
 
 
 
 
(table continued) 
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Author Popu-lation Age N Protocol 
Velocity 
(deg/s) 
Action 
Type 
Limb 
tested Measurement Reliability 
          
Surraka et al., 
2004 
Multiple 
Sclerosis 
30-54 28 30sec max 
isometric 
contractions of 
KE and KF 
 Isokinetic 
Isometric 
Both (See ref.) 
FI#1 
FI#2 
FI#3 
 
(ICC test-retest -1wk) 
KE / KF = .70 / .85 
KE / KF = .68 / .81 
KE / KF = .68 / .86 
 
Sunnerhagen et 
al., 1999 
CVA 40-65 16 Static: 40% max 
isometric 
contraction 
Dynamic: 50 
consecutive KE 
 
 
 
180 
Isokinetic 
Isometric 
 
Isokinetic 
Concentric 
Both Endurance time 
 
 
 
FI 
 
NR 
NR = not reported; R = right; L = left; DOM = dominant; NDOM = non-dominant; KF = knee flexion; KE = knee extension; FI = 
Fatigue index; ICC = Intraclass correlation coefficient; # = number; PT = peak torque; MPT = mean peak torque; ME = 
methodological error from duplicate determinations and linear correlation coefficient (r); MS = Multiple Sclerosis; CVA = 
Cerebrovascular accident; C = Control; EMG = electromyography 
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endurance in children utilized 90 degrees/second with high reliability and increased comfort 
level for the subjects (De Ste Croix et al., 2003). Speeds of 60, 90, and 100 degrees/second have 
also been deemed reliable in isokinetic strength testing of children with and without CP (Ayalon 
et al., 2000; Deighan et al., 2003; Kellis et al., 1999; Merlini et al., 1995). Third, concentric 
repetitions are more reliable than eccentric, especially in children. Lastly, because there is no 
consensus on the most reliable measurement of fatigue, several measurements should be made in 
order to find the best fit for the data. Furthermore, different parameters should be used to capture 
different aspects of the fatigue process, such as the FI, linear slope, and total work. 
 
Conclusion and Hypotheses 
 
Fatigue has been identified as a significant impairment in adolescents and adults with CP 
with serious consequences for function and quality of life issues. Further support for the 
significance of muscle fatigue in individuals with CP comes from studies of energy expenditure, 
morphological and histopathological changes in spastic muscles, and the presence of muscle 
fatigue in similar neurological populations (Figure 5). 
 Despite this evidence, fatigue has not been quantitatively assessed in this population. 
Therefore, it is important to specifically define the type of fatigue to be studied (i.e. muscle 
fatigue) and to provide an objective measurement that is more scientifically rigorous. 
Furthermore, we must understand the contributors to fatigue and their role in the fatigue process. 
Future research is needed to address the following aims: 1.) quantification of muscle fatigue in 
individuals with CP and in a control group without motor disability, 2.) examination of the 
relationships among muscle fatigue and other impairments in order to identify possible 
contributors to fatigue, 3.) identification of possible consequences (functional limitations) of 
muscle fatigue and the relationship to severity of disease (disability), and 4.) development of 
appropriate treatment interventions. Based on the literature presented here regarding the first two 
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aims, the central hypothesis is that 1.) individuals with CP will experience greater levels of 
muscle fatigue than those without motor disability and 2.) the amount of fatigue will be related to 
other impairments of muscle function, such as weakness, co-contraction, stiffness, and spasticity, 
in unique ways. 
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APPENDIX 2: CONSENT FORMS 
 
Louisiana State University 
Department of Kinesiology 
 
Consent Form 
 
 
1.   Study Title:     
 Quantification of Muscle Fatigue in Individuals with Cerebral Palsy 
 
2.   Performance Sites:    
Data will be collected in the Motor behavior laboratory in Room 2B of the Cox 
Communication Building at LSU (Gym Armory).                                 
                                   
3.   Contacts:    
 Dr. Li Li  phone: 225-578-9146  e-mail: lli3@lsu.edu    
Noelle Moreau, PT phone: 225-202-7854  e-mail: nmorea1@lsu.edu  
 
4.   Purpose of the Study: 
1.) to measure muscle fatigue in individuals with Cerebral Palsy (CP) compared 
to able-bodied individuals, 2.) to examine the relationships among muscle fatigue 
and other impairments in order to identify possible contributors to fatigue in 
individuals with CP, and 3.) to identify the relationship between muscle fatigue 
and mobility/functional level. 
 
5.   Subjects:       
  A.  Inclusion Criteria    
1.) Diagnosis of CP for experimental group 
2.) Age 10-30 
3.) Willingness to participate in study 
4.) Ability to follow instructions 
 
  B.  Exclusion Criteria    
1.) history of orthopedic surgery (affecting the knee) in the last 9   
 months 
2.) residual knee pain if surgery greater than 9 months 
3.) history of knee pain 
4.) deformity, malalignment, or significant contracture of knees 
5.) significant cognitive impairments (inability to follow commands) 
 
  C.  Maximum number of subjects: 100  
 
6. Study Procedures:     
Subjects with CP will be classified according to GMFCS (Gross Motor Function 
Classification System level), a self or parent-report scale. In addition, the parent, 
adolescent, or adult subject will complete the PODCI (The Pediatric Outcomes Data 
Collection Instrument) questionnaire, designed to assess function in children with mild to 
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moderate disability. The PODCI contains 52 short questions and takes about 10-20 
minutes to complete. You may already have experience with this questionnaire, as it is 
commonly used in pediatric practice.  
 
Next, walking speed will be determined by a timed walk test of 25 feet over level ground. 
Subjects will be allowed to use any assistive devices, such as walkers, they may use in 
the community. A physical therapist will be administering the test should any assistance 
be required.  
 
Next, we will use a device known as an isokinetic dynamometer to evaluate muscle 
function of the knee in individuals with CP compared to individuals who do not have a 
motor disability. The dynamometer is a device which moves the subject’s limb at a preset 
speed and range of motion (See figure 1). Isokinetic dynamometry provides a safe and 
controlled environment for children where no resistance is applied once the movement 
stops. Following familiarization with the isokinetic equipment and explanation of 
procedures, the subject will be positioned in the device chair in a semireclining sitting 
position. Both lower extremities will be tested for subjects with bilateral involvement and 
the involved lower extremity will be tested for subjects with unilateral involvement. The 
subject’s leg will be aligned so that the knee joint center is aligned with the center of 
rotation of the isokinetic device. The calf will be secured against the knee attachment pad 
and additional stabilizing straps around the waist, the torso, and over the mid-thigh 
portion will be used to restrain trunk and hip movement during testing. Following set-up, 
the complete passive range of motion in knee extension and flexion as designated as 
“comfortable” by the patient will be determined and this will be used to set the limits of 
motion. Passive testing will be performed prior to active testing. 
 
 
Figure 1: Isokinetic dynamometry testing of the right knee of a child with CP 
 
Passive testing: The passive tests will consist of repetitive flexion and extension of the 
knee within the preset range of motion (3-5 repetitions each) with a 2 second pause 
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during the reversal of motion. The subjects will be instructed to relax their muscles and 
surface electromyography (EMG) will be applied to the quadriceps and hamstrings to 
verify that the muscles are not active. Surface electromyography is a non-invasive, 
painless technique of measuring the activity or lack of activity of muscle groups. 
Repetitions will be performed at various speeds and the torque will be measured. 
 
Active testing: The subjects will perform 5-10 submaximal knee flexion and extension 
repetitions to familiarize themselves with the procedure. The subject will then perform 
two maximal exertions for each muscle group at 30 to 60 degrees per second in order to 
measure the strength of the muscles. The subjects will be instructed to “push” and “pull” 
their leg against the lever as hard as possible. One minute of rest will be given between 
exertions to prevent muscle fatigue. After a five minute rest, the fatigue protocol will 
consist of  repeated knee flexion and extension at 30 to 60 degrees per second until the 
peak torque declines to 50% of the maximum peak torque value for each muscle group 
(as determined prior to the fatigue test). Again, the subjects will be instructed to “push” 
and “pull” their leg against the lever as hard as possible. 
 
This is a single testing session. The total time for this process, including explanations and 
familiarization, is between one and two hours.  
           
 7. Benefits:  
Although there are no immediate benefits to participation in this study, the goal of this 
project is to gain a better understanding of muscle endurance in children with CP with the 
ultimate goal of improving current treatment protocols based on the information gained 
by this study. Therefore, it is likely that the knowledge gained from this study will benefit 
the participant in the future. Furthermore, the participants and family with have the self-
satisfaction of knowing that they contributed to the future body of knowledge regarding 
muscle performance in CP. 
 
8. Risks/Discomforts:  
  Self or Parent-Report Measures: no risks except confidentiality 
 
Gait Velocity: Assessment would involve less risk than that associated with walking 
during daily activities due to the controlled environment (level ground) and the 
supervision of a licensed physical therapist. 
 
Passive testing: Assessment should not involve any risk as the subject is relaxed during 
this portion of the test and will have the ability to terminate the test at any time through a 
hand-held safety switch. 
 
Active testing: Assessment should involve minimal risk as the strength assessment has 
been well established by Damiano and colleagues in children with CP. The fatigue 
assessment, however, may result in temporary mild post-testing soreness, similar to that 
experienced after a bout of exercise.  
 
9. Measures taken to reduce risk  
All tests and measures will be administrated and supervised by a licensed physical 
therapist, who has over 7 years experience in working with children with disabilities. 
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(Investigator, Noelle Moreau, P.T.).In addition, every effort will be made to maintain the 
confidentiality of the study records. Participants will be assigned a number for 
identification in the study (it will not be related to their social security number, birth date, 
etc) and all collected data will be coded by that number. Files will be kept in a secure 
room to which only investigators will have access. 
 
Gait Velocity: Two investigators, one of whom is a licensed physical therapist, will be 
close to the subject to offer additional support should imbalance occur.  
 
Passive testing: The passive range of motion will be predetermined according to what is 
comfortable for the subject. In addition, the subject will be given a hand-held safety 
switch which will immediately terminate the test at any point in time. Again, the testing 
will be supervised and administered by a licensed physical therapist for added safety. 
 
Active testing: The active range of motion will be predetermined according to what is 
comfortable for the subject. The subject will be also given a hand-held safety switch 
which will immediately terminate the test at any point in time. Furthermore, isokinetic 
dynamometry provides a safe and controlled environment for children where no 
resistance is applied once the movement stops. Therefore, there is minimal risk for injury. 
The fatigue assessment, however, may result in temporary mild post-testing soreness, 
similar to that experienced after a bout of exercise. A licensed physical therapist will be 
available by phone after testing to answer any questions or concerns regarding possible 
post-testing soreness.   
 
10. Right to Refuse:   
Participation in the study is voluntary. You may withdraw from the study at any time 
without penalty or loss of any benefit to which they may otherwise be entitled.   
 
11. Privacy:    
The results of the study may be published, but no names or identifying information will 
be included in the publication. Your identity will remain confidential unless disclosure is 
required by law. 
             
12. Financial Information:    
 Participation in this study is voluntary with no financial compensations.  
 
13. Withdrawal:    
There are no consequences if you choose to withdraw form participation at any time 
during this study.  
 
14. Removal:    
The investigators may remove you from the study for any number of reasons, including, 
but not limited to, the detection of adverse responses and technical difficulties in 
obtaining information during the testing session. If the investigators elect to remove you 
from the study they will provide you with the justification for doing so, and you will be 
given an opportunity to ask questions regarding your removal. 
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Part 5: Signatures: 
 
The study has been discussed with me and all my questions have been answered. I may 
direct additional questions regarding study specifics to the investigators. If I have 
questions about subjects' rights or other concerns, I can contact Robert C. Mathews, 
Chairman, LSU Institutional Review Board, (225)578-8692. I agree to participate in the 
study described above and acknowledge the researchers’ obligation to provide me with a 
copy of this consent form if signed by me.’ 
                                                                           
Subject Signature______________________________        Date ___________________ 
 
 Illiterate subjects:     
 
The study subject has indicated to me that he/she is unable to read. I certify that I have 
read this consent form to the subject and explained that by completing the signature line 
above, the subject has agreed to participate. 
 
Signature of Reader____________________________        Date ___________________ 
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Louisiana State University 
Department of Kinesiology 
 
Parental Permission/Consent Form 
 
 
1.   Study Title:     
 Quantification of Muscle Fatigue in Individuals with Cerebral Palsy 
 
2.   Performance Sites:    
Data will be collected in the Motor behavior laboratory in Room 2B of the Cox 
Communication Building at LSU (Gym Armory).                                 
                                   
3.   Contacts:    
 Dr. Li Li  phone: 225-578-9146  e-mail: lli3@lsu.edu    
Noelle Moreau, PT phone: 225-202-7854  e-mail: nmorea1@lsu.edu  
 
4.   Purpose of the Study: 
1.) to measure muscle fatigue in individuals with Cerebral Palsy (CP) compared 
to able-bodied individuals, 2.) to examine the relationships among muscle fatigue 
and other impairments in order to identify possible contributors to fatigue in 
individuals with CP, and 3.) to identify the relationship between muscle fatigue 
and mobility/functional level. 
 
5.   Subjects:       
  A.  Inclusion Criteria    
5.) Diagnosis of CP for experimental group 
6.) Age 10-30 
7.) Willingness to participate in study 
8.) Ability to follow instructions 
 
  B.  Exclusion Criteria    
1.) history of orthopedic surgery (affecting the knee) in the last 9   
 months 
6.) residual knee pain if surgery greater than 9 months 
7.) history of knee pain 
8.) deformity, malalignment, or significant contracture of knees 
9.) significant cognitive impairments (inability to follow commands) 
 
  C.  Maximum number of subjects: 100  
   
6. Study Procedures:     
Subjects with CP will be classified according to GMFCS (Gross Motor Function 
Classification System level), a self or parent-report scale. In addition, the parent, 
adolescent, or adult subject will complete the PODCI (The Pediatric Outcomes Data 
Collection Instrument) questionnaire, designed to assess function in children with mild to 
moderate disability. The PODCI contains 52 short questions and takes about 10-20 
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minutes to complete. You may already have experience with this questionnaire, as it is 
commonly used in pediatric practice.  
 
Next, walking speed will be determined by a timed walk test of 25 feet over level ground. 
Subjects will be allowed to use any assistive devices, such as walkers, they may use in 
the community. A physical therapist will be administering the test should any assistance 
be required.  
 
Next, we will use a device known as an isokinetic dynamometer to evaluate muscle 
function of the knee in individuals with CP compared to individuals who do not have a 
motor disability. The dynamometer is a device which moves the subject’s limb at a preset 
speed and range of motion (See figure 1). Isokinetic dynamometry provides a safe and 
controlled environment for children where no resistance is applied once the movement 
stops. Following familiarization with the isokinetic equipment and explanation of 
procedures, the subject will be positioned in the device chair in a semireclining sitting 
position. Both lower extremities will be tested for subjects with bilateral involvement and 
the involved lower extremity will be tested for subjects with unilateral involvement. The 
subject’s leg will be aligned so that the knee joint center is aligned with the center of 
rotation of the isokinetic device. The calf will be secured against the knee attachment pad 
and additional stabilizing straps around the waist, the torso, and over the mid-thigh 
portion will be used to restrain trunk and hip movement during testing. Following set-up, 
the complete passive range of motion in knee extension and flexion as designated as 
“comfortable” by the patient will be determined and this will be used to set the limits of 
motion. Passive testing will be performed prior to active testing. 
 
 
 
Figure 1: Isokinetic dynamometry testing of the right knee of a child with CP 
 
Passive testing: The passive tests will consist of repetitive flexion and extension of the 
knee within the preset range of motion (3-5 repetitions each) with a 2 second pause 
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during the reversal of motion. The subjects will be instructed to relax their muscles and 
surface electromyography (EMG) will be applied to the quadriceps and hamstrings to 
verify that the muscles are not active. Surface electromyography is a non-invasive, 
painless technique of measuring the activity or lack of activity of muscle groups. 
Repetitions will be performed at various speeds and the torque will be measured. 
 
Active testing: The subjects will perform 5-10 submaximal knee flexion and extension 
repetitions to familiarize themselves with the procedure. The subject will then perform 
two maximal exertions for each muscle group at 30 to 60 degrees per second in order to 
measure the strength of the muscles. The subjects will be instructed to “push” and “pull” 
their leg against the lever as hard as possible. One minute of rest will be given between 
exertions to prevent muscle fatigue. After a five minute rest, the fatigue protocol will 
consist of  repeated knee flexion and extension at 30 to 60 degrees per second until the 
peak torque declines to 50% of the maximum peak torque value for each muscle group 
(as determined prior to the fatigue test). Again, the subjects will be instructed to “push” 
and “pull” their leg against the lever as hard as possible. 
 
This is a single testing session. The total time for this process, including explanations and 
familiarization, is between one and two hours.  
           
 7. Benefits:  
Although there are no immediate benefits to participation in this study, the goal of this 
project is to gain a better understanding of muscle endurance in children with CP with the 
ultimate goal of improving current treatment protocols based on the information gained 
by this study. Therefore, it is likely that the knowledge gained from this study will benefit 
the participant in the future. Furthermore, the participants and family with have the self-
satisfaction of knowing that they contributed to the future body of knowledge regarding 
muscle performance in CP. 
 
8. Risks/Discomforts:  
  Self or Parent-Report Measures: no risks except confidentiality 
 
Gait Velocity: Assessment would involve less risk than that associated with walking 
during daily activities due to the controlled environment (level ground) and the 
supervision of a licensed physical therapist. 
 
Passive testing: Assessment should not involve any risk as the subject is relaxed during 
this portion of the test and will have the ability to terminate the test at any time through a 
hand-held safety switch. 
 
Active testing: Assessment should involve minimal risk as the strength assessment has 
been well established by Damiano and colleagues in children with CP. The fatigue 
assessment, however, may result in temporary mild post-testing soreness, similar to that 
experienced after a bout of exercise.  
 
9. Measures taken to reduce risk  
All tests and measures will be administrated and supervised by a licensed physical 
therapist, who has over 7 years experience in working with children with disabilities. 
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(Investigator, Noelle Moreau, P.T.).In addition, every effort will be made to maintain the 
confidentiality of the study records. Participants will be assigned a number for 
identification in the study (it will not be related to their social security number, birth date, 
etc) and all collected data will be coded by that number. Files will be kept in a secure 
room to which only investigators will have access. 
 
Gait Velocity: Two investigators, one of whom is a licensed physical therapist, will be 
close to the subject to offer additional support should imbalance occur.  
 
Passive testing: The passive range of motion will be predetermined according to what is 
comfortable for the subject. In addition, the subject will be given a hand-held safety 
switch which will immediately terminate the test at any point in time. Again, the testing 
will be supervised and administered by a licensed physical therapist for added safety. 
 
Active testing: The active range of motion will be predetermined according to what is 
comfortable for the subject. The subject will be also given a hand-held safety switch 
which will immediately terminate the test at any point in time. Furthermore, isokinetic 
dynamometry provides a safe and controlled environment for children where no 
resistance is applied once the movement stops. Therefore, there is minimal risk for injury. 
The fatigue assessment, however, may result in temporary mild post-testing soreness, 
similar to that experienced after a bout of exercise. A licensed physical therapist will be 
available by phone after testing to answer any questions or concerns regarding possible 
post-testing soreness.   
 
10. Right to Refuse:   
Participation in the study is voluntary. You may withdraw from the study at any time 
without penalty or loss of any benefit to which they may otherwise be entitled.   
 
11. Privacy:    
The results of the study may be published, but no names or identifying information will 
be included in the publication. Your identity will remain confidential unless disclosure is 
required by law. 
             
12. Financial Information:    
 Participation in this study is voluntary with no financial compensations.  
 
13. Withdrawal:    
There are no consequences if you choose to withdraw form participation at any time 
during this study.  
 
14. Removal:    
The investigators may remove you from the study for any number of reasons, including, 
but not limited to, the detection of adverse responses and technical difficulties in 
obtaining information during the testing session. If the investigators elect to remove you 
from the study they will provide you with the justification for doing so, and you will be 
given an opportunity to ask questions regarding your removal. 
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Part 5: Signatures: 
 
The study has been discussed with me and all my questions have been answered. I may 
direct additional questions regarding study specifics to the investigators. If I have 
questions about subjects' rights or other concerns, I can contact Robert C. Mathews, 
Chairman, LSU Institutional Review Board, (225)578-8692. I agree to participate in the 
study described above and acknowledge the researchers’ obligation to provide me with a 
copy of this consent form if signed by me.’ 
                                                                           
Parent Signature______________________________        Date ___________________ 
 
 Illiterate subjects:     
 
The study subject has indicated to me that he/she is unable to read. I certify that I have 
read this consent form to the subject and explained that by completing the signature line 
above, the subject has agreed to participate. 
 
Signature of Reader____________________________        Date ___________________ 
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Louisiana State University 
Department of Kinesiology 
 
Child Assent Form 
 
 
I,____________________________, agree to be in a study to help people better understand how 
the muscles of the knee work in people with and without Cerebral Palsy. I will be asked to 
“push” and “pull” my leg against a lever as hard as I can. Other times, I will just relax and the 
lever will move my leg for me. I will also walk a short distance and be timed. I agree to give my 
best effort throughout the test and to follow the instructions. I understand that I will be able to 
stop the test at any time if I feel pain or discomfort or for any other reason. I will not get in 
trouble for stopping the test.  
 
 
 
                                                                           
Child's Signature _________________________  Age ____  Date ______________ 
 
 
                                                                           
Witness ___________________________                              Date ______________ 
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APPENDIX 3: GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM 
 
Palisano, R., Rosenbaum, P., Walter, S., Russell, D., Wood, E., & Galuppi, B. (1997). 
Development and reliability of a system to classify gross motor function in children with cerebral 
palsy. Dev.Med.Child Neurol., 39, 214-223. 
LEVEL I--Walks without restrictions; limitations in more advanced gross motor skills. 
Before 2nd birthday: Infants move in and out of sitting and floor sit with both hands free to 
manipulate objects. Infants crawl on hands and knees, pull to stand and take steps holding onto 
furniture. Infants walk between 18 months and 2 years of age without the need for any assistive 
mobility device. 
From age 2 to 4th birthday: Children floor sit with both hands free to manipulate objects. 
Movements in and out of floor sitting and standing are performed without adult assistance. 
Children walk as the preferred method of mobility without the need for any assistive mobility 
device. 
From age 4 to 6th birthday: Children get into and out of, and sit in, a chair without the need for 
hand support. Children move from the floor and from chair sitting to standing without the need 
for objects for support. Children walk indoors and outdoors, and climb stairs. Emerging ability to 
run and jump. 
From age 6 to 12: children walk indoors and outdoors, and climb stairs without limitations. 
Children perform gross motor skills including running and jumping but speed, balance, and 
coordination are reduced. 
LEVEL II--Walks without assistive devices; limitations walking outdoors and in the 
community. 
Before 2nd birthday: Infants maintain floor sitting but may need to use their hands for support to 
maintain balance. Infants creep on their stomach or crawl on hands and knees. Infants may pull 
to stand and take steps holding onto furniture. 
From age 2 to 4th birthday: Children floor sit but may have difficulty with balance when both 
hands are free to manipulate objects. Movements in and out of sitting are performed without 
adult assistance. Children pull to stand on a stable surface. Children crawl on hands and knees 
with a reciprocal pattern, cruise holding onto furniture and walk using an assistive mobility 
device as preferred methods of mobility. 
From age 4 to 6th birthday: Children sit in a chair with both hands free to manipulate objects. 
Children move from the floor to standing and from chair sitting to standing but often require a 
stable surface to push or pull up on with their arms. Children walk without the need for any 
assistive mobility device indoors and for short distances on level surfaces outdoors. Children 
climb stairs holding onto a railing but are unable to run or jump. 
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From age 6 to 12: children walk indoors and outdoors, and climb stairs holding onto a railing but 
experience limitations walking on uneven surfaces and inclines, and walking in crowds or 
confined spaces. Children have at best only minimal ability to perform gross motor skills such as 
running and jumping. 
Distinctions between levels I and II: 
Compared with children in level I, children in level II have limitations in the ease of performing 
movement transitions; walking outdoors and in the community; the need for assistive mobility 
devices when beginning to walk; quality of movement; and the ability to perform gross motor 
skills such as running and jumping. 
LEVEL III--Walks with assistive mobility devices; limitations walking outdoors and in the 
community. 
Before 2nd birthday: Infants maintain floor sitting when the low back is supported. Infants roll 
and creep forward on their stomachs. 
From age 2 to 4th birthday: Children maintain floor sitting often by "W-sitting" (sitting between 
flexed and internally rotated hips and knees) and may require adult assistance to assume sitting. 
Children creep on their stomach or crawl on hands and knees (often without reciprocal leg 
movements) as their primary methods of self-mobility. Children may pull to stand on a stable 
surface and cruise short distances. Children may walk short distances indoors using an assistive 
mobility device and adult assistance for steering and turning. 
From age 4 to 6th birthday: Children sit on a regular chair but may require pelvic or trunk 
support to maximize hand function. Children move in and out of chair sitting using a stable 
surface to push on or pull up with their arms. Children walk with an assistive mobility device on 
level surfaces and climb stairs with assistance from an adult. Children frequently are transported 
when travelling for long distances or outdoors on uneven terrain. 
From age 6 to 12: children walk indoors or outdoors on a level surface with an assistive mobility 
device. Children may climb stairs holding onto a railing. Depending on upper limb function, 
children propel a wheel chair manually or are transported when traveling for long distances or 
outdoors on uneven terrain. 
Distinctions between levels II and III: 
Differences are seen in the degree of achievement of functional mobility. Children in level III 
need assistive mobility devices and frequently orthoses to walk, while children in level II do not 
require assistive mobility devices after age 4. 
LEVEL IV--Self-mobility with limitations; children are transported or use power mobility 
outdoors and in the community. 
 
Before 2nd birthday: Infants have head control, but trunk support is required for floor sitting. 
Infants can roll to supine and may roll to prone. 
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From age 2 to 4th birthday: Children floor sit when placed, but are unable to maintain alignment 
and balance without use of their hands for support. Children frequently require adaptive 
equipment for sitting and standing. Self-mobility for short distances (within a room) is achieved 
through rolling, creeping on stomach, or crawling on hands and knees without reciprocal leg 
movement. 
From age 4 to 6th birthday: Children sit on a chair but need adaptive seating for trunk control 
and to maximize hand function. Children move in and out of chair sitting with assistance from an 
adult or a stable surface to push or pull up on with their arms. Children may at best walk short 
distances with a walker and adult supervision but have difficulty turning and maintaining balance 
on uneven surfaces. Children are transported in the community. Children may achieve self-
mobility using a power wheelchair. 
From age 6 to 12: Children may maintain levels of function achieved before age 6 or rely more 
on wheeled mobility at home, school, and in the community. Children may achieve self-mobility 
using a power wheelchair. 
Distinctions between levels III and IV: 
Differences in sitting ability and mobility exist, even allowing for extensive use of assistive 
technology. Children in level III sit independently, have independent floor mobility, and walk 
with assistive mobility devices. Children in level IV function in sitting (usually supported), but 
independent mobility is very limited. Children in level IV are more likely to be transported or 
use power mobility. 
LEVEL V--Self-mobility is severely limited even with the use of assistive technology. 
Before 2nd birthday: Physical impairments limit voluntary control of movement. Infants are 
unable to maintain antigravity head and trunk postures in prone and sitting. Infants require adult 
assistance to roll. 
From age 2 to 12: Physical impairments restrict voluntary control of movement and the ability to 
maintain antigravity head and trunk postures. All areas of motor function are limited. Functional 
limitations in sitting and standing are not fully compensated for through the use of adaptive 
equipment and assistive technology. At level V, children have no means of independent mobility 
and are transported. Some children achieve self-mobility using a power wheelchair with 
extensive adaptations. 
Distinctions between levels IV and V: 
Children in level V lack independence even in basic antigravity postural control. Self mobility is 
achieved only if the child can learn how to operate an electrically powered wheelchair. 
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APPENDIX 4: PEDIATRIC OUTCOMES DATA COLLECTION INSTRUMENT 
 
 
 
 
PARENT FORM 
(BASELINE) 
 
TO BE COMPLETED BY THE PARENTS OF 
 CHILDREN 2-18 YEARS OLD 
 
We are asking you to complete this questionnaire about your child to better 
understand his/her health in general and problems related to bone and muscle 
conditions.  Your completion of this questionnaire is voluntary.  Your responses 
will be held in the strictest of confidence.  It will take about 15 to 20 minutes to 
complete. 
 
Please answer every question.  Some questions may look like others, but each 
one is different. 
 
Answer the questions by circling the appropriate number or by writing the 
answer as requested. 
 
There are no right or wrong answers.  If you are not sure how to answer a 
question, please give the best answer you can and make a comment in the 
margin.  We will read all your comments, so feel free to make as many as you 
wish. 
 
 
 
1.   Your Child’s Name:  
 
 
2.   Today’s Date: 
 
 
3.   Your Child’s Birth Date: 
 
 
 
OFFICE USE ONLY 
 
        
Subject ID: 
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Be sure to fill out both the front and back of all subsequent pages. 
 
 
 
 
 
 
 
 
 
 
 
 
           OFFICE USE ONLY 
Notes by clinician administering questionnaire:  
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For your child's right side please For your child's left side please 
indicate those areas that bother your indicate those areas that bother your 
child or limit his or her function. child or limit his or her function. 
 
 
 Neck Neck 
 
 Shoulder area  Shoulder area 
 
 Elbow/Forearm  Elbow/Forearm 
 
 Wrist/Hand  Wrist/Hand 
 
 Hip Hip 
 
 Thigh Thigh 
 
 Knee area Knee 
 
 Calf area Calf  
 
 Ankle/Foot area Ankle/Foot area 
 
 
For your child's back please 
indicate those areas that bother 
your child or limit his or her function. 
 
 
 Neck 
 
 Upper Back 
 
 
 
 
 
 Lower Back 
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Excellent Very Good Good Fair Poor 
5. In general, would you say your 
child’s health is: (Circle one 
number) 
1 2 3 4 5 
 
 
Much better 
than one 
year ago 
Somewhat 
better than 
one year ago 
About the 
same 
Somewhat 
worse than 
one year ago 
Much worse 
than one 
year ago 
6. Compared to one year ago, 
how would you rate your child’s 
health in general now? (Circle 
one number) 
1 2 3 4 5 
 
Have you ever been told by a doctor, nurse, teacher, or other health professional that your child has had any of 
the following conditions? (Please circle “yes” for all conditions that apply). If yes, indicate if your child is being 
treated for this condition and if your child is limited by those conditions. 
 
 
Has your child ever 
had it? 
Does your child 
receive treatment  
for it now? 
Are your child’s 
activities limited 
by it now? 
7. Juvenile arthritis (one or two joints). Yes      No Yes      No Yes      No 
8. Juvenile arthritis (many joints). Yes      No Yes      No Yes      No 
9. Anorexia or bulimia (eating 
disorders). Yes      No Yes      No Yes      No 
10. Asthma. Yes      No Yes      No Yes      No 
11. Attention or behavioral 
problems. Yes      No Yes      No Yes      No 
12. Chronic allergies or sinus 
trouble. Yes      No Yes      No Yes      No 
13. Developmental delay. Yes      No Yes      No Yes      No 
14. Mental retardation. Yes      No Yes      No Yes      No 
15. Diabetes. Yes      No Yes      No Yes      No 
16. Epilepsy (seizure disorder). Yes      No Yes      No Yes      No 
17. Hearing impairment or 
deafness. Yes      No Yes      No Yes      No 
18. Heart problem. Yes      No Yes      No Yes      No 
19. Learning problem. Yes      No Yes      No Yes      No 
20. Sleep disturbance. Yes      No Yes      No Yes      No 
21. Speech problems. Yes      No Yes      No Yes      No 
22. Vision problems. Yes      No Yes      No Yes      No 
 142 
Some kinds of problems can make it hard to do many activities, such as eating, bathing, school work and playing 
with friends. We would like to find out how your child is doing. 
 
During the last week was it easy or hard for your child to: 
 
 
Easy A little hard Very hard Can’t do at all Too young for this activity 
23. Lift heavy books? 1 2 3 4 5 
24. Pour a half gallon of milk? 1 2 3 4 5 
25. Open a jar that has been 
opened before? 1 2 3 4 5 
26. Use a fork and spoon? 1 2 3 4 5 
27. Comb his/her hair? 1 2 3 4 5 
28. Button buttons? 1 2 3 4 5 
29. Put on his/her socks? 1 2 3 4 5 
30. Write with a pencil? 1 2 3 4 5 
 
 
 
Rarely Once a 
month 
Two or  
three times 
a month 
Once a 
week 
More than 
once a 
week 
Does not 
attend 
school, etc. 
31. On average, over the last 12 
months, how often did your 
child miss school (preschool, 
day care, camp, etc.) because 
of his/her health? 
1 2 3 4 5 6 
 
 
During the last week, how happy has our child been with: 
 
 
Very happy Somewhat happy Not sure 
Somewhat 
unhappy 
Very 
unhappy 
Child is too 
young 
32. How he/she looks? 1 2 3 4 5 6 
33. His/her body? 1 2 3 4 5 6 
34. What clothes or shoes he/she 
can wear? 1 2 3 4 5 6 
35. His/her ability to do the same 
things his/her friends do? 1 2 3 4 5 6 
36. His/her health in general? 1 2 3 4 5 6 
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During the last week, how much of the time: 
 
 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
37. Did your child feel sick and tired? 1 2 3 4 
38. Was your child full of pep and energy? 1 2 3 4 
39. Did pain or discomfort interfere with your 
child’s activities? 1 2 3 4 
 
During the last week, has it been easy or hard for your child to: 
 
 
Easy A little hard Very hard Can’t do  
at all 
Too young for 
this activity 
40. Run short distances? 1 2 3 4 5 
41.  Bicycle or tricycle? 1 2 3 4 5 
42.  Climb three flights of stairs? 1 2 3 4 5 
43.  Climb one flight of stairs? 1 2 3 4 5 
44.  Walk more than a mile? 1 2 3 4 5 
45.  Walk three blocks? 1 2 3 4 5 
46.  Walk one block? 1 2 3 4 5 
47.  Get on and off a bus? 1 2 3 4 5 
 
 
 
Never Sometimes About half the time Often All the time 
48. How often does your child need help from 
another person for walking and climbing?  1 2 3 4 5 
 
 
 
Never Sometimes About half the time Often All the time 
49. How often does your child use assistive 
devices (such as braces, crutches, or 
wheelchair) for walking and climbing?  
1 2 3 4 5 
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During the last week, has it been easy or hard for your child to: 
 
 
Easy A little hard Very hard Can’t do 
at all 
Too young for 
this activity 
50.  Stand while washing his/ her hands 
and face at a sink? 1 2 3 4 5 
51. Sit in a regular chair without 
holding on? 1 2 3 4 5 
52. Get on and off a toilet or chair? 1 2 3 4 5 
53. Get in and out of bed? 1 2 3 4 5 
54. Turn door knobs? 1 2 3 4 5 
55. Bend over from a standing position 
and pick up something off the 
floor? 
1 2 3 4 5 
 
 
Never Sometimes About half the time Often 
All the 
time 
56. How often does your child need help from 
another person for sitting and standing? 1 2 3 4 5 
57. How often does your child use assistive 
devices (such as braces, crutches, or 
wheelchair) for sitting and standing? 
1 2 3 4 5 
 
 
Yes, easily Yes, but a little hard 
Yes, but  
very hard No 
58. Can your child participate in recreational outdoor 
activities with other children the same age? (For 
example: bicycling, tricycling, skating, hiking, jogging) 
1 2 3 4 
If you answered “no” to Question 58 above, was your child’s activity limited by: (Circle “yes” to all that apply.) 
 
 
Yes 
59. Pain? 1 
60. General Health? 1 
61. Doctor or parent instructions? 1 
62. Fear the other kids won’t like him/ her? 1 
63. Dislike of recreational outdoor activities? 1 
64. Too young? 1 
65. Activity not in season? 1 
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Yes, easily Yes, but a little hard 
Yes, but 
very hard No 
66. Can your child participate in pickup games or sports 
with other children the same age? (For example: tag, 
dodge ball, basketball, soccer, catch, jump rope, touch 
football, hop scotch) 
1 2 3 4 
 
If you answered “no” to Question 66 above, was your child’s activity limited by: (Circle “yes” to all that apply.) 
 
 
Yes 
67. Pain? 1 
68. General Health? 1 
69. Doctor or parent instructions? 1 
70. Fear the other kids won’t like him/ her? 1 
71. Dislike of pickup games or sports? 1 
72. Too young? 1 
73. Activity not in season? 1 
 
 
 
Yes, easily Yes, but a little hard 
Yes, but 
very hard No 
74. Can your child participate in competitive level sports 
with other children the same age? (For example: 
hockey, basketball, soccer, football, baseball, 
swimming, running [track or cross country], 
gymnastics, or dance) 
1 2 3 4 
 
If you answered “no” to Question 74 above, was your child’s activity limited by: (Circle “yes” to all that apply.) 
 
 
Yes 
75. Pain? 1 
76. General Health? 1 
77. Doctor or parent instructions? 1 
78. Fear the other kids won’t like him/ her? 1 
79. Dislike of competitive level sports? 1 
80. Too young? 1 
81. Activity not in season? 1 
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Often Sometimes Never or rarely 
82. How often in the past week did your 
child get together and do things with 
friends? 
1 2 3 
 
If you answered “sometimes” or “never or rarely” to Question 82 above, was your child’s activity limited by: 
(Circle “yes” to all that apply.) 
 
 
 
Yes 
83. Pain? 1 
84. General health? 1 
85. Doctor or parent instructions? 1 
86. Fear the other kids won’t like him/her? 1 
87. Friends not around? 1 
 
 
 
Often Sometimes Never or 
rarely 
No gym or 
recess 
88. How often in the past week did your child 
participate in gym/ recess? 1 2 3 4 
 
If you answered “sometimes” or “never or rarely” to Question 88 above, was your child’s activity limited by: 
(Circle “yes” to all that apply.) 
 
 
Yes 
89. Pain? 1 
90. General health? 1 
91. Doctor or parent instructions? 1 
92. Fear the other kids won’t like him/her? 1 
93. Dislike of gym/recess? 1 
94. School not in session? 1 
95. Does not attend school? 1 
 
 
 
Usually easy Sometimes 
easy 
Sometimes 
hard Usually hard 
96. Is it easy or hard for your child to make 
friends with children his/ her own age? 1 2 3 4 
 
 
 
None Very 
mild Mild Moderate Severe 
Very 
severe 
97. How much pain has your child had 
during the last week? 1 2 3 4 5 6 
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Not at all A little bit Moderately Quite a bit Extremely 
98. During the last week, how much did pain 
interfere with your child’s normal activities 
(including at home, outside of the home, 
and at school)? 
1 2 3 4 5 
 
What expectations do you have for your child’s treatment? 
As a result of my child’s treatment, I expect my child: 
 
 
Definitely 
yes 
Probably 
yes Not sure 
Probably 
not 
Definitely 
not 
99. To have pain relief. 1 2 3 4 5 
100. To look better. 1 2 3 4 5 
101. To feel better about himself/ herself. 1 2 3 4 5 
102. To sleep more comfortably. 1 2 3 4 5 
103. To be able to do activities at home. 1 2 3 4 5 
104. To be able to do more at school. 1 2 3 4 5 
105. To be able to do more play or recreational 
activities (biking, walking, doing things with 
friends). 
1 2 3 4 5 
106. To be able to do more sports. 1 2 3 4 5 
107. To be free from pain or disability as an adult. 1 2 3 4 5 
 
 
 
Very 
satisfied 
Somewhat 
satisfied Neutral 
Somewhat 
dissatisfied 
Very 
dissatisfied 
108. If your child had to spend the rest of 
his/ her life with his/ her bone and 
muscle condition as it is right now, 
how would you feel about it? 
1 2 3 4 5 
 
 
109. What is your child’s gender? 
 
  q  Male        q  Female 
 
 
110. What is your child’s race? (check all that apply) 
 
  q   White      q   Black or African-American 
  q   Hispanic 
 
 
 
  q   Asian or Pacific Islander   q   Native American Indian  
  
 q   Other (please specify) 
 
 
 
              
           
 _______________________ 
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111. Who lives at home with your child? (check all that apply) 
 
  q   Mother    q   Stepmother  q   Foster mother 
 q   Father    q   Stepfather  q   Foster father 
 q   Brothers and/or sisters (How many _______ ?)     
 q   Other adults 
 
 
 
 
 
112. What is your relationship to this child? 
 
  q   Mother    q   Stepmother  q   Foster mother 
 q   Father    q   Stepfather  q   Foster father 
 q   Brother    q   Sister   q   Grandmother 
 q   Grandfather 
  q   Aunt    q   Uncle   q   Guardian 
  q   Other ________________________ 
 
 
 
Please answer the next two questions about your health (not your child’s): 
 
 
 
113. In general, would you say your health is: 
 
  q   Excellent   q   Very good  q   Good  
  q   Fair    q   Poor 
 
 
114. Compared to one year ago, how would you rate your health in general now? 
 
  q   Much better now than 1 year ago    
   
  q   Somewhat better now than 1 year ago   
   
  q   About the same as 1 year ago     
   
  q   Somewhat worse now than 1 year ago     
   
  q   Much worse now than 1 year ago 
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ADOLESCENT / PATIENT FORM 
(BASELINE) 
 
 
TO BE COMPLETED BY ADOLESCENTS 11-18 YEARS 
OLD 
 
We are asking you to complete this questionnaire about you to better 
understand your health in general and problems related to bone and muscle 
conditions.  Your completion of this questionnaire is voluntary.  Your responses 
will be held in the strictest of confidence.  It will take about 15 to 20 minutes to 
complete. 
 
Please answer every question.  Some questions may look like others, but each 
one is different. 
 
Answer the questions by circling the appropriate number or by writing the 
answer as requested. 
 
There are no right or wrong answers.  If you are not sure how to answer a 
question, please give the best answer you can and make a comment in the 
margin.  We will read all your comments, so feel free to make as many as you 
wish. 
 
 
 
1.   Your Name:  
 
 
2.   Today’s Date: 
 
 
3.   Your Birth Date: 
 
 
 
OFFICE USE ONLY 
 
        
Subject ID: 
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Be sure to fill out both the front and back of all subsequent pages. 
 
 
 
 
 
 
 
 
 
 
 
 
           OFFICE USE ONLY 
Notes by clinician administering questionnaire:  
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For your right side please For your left side please 
indicate those areas that bother  indicate those areas that bother 
you or limit your function. you or limit your function. 
 
 
 Neck Neck 
 
 Shoulder area  Shoulder area 
 
 Elbow/Forearm  Elbow/Forearm 
 
 Wrist/Hand  Wrist/Hand 
 
 Hip Hip 
 
 Thigh Thigh 
 
 Knee area Knee 
 
 Calf area Calf  
 
 
 Ankle/Foot area Ankle/Foot area 
 
 
For your back please indicate 
 those areas that botheryou or  
limit your function. 
 
 
 Neck 
 
 Upper Back 
 
 
 
 
 
 Lower Back 
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Excellent Very Good Good Fair Poor 
5. In general, would you say your 
health is: (Circle one number) 1 2 3 4 5 
 
 
Much better 
than one 
year ago 
Somewhat 
better than 
one year ago 
About the 
same 
Somewhat 
worse than 
one year ago 
Much worse 
than one 
year ago 
6. Compared to one year ago, 
how would you rate your health 
in general now? (Circle one 
number) 
1 2 3 4 5 
 
Have you ever been told by a doctor, nurse, teacher, or other health professional that you have had any of the 
following conditions? (Please circle “yes” for all conditions that apply). If yes, indicate if you are being treated for 
this condition and if you are limited by those conditions. 
 
 
Have you ever  
had it? 
Do you receive 
treatment for it now? 
Are your activities 
limited by it now? 
7. Juvenile arthritis (one or two joints). Yes      No Yes      No Yes      No 
8. Juvenile arthritis (many joints). Yes      No Yes      No Yes      No 
9. Anorexia or bulimia (eating 
disorders). Yes      No Yes      No Yes      No 
10. Asthma. Yes      No Yes      No Yes      No 
11. Attention or behavioral 
problems. Yes      No Yes      No Yes      No 
12. Chronic allergies or sinus 
trouble. Yes      No Yes      No Yes      No 
13. Developmental delay. Yes      No Yes      No Yes      No 
14. Mental retardation. Yes      No Yes      No Yes      No 
15. Diabetes. Yes      No Yes      No Yes      No 
16. Epilepsy (seizure disorder). Yes      No Yes      No Yes      No 
17. Hearing impairment or 
deafness. Yes      No Yes      No Yes      No 
18. Heart problem. Yes      No Yes      No Yes      No 
19. Learning problem. Yes      No Yes      No Yes      No 
20. Sleep disturbance. Yes      No Yes      No Yes      No 
21. Speech problems. Yes      No Yes      No Yes      No 
22. Vision problems. Yes      No Yes      No Yes      No 
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Some kinds of problems can make it hard to do many activities, such as eating, bathing, school work and playing 
with friends. We would like to find out how you are doing. 
 
During the last week was it easy or hard for you to: 
 
 
Easy A little hard Very hard Can’t do at all 
23. Lift heavy books? 1 2 3 4 
24. Pour a half gallon of milk? 1 2 3 4 
25. Open a jar that has been 
opened before? 1 2 3 4 
26. Use a fork and spoon? 1 2 3 4 
27. Comb your hair? 1 2 3 4 
28. Button buttons? 1 2 3 4 
29. Put on your socks? 1 2 3 4 
30. Write with a pencil? 1 2 3 4 
 
 
 
Rarely Once a 
month 
Two or  
three times 
a month 
Once a 
week 
More than 
once a 
week 
Do not 
attend 
school, etc. 
31. On average, over the last 12 
months, how often did you 
miss school (camp, etc.) 
because of your health? 
1 2 3 4 5 6 
 
 
During the last week, how happy have you been with: 
 
 
Very happy Somewhat happy Not sure 
Somewhat 
unhappy 
Very 
unhappy 
32. How you look? 1 2 3 4 5 
33. Your body? 1 2 3 4 5 
34. What clothes or shoes you can 
wear? 1 2 3 4 5 
35. Your ability to do the same 
things your friends do? 1 2 3 4 5 
36. Your health in general? 1 2 3 4 5 
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During the last week, how much of the time: 
 
 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
37. Did you feel sick and tired? 1 2 3 4 
38. Were you full of pep and energy? 1 2 3 4 
39. Did pain or discomfort interfere with your 
activities? 1 2 3 4 
 
During the last week, has it been easy or hard for you to: 
 
 
Easy A little hard Very hard Can’t do  
at all 
40. Run short distances? 1 2 3 4 
41.  Bicycle or tricycle? 1 2 3 4 
42.  Climb three flights of stairs? 1 2 3 4 
43.  Climb one flight of stairs? 1 2 3 4 
44.  Walk more than a mile? 1 2 3 4 
45.  Walk three blocks? 1 2 3 4 
46.  Walk one block? 1 2 3 4 
47.  Get on and off a bus? 1 2 3 4 
 
 
 
Never Sometimes About half the time Often All the time 
48. How often do you need help from another 
person for walking and climbing?  1 2 3 4 5 
 
 
 
Never Sometimes About half the time Often All the time 
49. How often do you use assistive devices 
(such as braces, crutches, or wheelchair) 
for walking and climbing?  
1 2 3 4 5 
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During the last week, has it been easy or hard for you to: 
 
 
Easy A little hard Very hard Can’t do 
at all 
50.  Stand while washing your hands 
and face at a sink? 1 2 3 4 
51. Sit in a regular chair without 
holding on? 1 2 3 4 
52. Get on and off a toilet or chair? 1 2 3 4 
53. Get in and out of bed? 1 2 3 4 
54. Turn door knobs? 1 2 3 4 
55. Bend over from a standing position 
and pick up something off the 
floor? 
1 2 3 4 
 
 
Never Sometimes About half the time Often 
All the 
time 
56. How often do you need help from another 
person for sitting and standing? 1 2 3 4 5 
57. How often do you use assistive devices (such 
as braces, crutches, or wheelchair) for sitting 
and standing? 
1 2 3 4 5 
 
 
Yes, easily Yes, but a little hard 
Yes, but  
very hard No 
58. Can you participate in recreational outdoor activities 
with other kids the same age? (For example: bicycling, 
tricycling, skating, hiking, jogging) 
1 2 3 4 
 
If you answered “no” to Question 58 above, was your activity limited by: (Circle “yes” to all that apply.) 
 
 
Yes 
59. Pain? 1 
60. General Health? 1 
61. Doctor or parent instructions? 1 
62. Fear the other kids won’t like you? 1 
63. Dislike of recreational outdoor activities? 1 
64. Activity not in season? 1 
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Yes, easily Yes, but a little hard 
Yes, but 
very hard No 
65. Can you participate in pickup games or sports with 
other kids the same age? (For example: tag, dodge 
ball, basketball, soccer, catch, jump rope, touch 
football, hop scotch) 
1 2 3 4 
 
If you answered “no” to Question 65 above, was your activity limited by: (Circle “yes” to all that apply.) 
 
 
Yes 
66. Pain? 1 
67. General Health? 1 
68. Doctor or parent instructions? 1 
69. Fear the other kids won’t like you? 1 
70. Dislike of pickup games or sports? 1 
71. Activity not in season? 1 
 
 
 
Yes, easily Yes, but a little hard 
Yes, but 
very hard No 
72. Can you participate in competitive level sports with 
other kids the same age? (For example: hockey, 
basketball, soccer, football, baseball, swimming, 
running [track or cross country], gymnastics, or dance) 
1 2 3 4 
 
If you answered “no” to Question 72 above, was your activity limited by: (Circle “yes” to all that apply.) 
 
 
Yes 
73. Pain? 1 
74. General Health? 1 
75. Doctor or parent instructions? 1 
76. Fear the other kids won’t like you? 1 
77. Dislike of competitive level sports? 1 
78. Activity not in season? 1 
 
 
 
Often Sometimes Never or rarely 
79. How often in the past week did you 
get together and do things with 
friends? 
1 2 3 
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If you answered “sometimes” or “never or rarely” to Question 79 above, was your activity limited by: (Circle 
“yes” to all that apply.) 
 
 
 
Yes 
80. Pain? 1 
81. General health? 1 
82. Doctor or parent instructions? 1 
83. Fear the other kids won’t like you? 1 
84. Friends not around? 1 
 
 
Often Sometimes Never or 
rarely 
No gym or 
recess 
85. How often in the past week did you 
participate in gym/ recess? 1 2 3 4 
 
If you answered “sometimes” or “never or rarely” to Question 85 above, was your activity limited by: (Circle 
“yes” to all that apply.) 
 
 
Yes 
86. Pain? 1 
87. General health? 1 
88. Doctor or parent instructions? 1 
89. Fear the other kids won’t like you? 1 
90. Dislike of gym/recess? 1 
91. School not in session? 1 
92. Does not attend school? 1 
 
 
Usually easy Sometimes 
easy 
Sometimes 
hard Usually hard 
93. Is it easy or hard for you to make 
friends with kids your own age? 1 2 3 4 
 
 
None Very 
mild Mild Moderate Severe 
Very 
severe 
94. How much pain have you had during 
the last week? 1 2 3 4 5 6 
 
 
 
Not at all A little bit Moderately Quite a bit Extremely 
95. During the last week, how much did pain 
interfere with your normal activities 
(including at home, outside of the home, 
and at school)? 
1 2 3 4 5 
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What expectations do you have for your treatment? 
As a result of my treatment, I expect: 
 
 
Definitely 
yes 
Probably 
yes Not sure 
Probably 
not 
Definitely 
not 
96. To have pain relief. 1 2 3 4 5 
97. To look better. 1 2 3 4 5 
98. To feel better about myself. 1 2 3 4 5 
99. To sleep more comfortably. 1 2 3 4 5 
100. To be able to do activities at home. 1 2 3 4 5 
101. To be able to do more at school. 1 2 3 4 5 
102. To be able to do more play or recreational 
activities (biking, walking, doing things with 
friends). 
1 2 3 4 5 
103. To be able to do more sports. 1 2 3 4 5 
104. To be free from pain or disability as an adult. 1 2 3 4 5 
 
 
 
Very 
satisfied 
Somewhat 
satisfied Neutral 
Somewhat 
dissatisfied 
Very 
dissatisfied 
105. If you had to spend the rest of your 
life with your bone and muscle 
condition as it is right now, how 
would you feel about it? 
1 2 3 4 5 
 
 
106. What is your gender? 
 
  q  Male        q  Female 
 
 
107. What is your race? (check all that apply) 
 
  q   White          q  
 Black or African-American   q   Hispanic 
 
 
 
  q   Asian or Pacific Islander   q   Native American Indian  
  q   Other (please specify) 
 
 
 
              
   
108. Who lives at home with you? (check all that apply) 
 
  q   Mother    q   Stepmother   q   Foster 
mother  q   Father              q   Stepfather 
 
 
 
  q   Foster father   q   Brothers and/or sisters (How many _______ ?) 
      
q   Other adults
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APPENDIX 5: INSTITUTIONAL REVIEW BOARD APPROVAL 
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APPENDIX 6: COMPUTER PROGRAMS 
 
Fatigue Data Programs 
 
 
Sub ENDHeader() 
' 
    Name = ""  'manipulate name for different subjects 
    Num = ""      'manuipulate trial # 
     
    ChDir "C:\TestData\Process" 
        Workbooks.OpenText Filename:="C:\TestData\Process\" + Name + "ISOKBREP_END60" 
+ Num + ".txt" _ 
        , Origin:=437, StartRow:=1, DataType:=xlDelimited, TextQualifier:= _ 
        xlDoubleQuote, ConsecutiveDelimiter:=False, Tab:=True, Semicolon:=False, _ 
        Comma:=True, Space:=False, Other:=False, FieldInfo:=Array(Array(1, 1), _ 
        Array(2, 1), Array(3, 1), Array(4, 1), Array(5, 1), Array(6, 1), Array(7, 1), Array(8, 1), _ 
        Array(9, 1), Array(10, 1), Array(11, 1), Array(12, 1), Array(13, 1), Array(14, 1), Array(15 _ 
        , 1), Array(16, 1), Array(17, 1), Array(18, 1), Array(19, 1)), TrailingMinusNumbers:= _ 
        True 
     
    Rows("3:5").Select 
    Selection.Insert Shift:=xlDown 
    ChDir "C:\TestData" 
    Workbooks.Open Filename:="C:\TestData\Export_Rep_Headers.xls" 
    Rows("3:5").Select 
    Range("AK3").Activate 
    Selection.Copy 
    Windows(Name + "ISOKBREP_END60" + Num + ".txt").Activate 
    Rows("3:5").Select 
    ActiveSheet.Paste 
    Application.CutCopyMode = False 
    'ChDir "C:\TestData\Process" 
    ActiveWorkbook.SaveAs Filename:= _ 
        "C:\TestData\Process\" + Name + "ISOKBREP_END60" + Num + ".xls", 
FileFormat:=xlNormal, _ 
        Password:="", WriteResPassword:="", ReadOnlyRecommended:=False, _ 
        CreateBackup:=False 
    Windows("Export_Rep_Headers.xls").Activate 
    ActiveWindow.Close 
         
  End Sub 
 
Sub ConvertToNm() 
'copy Repnum over to new column 
 
N = 39  'N = # of reps + 4**************** 
For I = 5 To N 
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    Cells(I + 1, 22) = Cells(I + 1, 1) 
Next I 
 
'convert ft-lb to N-m 
K = 1.355 'conversion factor to N-m 
 
For J = 1 To 2 'for KE and KF 
    For I = 5 To N 
         PT = Cells(I + 1, J + 1) * K     'PT = PTKE and PTKF 
         'place PT in the columns for KE and KF 
              Cells(I + 1, J + 22) = PT 
    Next I 
Next J 
 
For L = 1 To 2 'for WKE and WKF 
    For I = 5 To N 
         W = Cells(I + 1, L + 11) * K     'W = Peak Work for KE and KF 
         'place W in the columns for WKE and WKF 
              Cells(I + 1, L + 24) = W 
    Next I 
Next L 
 
'Sub Normalize() 
'normalize PT and Work by mass in kg 
 
 'convert BW(body wt)to kg 
    BW = Cells(1, 11) * 0.4526 
    Cells(6, 21) = BW 
     
'N = 104  'N = # of reps + 4**** 
m = Cells(6, 21) 'm = mass in kg 
 
For J = 1 To 4 
    For I = 5 To N 
        Norm = Cells(I + 1, J + 22) / m * 100 'Norm = normalized data x 100% 
        'place normalized values in the appropriate columns 
            Cells(I + 1, J + 26) = Norm 
    Next I 
Next J 
  
'Sub Max() 
'max in N-m for PTKE,PTKF,TWKE,TWKF 
ReDim Max(4) 
ReDim MaxC(4) 
 
'N = 104   'N = # of reps + 4**** 
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For J = 1 To 4 
    Max(J) = 0 
    For I = 5 To N 
        If Cells(I + 1, J + 22) > Max(J) Then 
            Max(J) = Cells(I + 1, J + 22) 
            MaxC(J) = (I + 1) - 5 
        End If 
    Next I 
     'place max in appropriate column 
    Cells(6, J * 2 + 30) = Max(J) 
    'place rep # in column 
    Cells(6, J * 2 + 31) = MaxC(J) 
Next J 
 
' Three Reps Fifty percent 
'max in N-m for PTKE,PTKF,TWKE,TWKF 
 
For J = 1 To 4 
    For I = 5 To N - 2 
        If Cells(I + 1, J + 22) < 0.5 * Max(J) Then 
            If Cells(I + 2, J + 22) < 0.5 * Max(J) Then 
                If Cells(I + 3, J + 22) < 0.5 * Max(J) Then 
                    Cells(6, J + 39) = (I + 3) - 5 
                    Exit For 
                End If 
            End If 
        End If 
    Next I 
Next J 
 
'Two REPS Fiftypercent 
'max in N-m for PTKE,PTKF,TWKE,TWKF 
 
For J = 1 To 4 
    For I = 5 To N - 2 
        If Cells(I + 1, J + 22) < 0.5 * Max(J) Then 
            If Cells(I + 2, J + 22) < 0.5 * Max(J) Then 
                'If Cells(I + 3, J + 22) < 0.5 * Max(J) Then 
                    Cells(8, J + 39) = (I + 2) - 5 
                    Exit For 
                End If 
            End If 
    Next I 
Next J 
 
'One REP Fiftypercent 
'max in N-m for PTKE,PTKF,TWKE,TWKF 
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For J = 1 To 4 
    For I = 5 To N - 2 
        If Cells(I + 1, J + 22) < 0.5 * Max(J) Then 
            'If Cells(I + 2, J + 22) < 0.5 * Max(J) Then 
                'If Cells(I + 3, J + 22) < 0.5 * Max(J) Then 
                    Cells(9, J + 39) = (I + 1) - 5 
                    Exit For 
                End If 
    Next I 
Next J 
 
'Sub NormalizedMax() 
'max in N-m/kg for NORMALIZED VALUES of PTKE,PTKF,TWKE,TWKF 
ReDim Max(4) 
ReDim MaxC(4) 
 
'N = 104   'N = # of reps + 4**** 
Cells(3, 26) = "MaxNORM" 
 Range("Z3").Select 
    Selection.Font.Bold = True 
 
For J = 1 To 4 
    Max(J) = 0 
    For I = 5 To N 
        If Cells(I + 1, J + 26) > Max(J) Then 
            Max(J) = Cells(I + 1, J + 26) 
            MaxC(J) = (I + 1) - 5 
        End If 
    Next I 
     'place max in appropriate column 
    Cells(3, J + 26) = Max(J) 
    'place rep # in column 
    'Cells(6, J * 2 + 31) = MaxC(J) 
Next J 
 
End Sub 
 
Sub NEWFiftypercent() 
'Use if altered range is needed 
'max in N-m for PTKE,PTKF,TWKE,TWKF 
ReDim Max(4) 
ReDim MaxC(4) 
 
N = 39  'N =  # of Reps + 4 ***** 
For J = 1 To 4 
    Max(J) = 0 
    For I = 5 To N 
        If Cells(I + 1, J + 22) > Max(J) Then 
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            Max(J) = Cells(I + 1, J + 22) 
            MaxC(J) = (I + 1) - 5 
        End If 
    Next I 
     'place max in appropriate column 
    Cells(7, J * 2 + 30) = Max(J) 
    'place rep # in column 
    Cells(7, J * 2 + 31) = MaxC(J) 
Next J 
 
For J = 1 To 4 
    For I = 5 To N - 2    '********alter range here ********* 
        If Cells(I + 1, J + 22) < 0.5 * Max(J) Then 
            If Cells(I + 2, J + 22) < 0.5 * Max(J) Then 
                If Cells(I + 3, J + 22) < 0.5 * Max(J) Then 
                    Cells(7, J + 39) = (I + 3) - 5 
                    Exit For 
                End If 
            End If 
        End If 
    Next I 
Next J 
End Sub 
 
Sub TotalFatigueIndex() 
 
Cells(26, 53) = "Last5avgReps/BW"  'Labels for new rows 
Cells(28, 53) = "AvgLast5/Peak" 
Cells(30, 53) = "First5avgReps/BW" 
 
ReDim Startt(4) 
ReDim Stopp(4) 
ReDim First(5) 
ReDim Last(5) 
 
For J = 1 To 4 
       
     'get start/stop data from spreadsheet - ****far right data column where 35 reps lies 
    Startt(J) = Cells(6, J * 2 + 51) 
    Stopp(J) = Cells(6, J * 2 + 52) 
     
For I = 1 To 5  '5 numbers 
    'get data - don't change 
    First(I) = Cells(Startt(J) + I + 4, J + 22) 
    Last(I) = Cells(Stopp(J) + I, J + 22)     'Stop(number) + 5 -1 = + 1 
    'place numbers in columns 
    Cells(37 + I, J * 2 + 51) = First(I) 
    Cells(37 + I, J * 2 + 52) = Last(I) 
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Next I 
Next J 
 
For J = 1 To 4 
'add 1 to Cells(37 ..) above 
'First5 = first five values added together for FI calculation 
First5 = Cells(38, J * 2 + 51) + Cells(39, J * 2 + 51) + Cells(40, J * 2 + 51) + Cells(41, J * 2 + 
51) + Cells(42, J * 2 + 51) 
    Cells(9, J * 2 + 52) = First5 
'NEW: Avg of first 5 divided by BW in kg for 35 Reps method 
First5avgbyBW = (First5 / 5 / Cells(6, 21)) * 100 
    Cells(30, J * 2 + 52) = First5avgbyBW 
     
'Last5 = last five values added together for FI calculation 
Last5 = Cells(38, J * 2 + 52) + Cells(39, J * 2 + 52) + Cells(40, J * 2 + 52) + Cells(41, J * 2 + 
52) + Cells(42, J * 2 + 52) 
    Cells(10, J * 2 + 52) = Last5 
'NEW: Avg of last 5 divided by Peak value 
Last5avgbyMax = (Last5 / 5 / Cells(6, J * 2 + 30)) * 100 
    Cells(28, J * 2 + 52) = Last5avgbyMax 
'NEW: Avg of last 5 divided by BW in kg for 35 Reps method 
Last5avgbyBW = (Last5 / 5 / Cells(6, 21)) * 100 
    Cells(26, J * 2 + 52) = Last5avgbyBW 
'Fatigue Index 
FI = 100 - ((Last5 / First5) * 100) 
    Cells(11, J * 2 + 52) = FI 
 
Next J 
 
 Range("BA26:BA31").Select 
    Selection.Font.Bold = True 
     
End Sub 
Sub FiftyPercentFatigueIndex() 
 
Cells(27, 53) = "Last5avg50%/BW" 
Cells(31, 53) = "First5avg50%/BW" 
 
ReDim Startt(4) 
ReDim Stopp(4) 
ReDim First(5) 
ReDim Last(5) 
 
For J = 1 To 4 
     'get start/stop data from spreadsheet - **left lower data column where 50% of max data lies 
    Startt(J) = Cells(17, J * 2 + 42) 
    Stopp(J) = Cells(17, J * 2 + 43) 
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For I = 1 To 5  '5 numbers 
    First(I) = Cells(Startt(J) + I + 4, J + 22) 
    Last(I) = Cells(Stopp(J) + I, J + 22)     'Stop(number) + 5 -1 = + 1 
    'place numbers in columns 
    Cells(31 + I, J * 2 + 42) = First(I) 
    Cells(31 + I, J * 2 + 43) = Last(I) 
Next I 
Next J 
 
For J = 1 To 4 
 
'add 1 to Cells(31 ..) above 
First5 = Cells(32, J * 2 + 42) + Cells(33, J * 2 + 42) + Cells(34, J * 2 + 42) + Cells(35, J * 2 + 
42) + Cells(36, J * 2 + 42) 
    Cells(20, J * 2 + 43) = First5 
'NEW: Avg of first 5 divided by BW in kg for 50% of max method 
First5avg50byBW = (First5 / 5 / Cells(6, 21)) * 100 
    Cells(31, J * 2 + 52) = First5avg50byBW 
     
Last5 = Cells(32, J * 2 + 43) + Cells(33, J * 2 + 43) + Cells(34, J * 2 + 43) + Cells(35, J * 2 + 
43) + Cells(36, J * 2 + 43) 
    Cells(21, J * 2 + 43) = Last5 
'NEW: Avg of last 5 divided by BW in kg for 50% of max method 
Last5avg50byBW = (Last5 / 5 / Cells(6, 21)) * 100 
    Cells(27, J * 2 + 52) = Last5avg50byBW 
     
'Fatigue Index 
FI = 100 - ((Last5 / First5) * 100) 
Cells(22, J * 2 + 43) = FI 
 
Next J 
 
 
'*************MACRO to Place ALL CP ENDURANCE data in spreadsheet******* 
'*************DATA must end in numerical format, ie, subject# 1,2,3..... 
Sub ENDCPdata() 
' 
''Macro for CP subjects ENDURANCE files 
'EXCEL Files to process must be in the Process folder 
 
ChDir "C:\TestData" 
        Workbooks.OpenText Filename:="C:\TestData\CP_data.xls" 
 
For N = 1 To 17    'N = 1 to the # of subjects to process********CHANGE AS NEEDED**** 
 
'Macro to Process CP ENDURANCE STRENGTH DATA 
'Sub ENDCPStrengthdata() 
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ChDir "C:\TestData\Process\Endurance_REP" 
        Workbooks.OpenText 
Filename:="C:\TestData\Process\Endurance_REP\ISOKBREP_END60_CP" + Trim(Str(N)) + 
".xls" 
     
    'End strength data 
    Windows("ISOKBREP_END60_CP" + Trim(Str(N)) + ".xls").Activate 
    Range("AF6,AH6,AJ6,AL6").Select 
    Range("AL6").Activate 
    Selection.Copy 
    Windows("CP_data.xls").Activate 
    Range("AB55").Select 
    ActiveSheet.Paste 
     
    'End Normalized strength data 
    Windows("ISOKBREP_END60_CP" + Trim(Str(N)) + ".xls").Activate 
    Range("AA3:AD3").Select 
    Application.CutCopyMode = False 
    Selection.Copy 
    Windows("CP_data.xls").Activate 
    Range("AF55").Select 
    ActiveSheet.Paste 
     
    'FI35Reps data 
    Windows("ISOKBREP_END60_CP" + Trim(Str(N)) + ".xls").Activate 
    Range("BB11,BD11,BF11,BH11").Select 
    Range("BH11").Activate 
    Selection.Copy 
    Windows("CP_data.xls").Activate 
    Range("AJ55").Select 
    ActiveSheet.Paste 
     
    'FI50% data 
    Windows("ISOKBREP_END60_CP" + Trim(Str(N)) + ".xls").Activate 
    Range("AS22,AU22,AW22,AY22").Select 
    Range("AY22").Activate 
    Selection.Copy 
    Windows("CP_data.xls").Activate 
    Range("AN55").Select 
    ActiveSheet.Paste 
     
    'AvgLast5 data 
    Windows("ISOKBREP_END60_CP" + Trim(Str(N)) + ".xls").Activate 
    Range("BB26,BD26,BF26,BH26").Select 
    Range("BH26").Activate 
    Selection.Copy 
    Windows("CP_data.xls").Activate 
    Range("AR55").Select 
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    ActiveSheet.Paste 
     
    'AvgLast5 50% data 
    Windows("ISOKBREP_END60_CP" + Trim(Str(N)) + ".xls").Activate 
    Range("BB27,BD27,BF27,BH27").Select 
    Range("BH27").Activate 
    Selection.Copy 
    Windows("CP_data.xls").Activate 
    Range("AV55").Select 
    ActiveSheet.Paste 
     
    'Max Rep #'s 
    Windows("ISOKBREP_END60_CP" + Trim(Str(N)) + ".xls").Activate 
    Range("AG6,AI6,AK6,AM6").Select 
    Range("AM6").Activate 
    Selection.Copy 
    Windows("CP_data.xls").Activate 
    Range("AZ55").Select 
    ActiveSheet.Paste 
     
     'AVGLast5 Norm by PT 
    Windows("ISOKBREP_END60_CP" + Trim(Str(N)) + ".xls").Activate 
    Range("BB28,BD28,BF28,BH28").Select 
    Range("BH28").Activate 
    Selection.Copy 
    Windows("CP_data.xls").Activate 
    Range("BD55").Select 
    ActiveSheet.Paste 
     
'move ENDMax(s,)FI(s),AvgLast5(s), and MaxRep#'s in row 55 to columns in data.xls file 
 For J = 1 To 32 
    Cells(N + 3, J + 27) = Cells(55, J + 27) 
    Next J 
     
    Windows("CP_data.xls").Activate 
    Range("AB55:BG55").Select 
    Selection.ClearContents  'clear temp placement holder row55 
    ActiveWorkbook.Save 
       
    Windows("ISOKBREP_END60_CP" + Trim(Str(N)) + ".xls").Activate 
    ActiveWindow.Close 
     
 Next N  'For loop to next subjectN 
  
End Sub 
 
 
 
 169 
'******MACRO to Place ALL CONTROL(Normal) ENDURANCE data in spreadsheet******* 
'*************DATA must end in numerical format, ie, subject# 1,2,3..... 
Sub ENDNdata() 
' 
''Macro for CONTROL(Normal) subjects ENDURANCE files 
'EXCEL Files to process must be in the Process folder 
 
ChDir "C:\TestData" 
        Workbooks.OpenText Filename:="C:\TestData\Control_data.xls" 
 
For N = 1 To 16    'N = 1 to the # of subjects to process********CHANGE AS NEEDED**** 
 
'Macro to Process CONTROL ENDURANCE STRENGTH DATA 
'Sub ENDNStrengthdata() 
 
ChDir "C:\TestData\Process\Endurance_REP" 
        Workbooks.OpenText 
Filename:="C:\TestData\Process\Endurance_REP\ISOKBREP_END60_N" + Trim(Str(N)) + 
".xls" 
 
     'End strength data 
    Windows("ISOKBREP_END60_N" + Trim(Str(N)) + ".xls").Activate 
    Range("AF6,AH6,AJ6,AL6").Select 
    Range("AL6").Activate 
    Selection.Copy 
    Windows("Control_data.xls").Activate 
    Range("AB55").Select 
    ActiveSheet.Paste 
     
    'End Normalized strength data 
    Windows("ISOKBREP_END60_N" + Trim(Str(N)) + ".xls").Activate 
    Range("AA3:AD3").Select 
    Application.CutCopyMode = False 
    Selection.Copy 
    Windows("Control_data.xls").Activate 
    Range("AF55").Select 
    ActiveSheet.Paste 
     
    'FI35Reps data 
    Windows("ISOKBREP_END60_N" + Trim(Str(N)) + ".xls").Activate 
    Range("BB11,BD11,BF11,BH11").Select 
    Range("BH11").Activate 
    Selection.Copy 
    Windows("Control_data.xls").Activate 
    Range("AJ55").Select 
    ActiveSheet.Paste 
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 'FI50% data 
    Windows("ISOKBREP_END60_N" + Trim(Str(N)) + ".xls").Activate 
    Range("AS22,AU22,AW22,AY22").Select 
    Range("AY22").Activate 
    Selection.Copy 
    Windows("Control_data.xls").Activate 
    Range("AN55").Select 
    ActiveSheet.Paste 
     
    'AvgLast5 data 
    Windows("ISOKBREP_END60_N" + Trim(Str(N)) + ".xls").Activate 
    Range("BB26,BD26,BF26,BH26").Select 
    Range("BH26").Activate 
    Selection.Copy 
    Windows("Control_data.xls").Activate 
    Range("AR55").Select 
    ActiveSheet.Paste 
     
    'AvgLast5 50% data 
    Windows("ISOKBREP_END60_N" + Trim(Str(N)) + ".xls").Activate 
    Range("BB27,BD27,BF27,BH27").Select 
    Range("BH27").Activate 
    Selection.Copy 
    Windows("Control_data.xls").Activate 
    Range("AV55").Select 
    ActiveSheet.Paste 
     
    'Max Rep #'s 
    Windows("ISOKBREP_END60_N" + Trim(Str(N)) + ".xls").Activate 
    Range("AG6,AI6,AK6,AM6").Select 
    Range("AM6").Activate 
    Selection.Copy 
    Windows("Control_data.xls").Activate 
    Range("AZ55").Select 
    ActiveSheet.Paste 
     
     'AVGLast5 Norm by PT 
    Windows("ISOKBREP_END60_N" + Trim(Str(N)) + ".xls").Activate 
    Range("BB28,BD28,BF28,BH28").Select 
    Range("BH28").Activate 
    Selection.Copy 
    Windows("Control_data.xls").Activate 
    Range("BD55").Select 
    ActiveSheet.Paste 
     
'move ENDMax(s,)FI(s),AvgLast5(s), and MaxRep#'s in row 55 to columns in data.xls file 
 For J = 1 To 32 
    Cells(N + 3, J + 27) = Cells(55, J + 27) 
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    Next J 
         
Windows("Control_data.xls").Activate 
    Range("AB55:BG55").Select 
    Selection.ClearContents  'clear temp placement holder row55 
    ActiveWorkbook.Save 
       
    Windows("ISOKBREP_END60_N" + Trim(Str(N)) + ".xls").Activate 
    ActiveWindow.Close 
     
 Next N  'For loop to next subjectN 
  
End Sub
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Strength Data Programs 
 
 
'*************MACRO to Process ALL CP Strength Files******* 
'*************DATA must end in numerical format, ie, subject# 1,2,3..... 
Sub CPSTRHeader() 
'Macro for CP subjects Strength files 
'Files to process must be in the Process folder 
 
ChDir "C:\TestData" 
        Workbooks.OpenText Filename:="C:\TestData\CP_data.xls" 
 
For N = 1 To 15    'N = 1 to the # of subjects to process********CHANGE AS NEEDED**** 
' 
' STHeader Macro 
' Macro recorded 11/8/2005 by Noelle Moreau 
' 
      
    ChDir "C:\TestData\Process\Strength_REP" 
        Workbooks.OpenText 
Filename:="C:\TestData\Process\Strength_REP\ISOKBREP_ST60_CP" + Trim(Str(N)) + ".txt"  
        , Origin:=437, StartRow:=1, DataType:=xlDelimited, TextQualifier:= _ 
        xlDoubleQuote, ConsecutiveDelimiter:=False, Tab:=True, Semicolon:=False, _ 
        Comma:=True, Space:=False, Other:=False, FieldInfo:=Array(Array(1, 1), _ 
        Array(2, 1), Array(3, 1), Array(4, 1), Array(5, 1), Array(6, 1), Array(7, 1), Array(8, 1), _ 
        Array(9, 1), Array(10, 1), Array(11, 1), Array(12, 1), Array(13, 1), Array(14, 1), Array(15 _ 
        , 1), Array(16, 1), Array(17, 1), Array(18, 1), Array(19, 1)), TrailingMinusNumbers:= _ 
        True 
        
    Rows("3:5").Select 
    Selection.Insert Shift:=xlDown 
    ChDir "C:\TestData" 
    Workbooks.Open Filename:="C:\TestData\Export_RepSTR_Headers.xls" 
    Rows("3:5").Select 
    Range("AK3").Activate 
    Selection.Copy 
    'Windows(Name + "ISOKBREP_ST60_CP" + Num + ".txt").Activate 
    Windows("ISOKBREP_ST60_CP" + Trim(Str(N)) + ".txt").Activate 
    Rows("3:5").Select 
    ActiveSheet.Paste 
    Application.CutCopyMode = False 
    'ChDir "C:\TestData\Process" 
    ' 
    'Windows(Name + "ISOKBREP_ST60_CP" + Num + ".txt").Activate 
    Windows("ISOKBREP_ST60_CP" + Trim(Str(N)) + ".txt").Activate 
    Rows("7:7").Select 
    Selection.Delete Shift:=xlUp 
    Rows("8:8").Select 
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    Selection.Delete Shift:=xlUp 
    Range("F15").Select 
     
' Change rep #'s to 1,2,3 
 
    'Windows(Name + "ISOKBREP_ST60_CP" + Num + ".txt").Activate 
    Windows("ISOKBREP_ST60_CP" + Trim(Str(N)) + ".txt").Activate 
    Range("A7").Select 
    ActiveCell.FormulaR1C1 = "2" 
    Range("A8").Select 
    ActiveCell.FormulaR1C1 = "3" 
    Range("V7").Select 
   
    'Autofit columns 
    ActiveWindow.ScrollColumn = 26 
    ActiveWindow.ScrollColumn = 25 
    ActiveWindow.ScrollColumn = 24 
    ActiveWindow.ScrollColumn = 23 
    ActiveWindow.ScrollColumn = 22 
    ActiveWindow.ScrollColumn = 21 
    ActiveWindow.ScrollColumn = 20 
    ActiveWindow.ScrollColumn = 18 
    ActiveWindow.ScrollColumn = 17 
    ActiveWindow.ScrollColumn = 16 
    ActiveWindow.ScrollColumn = 15 
    ActiveWindow.ScrollColumn = 14 
    ActiveWindow.ScrollColumn = 13 
    ActiveWindow.ScrollColumn = 12 
    ActiveWindow.ScrollColumn = 11 
    ActiveWindow.ScrollColumn = 10 
    ActiveWindow.ScrollColumn = 9 
    ActiveWindow.ScrollColumn = 8 
    ActiveWindow.ScrollColumn = 7 
    ActiveWindow.ScrollColumn = 6 
    ActiveWindow.ScrollColumn = 5 
    ActiveWindow.ScrollColumn = 4 
    ActiveWindow.ScrollColumn = 3 
    ActiveWindow.ScrollColumn = 2 
    ActiveWindow.ScrollColumn = 1 
    Cells.Select 
    Selection.Columns.AutoFit 
    Range("I18").Select 
         
     ActiveWorkbook.SaveAs Filename:= _ 
        "C:\TestData\Process\Strength_REP\ISOKBREP_ST60_CP" + Trim(Str(N)) + ".xls", 
FileFormat:=xlNormal, _ 
        Password:="", WriteResPassword:="", ReadOnlyRecommended:=False, _ 
        CreateBackup:=False 
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'Sub ConvertToNm() 
'copy Repnum over to new column 
Windows("ISOKBREP_ST60_CP" + Trim(Str(N)) + ".xls").Activate 
 
For I = 5 To 7 
    Cells(I + 1, 22) = Cells(I + 1, 1) 
Next I 
 
'Convert ft-lb to N-m 
K = 1.355 'conversion factor to N-m 
 
For J = 1 To 2 'for KE and KF 
    For I = 5 To 7 
         PT = Cells(I + 1, J + 1) * K     'PT = PTKE and PTKF 
         'place PT in the columns for KE and KF 
              Cells(I + 1, J + 22) = PT 
    Next I 
Next J 
 
For L = 1 To 2 'for WKE and WKF 
    For I = 5 To 7 
         W = Cells(I + 1, L + 11) * K     'W = Peak Work for KE and KF 
         'place W in the columns for WKE and WKF 
              Cells(I + 1, L + 24) = W 
    Next I 
Next L 
 
'Sub Normalize() 
'normalize PT and Work by mass in kg 
 
 'convert BW(body wt)to kg 
    BW = Cells(1, 11) * 0.4526 
    Cells(6, 21) = BW 
     
m = Cells(6, 21) 'm = mass in kg 
 
For J = 1 To 4 
    For I = 5 To 7 
        Norm = Cells(I + 1, J + 22) / m * 100 'Norm = normalized data x 100% 
        'place normalized values in the appropriate columns 
            Cells(I + 1, J + 26) = Norm 
    Next I 
Next J 
     
'Sub Max() 
'max in N-m for PTKE,PTKF,TWKE,TWKF and Norm values 
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ReDim Max(8) 
ReDim MaxC(8) 
 
For J = 1 To 8 
    Max(J) = 0 
    For I = 5 To 7 
        If Cells(I + 1, J + 22) > Max(J) Then 
            Max(J) = Cells(I + 1, J + 22) 
            MaxC(J) = (I + 1) - 5 
        End If 
    Next I 
     'place max in appropriate column 
    Cells(6, J * 2 + 30) = Max(J) 
    'place rep # in column 
    Cells(6, J * 2 + 31) = MaxC(J) 
 Next J 
 
' PlaceMAXinspreadsheet Macro 
 
    Windows("ISOKBREP_ST60_CP" + Trim(Str(N)) + ".xls").Activate 
    Range("AF6,AH6,AJ6,AL6").Select 
    Range("AL6").Activate 
    Selection.Copy 
    'ChDir "C:\TestData" 
    'Workbooks.Open Filename:="C:\TestData\CP_data.xls" 
    Windows("CP_data.xls").Activate 
    Range("T45").Select 
    ActiveSheet.Paste 
 
    Windows("ISOKBREP_ST60_CP" + Trim(Str(N)) + ".xls").Activate 
    Range("AN6,AP6,AR6,AT6").Select 
    Range("AT6").Activate 
    Selection.Copy 
    Windows("CP_data.xls").Activate 
    Range("X45").Select 
    ActiveSheet.Paste 
         
'move Max(s) in row 45 to columns in data.xls file 
 For J = 1 To 8 
    Cells(N + 3, J + 19) = Cells(45, J + 19) 
    Next J 
     
    'Save and close file 
     
    Windows("ISOKBREP_ST60_CP" + Trim(Str(N)) + ".xls").Activate 
    ActiveWorkbook.Save 
    ActiveWindow.Close 
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Next N   'Loop to next subject 
 
 Windows("CP_data.xls").Activate 
    Range("T45:AA45").Select 
    Selection.ClearContents  'clear temp placement holder row45 
    ActiveWorkbook.Save 
     
Windows("Export_RepSTR_Headers.xls").Activate 
    ActiveWindow.Close 
     
End Sub 
 
 
'*************MACRO to Process ALL CONTROL(Normal) Strength Files******* 
'*************DATA must end in numerical format, ie, subject# 1,2,3..... 
Sub CONTROLSTRHeader() 
'Macro for CONTROL(Normal)Strength files 
'Files to process must be in the Process folder 
 
ChDir "C:\TestData" 
        Workbooks.OpenText Filename:="C:\TestData\Control_data.xls" 
 
For N = 1 To 16    'N = 1 to the # of subjects to process********CHANGE AS NEEDED**** 
' 
' STHeader Macro 
      
    ChDir "C:\TestData\Process\Strength_REP" 
        Workbooks.OpenText 
Filename:="C:\TestData\Process\Strength_REP\ISOKBREP_ST60_N" + Trim(Str(N)) + ".txt" _ 
        , Origin:=437, StartRow:=1, DataType:=xlDelimited, TextQualifier:= _ 
        xlDoubleQuote, ConsecutiveDelimiter:=False, Tab:=True, Semicolon:=False, _ 
        Comma:=True, Space:=False, Other:=False, FieldInfo:=Array(Array(1, 1), _ 
        Array(2, 1), Array(3, 1), Array(4, 1), Array(5, 1), Array(6, 1), Array(7, 1), Array(8, 1), _ 
        Array(9, 1), Array(10, 1), Array(11, 1), Array(12, 1), Array(13, 1), Array(14, 1), Array(15 _ 
        , 1), Array(16, 1), Array(17, 1), Array(18, 1), Array(19, 1)), TrailingMinusNumbers:= _ 
        True 
        
    Rows("3:5").Select 
    Selection.Insert Shift:=xlDown 
    ChDir "C:\TestData" 
    Workbooks.Open Filename:="C:\TestData\Export_RepSTR_Headers.xls" 
    Rows("3:5").Select 
    Range("AK3").Activate 
    Selection.Copy 
    'Windows(Name + "ISOKBREP_ST60_N" + Num + ".txt").Activate 
    Windows("ISOKBREP_ST60_N" + Trim(Str(N)) + ".txt").Activate 
    Rows("3:5").Select 
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    ActiveSheet.Paste 
    Application.CutCopyMode = False 
    'ChDir "C:\TestData\Process" 
     
    'Windows(Name + "ISOKBREP_ST60_N" + Num + ".txt").Activate 
    Windows("ISOKBREP_ST60_N" + Trim(Str(N)) + ".txt").Activate 
    Rows("7:7").Select 
    Selection.Delete Shift:=xlUp 
    Rows("8:8").Select 
    Selection.Delete Shift:=xlUp 
    Range("F15").Select 
     
' Change rep #'s to 1,2,3 
    'Windows(Name + "ISOKBREP_ST60_N" + Num + ".txt").Activate 
    Windows("ISOKBREP_ST60_N" + Trim(Str(N)) + ".txt").Activate 
    Range("A7").Select 
    ActiveCell.FormulaR1C1 = "2" 
    Range("A8").Select 
    ActiveCell.FormulaR1C1 = "3" 
    Range("V7").Select 
   
    'Autofit columns 
    ActiveWindow.ScrollColumn = 26 
    ActiveWindow.ScrollColumn = 25 
    ActiveWindow.ScrollColumn = 24 
    ActiveWindow.ScrollColumn = 23 
    ActiveWindow.ScrollColumn = 22 
    ActiveWindow.ScrollColumn = 21 
    ActiveWindow.ScrollColumn = 20 
    ActiveWindow.ScrollColumn = 18 
    ActiveWindow.ScrollColumn = 17 
    ActiveWindow.ScrollColumn = 16 
    ActiveWindow.ScrollColumn = 15 
    ActiveWindow.ScrollColumn = 14 
    ActiveWindow.ScrollColumn = 13 
    ActiveWindow.ScrollColumn = 12 
    ActiveWindow.ScrollColumn = 11 
    ActiveWindow.ScrollColumn = 10 
    ActiveWindow.ScrollColumn = 9 
    ActiveWindow.ScrollColumn = 8 
    ActiveWindow.ScrollColumn = 7 
    ActiveWindow.ScrollColumn = 6 
    ActiveWindow.ScrollColumn = 5 
    ActiveWindow.ScrollColumn = 4 
    ActiveWindow.ScrollColumn = 3 
    ActiveWindow.ScrollColumn = 2 
    ActiveWindow.ScrollColumn = 1 
    Cells.Select 
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    Selection.Columns.AutoFit 
    Range("I18").Select 
     
          ActiveWorkbook.SaveAs Filename:= _ 
        "C:\TestData\Process\Strength_REP\ISOKBREP_ST60_N" + Trim(Str(N)) + ".xls", 
FileFormat:=xlNormal, _ 
        Password:="", WriteResPassword:="", ReadOnlyRecommended:=False, _ 
        CreateBackup:=False 
 'Sub ConvertToNm() 
'copy Repnum over to new column 
 
Windows("ISOKBREP_ST60_N" + Trim(Str(N)) + ".xls").Activate 
 
For I = 5 To 7 
    Cells(I + 1, 22) = Cells(I + 1, 1) 
Next I 
 
'Convert ft-lb to N-m 
K = 1.355 'conversion factor to N-m 
 
For J = 1 To 2 'for KE and KF 
    For I = 5 To 7 
         PT = Cells(I + 1, J + 1) * K     'PT = PTKE and PTKF 
         'place PT in the columns for KE and KF 
              Cells(I + 1, J + 22) = PT 
    Next I 
Next J 
 
For L = 1 To 2 'for WKE and WKF 
    For I = 5 To 7 
         W = Cells(I + 1, L + 11) * K     'W = Peak Work for KE and KF 
         'place W in the columns for WKE and WKF 
              Cells(I + 1, L + 24) = W 
    Next I 
Next L 
 
'Sub Normalize() 
'normalize PT and Work by mass in kg 
 
 'convert BW(body wt)to kg 
    BW = Cells(1, 11) * 0.4526 
    Cells(6, 21) = BW 
     
m = Cells(6, 21) 'm = mass in kg 
 
For J = 1 To 4 
    For I = 5 To 7 
        Norm = Cells(I + 1, J + 22) / m * 100 'Norm = normalized data x 100% 
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        'place normalized values in the appropriate columns 
            Cells(I + 1, J + 26) = Norm 
    Next I 
Next J 
     
'Sub Max() 
'max in N-m for PTKE,PTKF,TWKE,TWKF and Norm values 
ReDim Max(8) 
ReDim MaxC(8) 
 
For J = 1 To 8 
    Max(J) = 0 
    For I = 5 To 7 
        If Cells(I + 1, J + 22) > Max(J) Then 
            Max(J) = Cells(I + 1, J + 22) 
            MaxC(J) = (I + 1) - 5 
        End If 
    Next I 
     'place max in appropriate column 
    Cells(6, J * 2 + 30) = Max(J) 
    'place rep # in column 
    Cells(6, J * 2 + 31) = MaxC(J) 
Next J 
 
' PlaceMAXinspreadsheet Macro 
 
    Windows("ISOKBREP_ST60_N" + Trim(Str(N)) + ".xls").Activate 
    Range("AF6,AH6,AJ6,AL6").Select 
    Range("AL6").Activate 
    Selection.Copy 
    'ChDir "C:\TestData" 
    'Workbooks.Open Filename:="C:\TestData\Control_data.xls" 
    Windows("Control_data.xls").Activate 
    Range("T45").Select 
    ActiveSheet.Paste 
 
    Windows("ISOKBREP_ST60_N" + Trim(Str(N)) + ".xls").Activate 
    Range("AN6,AP6,AR6,AT6").Select 
    Range("AT6").Activate 
    Selection.Copy 
    Windows("Control_data.xls").Activate 
    Range("X45").Select 
    ActiveSheet.Paste 
            
 'move Max(s) in row 45 to columns in data.xls file 
  For J = 1 To 8 
    Cells(N + 3, J + 19) = Cells(45, J + 19) 
    Next J 
 180 
     
    'Save and close file 
    Windows("ISOKBREP_ST60_N" + Trim(Str(N)) + ".xls").Activate 
    ActiveWorkbook.Save 
    ActiveWindow.Close 
         
Next N   'Loop to next subject 
 
 Windows("Control_data.xls").Activate 
    Range("T45:AA45").Select 
    Selection.ClearContents  'clear temp placement holder row45 
    ActiveWorkbook.Save 
     
Windows("Export_RepSTR_Headers.xls").Activate 
    ActiveWindow.Close 
     
End Sub
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EMG Program: EMG Mean Removal, Rectification, Low Pass Filtering, Rescaling separately for 
knee extension and flexion, and calculation of cocontraction 
 
 
Sub emg() 
 
'*****Individual Parameters**************** 
 Group = "N"    'CP or N 
 Num = "3"         'Subject # 
'******************************************* 
For N = 1 To 3 
  Workbooks.OpenText Filename:= _ 
        "C:\TestData\Process\EMG\" + Group + "\" + Group + Num + "\ST60_" + Trim(Str(N)) + 
".xls", Origin:=437, _ 
        StartRow:=1, DataType:=xlFixedWidth, FieldInfo:=Array(Array(0, 1), Array(6, _ 
        1), Array(18, 1), Array(27, 1), Array(42, 1)), TrailingMinusNumbers:=True 
         
'find total # of points 
For I = 1 To 8000 
    If Cells(I + 4, 1) = "" Then Exit For 
Next I 
ttlpnt = I - 1  'Total # of points 
'read in data 
For I = 1 To 4 
    'define the array 
    ReDim dat(ttlpnt)  'column/row 
    dat(0) = Cells(4, I + 1) 
    For J = 1 To ttlpnt 
        dat(J) = Cells(J + 4, I + 1) 
    Next J 
    'replace the title of each channel 
    Cells(4, I + 10) = dat(0) 
    'calculate means 
    dat(0) = 0 
    For J = 1 To ttlpnt 
        dat(0) = dat(0) + dat(J)     'all all the emg values together 
    Next J 
    dat(0) = dat(0) / ttlpnt     'divided by # of data points 
    For J = 1 To ttlpnt 
        'full wave rectification and subtract the mean 
        dat(J) = Abs(dat(J) - dat(0)) 
    Next J 
'*********Filter ***************** 
'Following are the variables needed to be defined outside 
'of the sub in order to get the sub "DFilter" to operate 
DFNumpnt = ttlpnt      ' Number of points in the set of data being passed in 
Const DFPi = 3.1415926 
Const DFcutoff = 6      ' Cutoff frequency for either a hi-pass or a low-pass 
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Const DFfiltertype = "lp"  ' can be either "lp" for low pass or "hp" for high pass 
Const DFSrate = 1000       'Sampling rate of the original date 
Const DFtypef = "Butterworth" 
Dim DFti    ' time interval (period) of the original data, 1/sampling rate 
Dim DFpcut 
Dim DFWC 
Dim DFk1, DFk2, DFk3 
Dim DFa0, DFa1, DFa2 
Dim DFb1, DFb2 
Dim DFfiltoption As String 
ReDim DFdata(DFNumpnt)    ' original data set need to be passed in to the sub 
ReDim DFnewdata(DFNumpnt) ' Filtered data at the end of the sub 
ReDim DFTemp(1 To DFNumpnt + 4), DFprime(1 To DFNumpnt + 4) As Single 
'generate data 
For DFi = 1 To DFNumpnt 
    DFdata(DFi) = dat(DFi) 
Next DFi 
'Fourth order, zero lag filter 
'correction to cutoff for high-pass filter 
DFfiltoption = DFfiltertype 
DFti = 1 / DFSrate 
If DFfiltoption = "hp" Then 
    DFpcut = (1 / (2 * DFti)) - DFcutoff 
Else 
    DFpcut = DFcutoff 
End If 
DFWC = Tan(DFPi * DFpcut * DFti) 
'Wc need to be corrected for the dual pass 
'Murphy and Robertson (1994), 
'J. of Applied Biomechanics, 10:374-381 
'And also, Robertson, Barden and Dowling 
'NACOB II, 1992 
If DFtypef = "Butterworth" Then 
    DFWC = DFWC / Sqr(Sqr(Sqr(2) - 1)) 
Else 
    DFWC = DFWC / Sqr(Sqr(Sqr(2)) - 1) 
End If 
If DFtypef = "Butterworth" Then 
    DFk1 = Sqr(2) * DFWC 
Else 
    DFk1 = 2 * DFWC 
End If 
DFk2 = DFWC ^ 2 
DFa0 = DFk2 / (1 + DFk1 + DFk2) 
DFa1 = 2 * DFa0 
DFa2 = DFa0 
DFk3 = (2 * DFa0) / DFk2 
DFb1 = (-2 * DFa0) + DFk3 
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DFb2 = 1 - (2 * DFa0) - DFk3 
'correction to coefficients for high-pass filter 
If DFfiltoption = "hp" Then 
    DFa1 = -DFa1 
    DFb1 = -DFb1 
End If 
'Filter 
DFTemp(1) = DFdata(1) + (DFdata(1) - DFdata(2)) 
DFTemp(2) = DFdata(1) + (DFdata(1) - DFdata(3)) 
DFTemp(DFNumpnt + 4) = DFdata(DFNumpnt) + (DFdata(DFNumpnt) - DFdata(DFNumpnt - 
1)) 
DFTemp(DFNumpnt + 3) = DFdata(DFNumpnt) + (DFdata(DFNumpnt) - DFdata(DFNumpnt - 
2)) 
For DFi = 1 To DFNumpnt 
    DFTemp(DFi + 2) = DFdata(DFi) 
Next DFi 
For DFi = 1 To DFNumpnt + 4 
    DFprime(DFi) = DFTemp(DFi) 
Next DFi 
For DFi = 3 To DFNumpnt + 4 
    DFprime(DFi) = DFa0 * DFTemp(DFi) + DFa1 * DFTemp(DFi - 1) + DFa2 * DFTemp(DFi - 
2) + DFb1 * DFprime(DFi - 1) + DFb2 * DFprime(DFi - 2) 
Next DFi 
For DFi = 1 To DFNumpnt + 4 
    DFTemp(DFi) = DFprime(DFi) 
Next DFi 
For DFi = DFNumpnt + 2 To 1 Step -1 
    DFprime(DFi) = DFa0 * DFTemp(DFi) + DFa1 * DFTemp(DFi + 1) + DFa2 * DFTemp(DFi 
+ 2) + DFb1 * DFprime(DFi + 1) + DFb2 * DFprime(DFi + 2) 
Next DFi 
For DFi = 1 To DFNumpnt 
    dat(DFi) = DFprime(DFi + 2) 
Next DFi 
'*******Filter************ 
    For J = 1 To ttlpnt 
        'print rectified data back to the spread sheet 
        Cells(J + 4, I + 10) = dat(J) 
    Next J 
Next I 
 
Cells(1, 10) = ttlpnt 
 
Next N 
 
End Sub 
'*******Program for the RightLE where ext motion is (+)velocity and flex motion (-)velocity 
Sub RIGHTConstantVelocity() 
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For N = 1 To 3 
 
  sheetname = "ST60_" + Trim(Str(N)) 
  Windows(sheetname + ".xls").Activate 
 
 'Format velocity into numerical format 
 Range("F5").Select 
    Range(Selection, Selection.End(xlDown)).Select 
    Selection.NumberFormat = "0.00" 
 Range("S1").Select 
  
th = 1.9   'threshold   Change as needed************************ 
Speed = 60 
Speed = Speed - th 
'read in numbers and find total # of data points 
ReDim dat(6, 7000) 
For I = 1 To 7000 
    If Cells(I + 4, 1) = "" Then Exit For 
    dat(1, I) = Cells(I + 4, 1)  'Time (ms) 
    dat(2, I) = Cells(I + 4, 6)  'Velocity 
    dat(3, I) = Cells(I + 4, 11) 'Rectus Femoris EMG 
    dat(4, I) = Cells(I + 4, 12) 'Vastus Medialis EMG 
    dat(5, I) = Cells(I + 4, 13) 'Lat. Hamstrings EMG 
    dat(6, I) = Cells(I + 4, 14) 'Med. Hamstrings EMG 
Next I 
ttlpnt = I - 1  'ttlpnt = total # of data points 
'+++++++++++++++++++++++++++++++++++++++++ 
'find the extension phase 
ReDim est(1)    'starting of the extension phase 
ReDim eend(1)   'end of the extension phase 
For I = 1 To ttlpnt 
    If dat(2, I) > Speed And dat(2, I + 1) > Speed And dat(2, I + 2) > Speed And dat(2, I + 3) Then 
        est(1) = I 
        Exit For 
    End If 
Next I 
For I = est(1) To ttlpnt 
    If dat(2, I) < Speed And dat(2, I + 1) < Speed And dat(2, I + 2) < Speed And dat(2, I + 3) < 
Speed And dat(2, I + 4) Then 
        eend(1) = I - 1 
        Exit For 
    End If 
Next I 
'+++++++++++++++++++++++++++++++++++++++++ 
'find the flexion phase 
ReDim fst(1)    'starting of the flexion phase 
ReDim fend(1)   'end of the flexion phase 
For I = eend(1) To ttlpnt 
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    If dat(2, I) < -Speed And dat(2, I + 1) < -Speed And dat(2, I + 2) Then 
        fst(1) = I 
        Exit For 
    End If 
Next I 
For I = fst(1) To ttlpnt 
    If dat(2, I) > -Speed And dat(2, I + 1) > -Speed And dat(2, I + 2) > -Speed And dat(2, I + 3) 
Then 
        fend(1) = I - 1 
        Exit For 
    End If 
Next I 
 
'Print data to spread sheet and :calculate the sum of each EMG channel for Extension 
aRFe = 0: aVMe = 0: aLHe = 0: aMHe = 0 
aRFf = 0: aVMf = 0: aLHf = 0: aMHf = 0 
    For I = 1 To eend(1) - est(1) + 1 
        Cells(I + 4, 16) = dat(1, I + est(1) - 1) - dat(1, est(1)) 'correct time to start at 0 
        Cells(I + 4, 17) = dat(2, I + est(1) - 1) 
        Cells(I + 4, 18) = dat(3, I + est(1) - 1): aRFe = aRFe + dat(3, I + est(1) - 1) 
        Cells(I + 4, 19) = dat(4, I + est(1) - 1): aVMe = aVMe + dat(4, I + est(1) - 1) 
        Cells(I + 4, 20) = dat(5, I + est(1) - 1): aLHe = aLHe + dat(5, I + est(1) - 1) 
        Cells(I + 4, 21) = dat(6, I + est(1) - 1): aMHe = aMHe + dat(6, I + est(1) - 1) 
    Next I 
'Calculate averages of each EMG channel for Extension phase 
    'aRFe = Avg of the RF EMG acting in extension (agonist) 
    'aVMe = Avg of the VM EMG acting in extension (agonist) 
    'aLHe = Avg of the LH EMG acting in extension (antagonist) 
    'aMHe = Avg of the MH EMG acting in extension (antagonist) 
aRFe = aRFe / (eend(1) - est(1) + 1) 
aVMe = aVMe / (eend(1) - est(1) + 1) 
aLHe = aLHe / (eend(1) - est(1) + 1) 
aMHe = aMHe / (eend(1) - est(1) + 1) 
'Print data to spread sheet and :calculate the sum of each EMG channel for Flexion 
    For I = 1 To fend(1) - fst(1) + 1 
        Cells(I + 4, 23) = dat(1, I + fst(1) - 1) - dat(1, fst(1)) 
        Cells(I + 4, 24) = dat(2, I + fst(1) - 1) 
        Cells(I + 4, 25) = dat(3, I + fst(1) - 1): aRFf = aRFf + dat(3, I + fst(1) - 1) 
        Cells(I + 4, 26) = dat(4, I + fst(1) - 1): aVMf = aVMf + dat(4, I + fst(1) - 1) 
        Cells(I + 4, 27) = dat(5, I + fst(1) - 1): aLHf = aLHf + dat(5, I + fst(1) - 1) 
        Cells(I + 4, 28) = dat(6, I + fst(1) - 1): aMHf = aMHf + dat(6, I + fst(1) - 1) 
    Next I 
'Calculate averages of each EMG channel for Flexion phase 
    'aRFf = Avg of the RF EMG acting in flexion (antagonist) 
    'aVMf = Avg of the VM EMG acting in flexion (antagonist) 
    'aLHf = Avg of the LH EMG acting in flexion (agonist) 
    'aMHf = Avg of the MH EMG acting in flexion (agonist) 
aRFf = aRFf / (fend(1) - fst(1) + 1) 
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aVMf = aVMf / (fend(1) - fst(1) + 1) 
aLHf = aLHf / (fend(1) - fst(1) + 1) 
aMHf = aMHf / (fend(1) - fst(1) + 1) 
'Print Avg values to spreadsheet 
Cells(2, 18) = aRFe 
Cells(2, 19) = aVMe 
Cells(2, 20) = aLHe 
Cells(2, 21) = aMHe 
Cells(2, 25) = aRFf 
Cells(2, 26) = aVMf 
Cells(2, 27) = aLHf 
Cells(2, 28) = aMHf 
'Print Normalized Cocontraction data (antagonist/agonist) to spreadsheet in % format 
Cells(1, 20) = Int(0.5 + 1000 * aLHe / aLHf) / 10  'Cocontraction of LH during Extension 
Cells(1, 21) = Int(0.5 + 1000 * aMHe / aMHf) / 10  'Cocontraction of MH during Extension 
Cells(1, 25) = Int(0.5 + 1000 * aRFf / aRFe) / 10  'Cocontraction of RF during Flexion 
Cells(1, 26) = Int(0.5 + 1000 * aVMf / aVMe) / 10  'Cocontraction of VM during Flexion 
'Print ttlpnt and start/stop points to spreadsheet 
Cells(1, 10) = ttlpnt 
Cells(1, 11) = est(1) + 4 
Cells(1, 12) = eend(1) + 4 
Cells(2, 11) = fst(1) + 4 
Cells(2, 12) = fend(1) + 4 
'Print headers 
Cells(4, 16) = Cells(4, 1) 
Cells(4, 23) = Cells(4, 1) 
Cells(4, 17) = Cells(4, 6) 
Cells(4, 24) = Cells(4, 6) 
Cells(4, 18) = Cells(4, 2) 
Cells(4, 25) = Cells(4, 2) 
Cells(4, 19) = Cells(4, 3) 
Cells(4, 26) = Cells(4, 3) 
Cells(4, 20) = Cells(4, 4) 
Cells(4, 27) = Cells(4, 4) 
Cells(4, 21) = Cells(4, 5) 
Cells(4, 28) = Cells(4, 5) 
Cells(3, 16) = "Extension motion" 
Cells(3, 23) = "Flexion motion" 
 
Next N 
End Sub 
 
'*******Program for Left sided trials to make ext motion (+)velocity and flex motion (-)velocity 
Sub LEFTMultiplyVelocity() 
 
For N = 1 To 3 
 
  sheetname = "ST60_" + Trim(Str(N)) 
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  Windows(sheetname + ".xls").Activate 
  
 'Format velocity into numerical format 
 Range("F5").Select 
    Range(Selection, Selection.End(xlDown)).Select 
    Selection.NumberFormat = "0.00" 
 Range("S1").Select 
 
  ' Multiply velocity cells by -1 to make ext motion (+)velocity and flex motion (-)velocity 
    Cells(1, 5) = -1 
    Range("E1").Select 
    Application.CutCopyMode = False 
    Selection.Copy 
    Range("F5").Select 
    Range(Selection, Selection.End(xlDown)).Select 
    Selection.PasteSpecial Paste:=xlPasteAll, Operation:=xlMultiply, _ 
        SkipBlanks:=False, Transpose:=False 
    Range("E1").Select 
    Selection.ClearContents 
   Next N 
End Sub 
 
'*******Program for the RightLE where ext motion is (+)velocity and flex motion (-)velocity 
Sub MANUALRightConstantVelocity() 
 
For N = 1 To 3     'ST60_ trial # 
 
  sheetname = "ST60_" + Trim(Str(N)) 
  Windows(sheetname + ".xls").Activate 
 
 'Format velocity into numerical format 
 Range("F5").Select 
    Range(Selection, Selection.End(xlDown)).Select 
 Selection.NumberFormat = "0.00" 
 Range("S1").Select 
  
'*******MANUAL - Change Start/Stop data points on spreadsheet*********************** 
est = Cells(1, 11)      'start of extension phase 
eend = Cells(1, 12)     'end of extension phase 
fst = Cells(2, 11)      'start of flexion phase 
fend = Cells(2, 12)     'end of flexion phase 
'***************************************************************************** 
'read in numbers and find total # of data points 
ReDim dat(6, 7000) 
For I = 1 To 7000 
    If Cells(I + 4, 1) = "" Then Exit For 
    dat(1, I) = Cells(I + 4, 1)  'Time (ms) 
    dat(2, I) = Cells(I + 4, 6)  'Velocity 
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    dat(3, I) = Cells(I + 4, 11) 'Rectus Femoris EMG 
    dat(4, I) = Cells(I + 4, 12) 'Vastus Medialis EMG 
    dat(5, I) = Cells(I + 4, 13) 'Lat. Hamstrings EMG 
    dat(6, I) = Cells(I + 4, 14) 'Med. Hamstrings EMG 
Next I 
ttlpnt = I - 1  'ttlpnt = total # of data points 
'+++++++++++++++++++++++++++++++++++++++++ 
'Print data to spread sheet and :calculate the sum of each EMG channel for Extension 
aRFe = 0: aVMe = 0: aLHe = 0: aMHe = 0 
aRFf = 0: aVMf = 0: aLHf = 0: aMHf = 0 
    For I = 1 To eend - est + 1 
        Cells(I + 4, 16) = dat(1, I + est - 1) - dat(1, est) 'correct time to start at 0 
        Cells(I + 4, 17) = dat(2, I + est - 1) 
        Cells(I + 4, 18) = dat(3, I + est - 1): aRFe = aRFe + dat(3, I + est - 1) 
        Cells(I + 4, 19) = dat(4, I + est - 1): aVMe = aVMe + dat(4, I + est - 1) 
        Cells(I + 4, 20) = dat(5, I + est - 1): aLHe = aLHe + dat(5, I + est - 1) 
        Cells(I + 4, 21) = dat(6, I + est - 1): aMHe = aMHe + dat(6, I + est - 1) 
    Next I 
'Calculate averages of each EMG channel for Extension phase 
    'aRFe = Avg of the RF EMG acting in extension (agonist) 
    'aVMe = Avg of the VM EMG acting in extension (agonist) 
    'aLHe = Avg of the LH EMG acting in extension (antagonist) 
    'aMHe = Avg of the MH EMG acting in extension (antagonist) 
aRFe = aRFe / (eend - est + 1) 
aVMe = aVMe / (eend - est + 1) 
aLHe = aLHe / (eend - est + 1) 
aMHe = aMHe / (eend - est + 1) 
'Print data to spread sheet and :calculate the sum of each EMG channel for Flexion 
    For I = 1 To fend - fst + 1 
        Cells(I + 4, 23) = dat(1, I + fst - 1) - dat(1, fst) 
        Cells(I + 4, 24) = dat(2, I + fst - 1) 
        Cells(I + 4, 25) = dat(3, I + fst - 1): aRFf = aRFf + dat(3, I + fst - 1) 
        Cells(I + 4, 26) = dat(4, I + fst - 1): aVMf = aVMf + dat(4, I + fst - 1) 
        Cells(I + 4, 27) = dat(5, I + fst - 1): aLHf = aLHf + dat(5, I + fst - 1) 
        Cells(I + 4, 28) = dat(6, I + fst - 1): aMHf = aMHf + dat(6, I + fst - 1) 
    Next I 
'Calculate averages of each EMG channel for Flexion phase 
    'aRFf = Avg of the RF EMG acting in flexion (antagonist) 
    'aVMf = Avg of the VM EMG acting in flexion (antagonist) 
    'aLHf = Avg of the LH EMG acting in flexion (agonist) 
    'aMHf = Avg of the MH EMG acting in flexion (agonist) 
aRFf = aRFf / (fend - fst + 1) 
aVMf = aVMf / (fend - fst + 1) 
aLHf = aLHf / (fend - fst + 1) 
aMHf = aMHf / (fend - fst + 1) 
'Print Avg values to spreadsheet 
Cells(2, 18) = aRFe 
Cells(2, 19) = aVMe 
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Cells(2, 20) = aLHe 
Cells(2, 21) = aMHe 
Cells(2, 25) = aRFf 
Cells(2, 26) = aVMf 
Cells(2, 27) = aLHf 
Cells(2, 28) = aMHf 
'Print Normalized Cocontraction data (antagonist/agonist) to spreadsheet in % format 
Cells(1, 20) = Int(0.5 + 1000 * aLHe / aLHf) / 10  'Cocontraction of LH during Extension 
Cells(1, 21) = Int(0.5 + 1000 * aMHe / aMHf) / 10  'Cocontraction of MH during Extension 
Cells(1, 25) = Int(0.5 + 1000 * aRFf / aRFe) / 10  'Cocontraction of RF during Flexion 
Cells(1, 26) = Int(0.5 + 1000 * aVMf / aVMe) / 10  'Cocontraction of VM during Flexion 
Cells(1, 10) = ttlpnt 
'Print headers 
Cells(4, 16) = Cells(4, 1) 
Cells(4, 23) = Cells(4, 1) 
Cells(4, 17) = Cells(4, 6) 
Cells(4, 24) = Cells(4, 6) 
Cells(4, 18) = Cells(4, 2) 
Cells(4, 25) = Cells(4, 2) 
Cells(4, 19) = Cells(4, 3) 
Cells(4, 26) = Cells(4, 3) 
Cells(4, 20) = Cells(4, 4) 
Cells(4, 27) = Cells(4, 4) 
Cells(4, 21) = Cells(4, 5) 
Cells(4, 28) = Cells(4, 5) 
Cells(3, 16) = "Extension motion" 
Cells(3, 23) = "Flexion motion" 
 
Next N 
End Sub
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Passive Data Programs: Resistance torque (spasticity) and stiffness 
 
 
Sub openfileP5() 
'++++++++++++++++++For P5 - To determine Gravity Correction++++++++++++++ 
 
'*****Individual Parameters**************** 
 Group = "CP"    'CP or N 
 Num = "4"       'Subject # 
 Speed = "5"     'Speed 
'******************************************* 
  Workbooks.OpenText Filename:= _ 
        "C:\TestData\Process\Passive_Log to\" + Group + "\" + Group + Num + "\" + Group + Num 
+ "_P" + Speed + ".txt", Origin:=437, _ 
        StartRow:=1, DataType:=xlFixedWidth, FieldInfo:=Array(Array(0, 1), Array(6, _ 
        1), Array(18, 1), Array(27, 1), Array(42, 1)), TrailingMinusNumbers:=True 
         
        ActiveWorkbook.saveas Filename:= _ 
        "C:\TestData\Process\Passive_Log to\" + Group + "\" + Group + Num + "\" + Group + Num 
+ "_P" + Speed + ".xls", FileFormat:=xlNormal _ 
        , Password:="", WriteResPassword:="", ReadOnlyRecommended:=False, _ 
        CreateBackup:=False 
         
   'Sub graf() 
    sheetname = Group + Num + "_P" + Speed 
    Windows(sheetname + ".xls").Activate 
    Charts.Add 
    ActiveChart.ChartType = xlXYScatterLinesNoMarkers 
    ActiveChart.SetSourceData Source:=Sheets(sheetname).Range("F18") 
    ActiveChart.SeriesCollection.NewSeries 
    ActiveChart.SeriesCollection(1).XValues = Sheets(sheetname).Range("D7:D12199") 
    ActiveChart.SeriesCollection(1).Values = Sheets(sheetname).Range("B7:B12199") 
    ActiveChart.Location Where:=xlLocationAsObject, Name:=sheetname 
    With ActiveChart.Axes(xlCategory) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlValue) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    ActiveChart.HasLegend = False 
    ActiveChart.PlotArea.Select 
    Selection.ClearFormats 
     
    Range("E11").Select 
Select Case Speed 
    Case 5 
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        th = 0.5 
    Case Else 
        th = 1.1 
End Select 
 
Cells(3, 7) = "Extension motion" 
Cells(3, 14) = "Flexion motion" 
 
Speed = Speed - th 
'read in numbers 
ReDim dat(4, 13000) 
For I = 1 To 13000 
    If Cells(I + 6, 1) = "" Then Exit For 
    dat(1, I) = Cells(I + 6, 1) 'Time (ms) 
    dat(2, I) = Cells(I + 6, 2) 'Torque (Nm) 
    dat(3, I) = Cells(I + 6, 4) 'Position (Anatonical, degree) 
    dat(4, I) = Cells(I + 6, 5) 'Velocity (deg/sec) 
Next I 
ttlpnt = I - 1 
'find the three extension trials 
ReDim est(3)    'starting of the extension phase 
ReDim eend(3)   'end of the extension phase 
'first extension 
For I = 1 To ttlpnt 
    If dat(4, I) > Speed And dat(4, I + 1) > Speed And dat(4, I + 2) > Speed Then 
        est(1) = I 
        Exit For 
    End If 
Next I 
For I = est(1) To ttlpnt 
    If dat(4, I) < Speed And dat(4, I + 1) < Speed And dat(4, I + 2) < Speed Then 
        eend(1) = I - 1 
        Exit For 
    End If 
Next I 
'second extension 
'**************find the beginning of the next extension phase 
For I = eend(1) To ttlpnt 
    If dat(4, I) < 0 Then Exit For 
Next I 
nst = I 'new starting point 
For I = nst To ttlpnt 
    If dat(4, I) > 0 Then Exit For 
Next I 
nst = I 
'******************************************************** 
For I = nst To ttlpnt 
    If dat(4, I) > Speed And dat(4, I + 1) > Speed And dat(4, I + 2) > Speed Then 
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        est(2) = I 
        Exit For 
    End If 
Next I 
For I = est(2) To ttlpnt 
    If dat(4, I) < Speed And dat(4, I + 1) < Speed And dat(4, I + 2) < Speed Then 
        eend(2) = I - 1 
        Exit For 
    End If 
Next I 
'Third extension 
'**************find the beginning of the next extension phase 
For I = eend(2) To ttlpnt 
    If dat(4, I) < 0 Then Exit For 
Next I 
nst = I 'new starting point 
For I = nst To ttlpnt 
    If dat(4, I) > 0 Then Exit For 
Next I 
nst = I 
'******************************************************** 
For I = nst To ttlpnt 
    If dat(4, I) > Speed And dat(4, I + 1) > Speed And dat(4, I + 2) > Speed Then 
        est(3) = I 
        Exit For 
    End If 
Next I 
For I = est(3) To ttlpnt 
    If dat(4, I) < Speed And dat(4, I + 1) < Speed And dat(4, I + 2) < Speed Then 
        eend(3) = I - 1 
        Exit For 
    End If 
Next I 
'+++++++++++++++++++++++++++++++++++++++++ 
'find the three flexion trials 
ReDim fst(3)    'starting of the flexion phase 
ReDim fend(3)   'end of the flexion phase 
'first flexion 
For I = eend(1) To ttlpnt 
    If dat(4, I) < -Speed And dat(4, I + 1) < -Speed And dat(4, I + 2) < -Speed Then 
        fst(1) = I 
        Exit For 
    End If 
Next I 
For I = fst(1) To ttlpnt 
    If dat(4, I) > -Speed And dat(4, I + 1) > -Speed And dat(4, I + 2) > -Speed Then 
        fend(1) = I - 1 
        Exit For 
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    End If 
Next I 
'second flexion 
For I = eend(2) To ttlpnt 
    If dat(4, I) < -Speed And dat(4, I + 1) < -Speed And dat(4, I + 2) < -Speed Then 
        fst(2) = I 
        Exit For 
    End If 
Next I 
For I = fst(2) To ttlpnt 
    If dat(4, I) > -Speed And dat(4, I + 1) > -Speed And dat(4, I + 2) > -Speed Then 
        fend(2) = I - 1 
        Exit For 
    End If 
Next I 
'Third flexion 
For I = eend(3) To ttlpnt 
    If dat(4, I) < -Speed And dat(4, I + 1) < -Speed And dat(4, I + 2) < -Speed Then 
        fst(3) = I 
        Exit For 
    End If 
Next I 
For I = fst(3) To ttlpnt 
    If dat(4, I) > -Speed And dat(4, I + 1) > -Speed And dat(4, I + 2) > -Speed Then 
        fend(3) = I - 1 
        Exit For 
    End If 
Next I 
'Export trials into new array 
'find max number of data points in all six trials 
maxp = 0 
For I = 1 To 3 
    If maxp < eend(I) - est(I) + 1 Then maxp = eend(I) - est(I) + 1 
    If maxp < fend(I) - fst(I) + 1 Then maxp = fend(I) - fst(I) + 1 
Next I 
ReDim newdat(2, 2, 3, maxp) '2-exten(1)/flex(2); 2-angle(1)/torque(2); 3-three trials; and maxp - 
maxnumber in all trials 
For J = 1 To 3 
    For I = est(J) To eend(J) 
        newdat(1, 1, J, I - est(J) + 1) = dat(3, I) 
    'without gravity correction 
        newdat(1, 2, J, I - est(J) + 1) = dat(2, I) 
    'with gravity correction 
        'newdat(1, 2, J, I - est(J) + 1) = dat(2, I) + gc * Cos((dat(3, I) - 0) * 3.14 / 180) / Cos(cosgc * 
3.14 / 180) 
    'gravity correction by itself 
        'newdat(1, 2, J, I - est(J) + 1) = gc * Cos(dat(3, I) * 3.14 / 180) / Cos(cosgc * 3.14 / 180) 
    Next I 
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Next J 
For J = 1 To 3 
    For I = fst(J) To fend(J) 
        newdat(2, 1, J, I - fst(J) + 1) = dat(3, I) 
    'without gravity correction 
        newdat(2, 2, J, I - fst(J) + 1) = dat(2, I) 
    'with gravity correction 
        'newdat(2, 2, J, I - fst(J) + 1) = dat(2, I) + gc * Cos((dat(3, I) - 0) * 3.14 / 180) / Cos(cosgc * 
3.14 / 180) 
    'gravity correction by itself 
        'newdat(2, 2, J, I - fst(J) + 1) = gc * Cos(dat(3, I) * 3.14 / 180) / Cos(cosgc * 3.14 / 180) 
    Next I 
Next J 
'find minimum torque (@angle) during extension motion 
ReDim minT(2, 3)    '2- angle(1)/torque(2); 3- three trials 
For J = 1 To 3 
    minT(2, J) = 1000 
    For I = 1 To eend(J) - est(J) + 1 
        If minT(2, J) > newdat(1, 2, J, I) Then 
            minT(2, J) = newdat(1, 2, J, I) 'find the minimum torque 
            minT(1, J) = newdat(1, 1, J, I) 'find the angle with it 
        End If 
    Next I 
Next J 
'find maximum torque (@angle) during flexion motion 
ReDim maxT(2, 3) 
For J = 1 To 3 
    maxT(2, J) = -1000 
    For I = 1 To fend(J) - fst(J) + 1 
        If maxT(2, J) < newdat(2, 2, J, I) Then 
            maxT(2, J) = newdat(2, 2, J, I) 'find the maximum torque 
            maxT(1, J) = newdat(2, 1, J, I) 'find the angle with it 
        End If 
    Next I 
Next J 
'Print data to spread sheet 
For J = 1 To 3 
    For I = 1 To eend(J) - est(J) + 1 
        Cells(I + 6, 7 + (J - 1) * 2) = newdat(1, 1, J, I) 
        Cells(I + 6, 8 + (J - 1) * 2) = newdat(1, 2, J, I) 
    Next I 
Next J 
For J = 1 To 3 
    For I = 1 To fend(J) - fst(J) + 1 
        Cells(I + 6, 14 + (J - 1) * 2) = newdat(2, 1, J, I) 
        Cells(I + 6, 15 + (J - 1) * 2) = newdat(2, 2, J, I) 
    Next I 
Next J 
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Cells(1, 7) = ttlpnt 
Cells(1, 8) = est(1) + 6 
Cells(1, 9) = eend(1) + 6 
Cells(1, 10) = est(2) + 6 
Cells(1, 11) = eend(2) + 6 
Cells(1, 12) = est(3) + 6 
Cells(1, 13) = eend(3) + 6 
Cells(2, 8) = fst(1) + 6 
Cells(2, 9) = fend(1) + 6 
Cells(2, 10) = fst(2) + 6 
Cells(2, 11) = fend(2) + 6 
Cells(2, 12) = fst(3) + 6 
Cells(2, 13) = fend(3) + 6 
'For J = 1 To 3 
    'Cells(5, 7 + (J - 1) * 2) = minT(1, J) 
    'Cells(5, 8 + (J - 1) * 2) = minT(2, J) 
    'Cells(5, 14 + (J - 1) * 2) = maxT(1, J) 
    'Cells(5, 15 + (J - 1) * 2) = maxT(2, J) 
'Next J 
'End Sub 
'******************************************************** 
'Sub graf2()  'Extension movement 
 
    'sheetname = Group + Num + "_P" + Speed 
    Windows(sheetname + ".xls").Activate 
    Charts.Add 
    ActiveChart.ChartType = xlXYScatterLinesNoMarkers 
    ActiveChart.SetSourceData Source:=Sheets(sheetname).Range("I18") 
    ActiveChart.SeriesCollection.NewSeries 
    ActiveChart.SeriesCollection(1).XValues = Sheets(sheetname).Range("G7:G2863") 
    ActiveChart.SeriesCollection(1).Values = Sheets(sheetname).Range("H7:H2863") 
    ActiveChart.SeriesCollection(2).XValues = Sheets(sheetname).Range("I7:I2863") 
    ActiveChart.SeriesCollection(2).Values = Sheets(sheetname).Range("J7:J2863") 
    ActiveChart.SeriesCollection.NewSeries 
    ActiveChart.SeriesCollection(3).XValues = Sheets(sheetname).Range("K7:K2863") 
    ActiveChart.SeriesCollection(3).Values = Sheets(sheetname).Range("L7:L2863") 
    ActiveChart.Location Where:=xlLocationAsObject, Name:=sheetname 
    With ActiveChart 
        .HasTitle = True 
        .ChartTitle.Characters.Text = "Knee extension movement" 
        .Axes(xlCategory, xlPrimary).HasTitle = False 
        .Axes(xlValue, xlPrimary).HasTitle = False 
    End With 
    With ActiveChart.Axes(xlCategory) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlValue) 
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        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlCategory) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlValue) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    ActiveChart.HasLegend = False 
    ActiveChart.PlotArea.Select 
    Selection.ClearFormats 
    'End Sub 
     
    'Sub graf3()  'Flexion movement 
    'sheetname = "P5" 
    Windows(sheetname + ".xls").Activate 
    
    Charts.Add 
    ActiveChart.ChartType = xlXYScatterLinesNoMarkers 
    ActiveChart.SetSourceData Source:=Sheets(sheetname).Range("Q18") 
    ActiveChart.SeriesCollection.NewSeries 
    ActiveChart.SeriesCollection(1).XValues = Sheets(sheetname).Range("N7:N2863") 
    ActiveChart.SeriesCollection(1).Values = Sheets(sheetname).Range("O7:O2863") 
    ActiveChart.SeriesCollection.NewSeries 
    ActiveChart.SeriesCollection(2).XValues = Sheets(sheetname).Range("P7:P2863") 
    ActiveChart.SeriesCollection(2).Values = Sheets(sheetname).Range("Q7:Q2863") 
    ActiveChart.SeriesCollection.NewSeries 
    ActiveChart.SeriesCollection(3).XValues = Sheets(sheetname).Range("R7:R2863") 
    ActiveChart.SeriesCollection(3).Values = Sheets(sheetname).Range("S7:S2863") 
    ActiveChart.Location Where:=xlLocationAsObject, Name:=sheetname 
    With ActiveChart 
        .HasTitle = True 
        .ChartTitle.Characters.Text = "Knee flexion movement" 
        .Axes(xlCategory, xlPrimary).HasTitle = False 
        .Axes(xlValue, xlPrimary).HasTitle = False 
    End With 
    With ActiveChart.Axes(xlCategory) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlValue) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlCategory) 
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        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlValue) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    ActiveChart.HasLegend = False 
    ActiveChart.PlotArea.Select 
    Selection.ClearFormats 
    End Sub 
 
Sub openfile() 
'++++++++++++++++++After Gravity Correction has been determined++++++++++++++ 
 
'*****Individual Parameters**************** 
 Group = "CP"    'CP or N 
 Num = "4"      'Subject # 
 GC = 12        'gravity correction in NM 
 cosgc = 30      'Angle of the GC was measured 
 minAext = 17    'angle to measure torque for all Extension trials determined from 120deg/s 
 maxAflx = 86   'angle to measure torque for all Flexion trials determined from 120deg/s 
  
 Speed = "120"    'Change Speed for each trial!!!!!!! 
'******************************************* 
   
Workbooks.OpenText Filename:= _ 
        "C:\TestData\Process\Passive_Log to\" + Group + "\" + Group + Num + "\" + Group + Num 
+ "_P" + Speed + ".txt", Origin:=437, _ 
        StartRow:=1, DataType:=xlFixedWidth, FieldInfo:=Array(Array(0, 1), Array(6, _ 
        1), Array(18, 1), Array(27, 1), Array(42, 1)), TrailingMinusNumbers:=True 
         
        ActiveWorkbook.saveas Filename:= _ 
        "C:\TestData\Process\Passive_Log to\" + Group + "\" + Group + Num + "\" + Group + Num 
+ "_P" + Speed + ".xls", FileFormat:=xlNormal _ 
        , Password:="", WriteResPassword:="", ReadOnlyRecommended:=False, _ 
        CreateBackup:=False 
         
  Cells(3, 7) = "Extension motion" 
  Cells(3, 14) = "Flexion motion" 
   
    'Sub graf() 'Raw data 
    sheetname = Group + Num + "_P" + Speed 
    Windows(sheetname + ".xls").Activate 
    Charts.Add 
    ActiveChart.ChartType = xlXYScatterLinesNoMarkers 
    ActiveChart.SetSourceData Source:=Sheets(sheetname).Range("F18") 
    ActiveChart.SeriesCollection.NewSeries 
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    ActiveChart.SeriesCollection(1).XValues = Sheets(sheetname).Range("D7:D12199") 
    ActiveChart.SeriesCollection(1).Values = Sheets(sheetname).Range("B7:B12199") 
    ActiveChart.Location Where:=xlLocationAsObject, Name:=sheetname 
    With ActiveChart.Axes(xlCategory) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlValue) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    ActiveChart.HasLegend = False 
    ActiveChart.PlotArea.Select 
    Selection.ClearFormats 
     
    Range("E11").Select 
    'End Sub 
 
'Sub GCtrialid() 
 
Cells(1, 15) = "GC(Nm)" 'Gravity correction in Nm 
Cells(2, 15) = GC 
Cells(1, 16) = "Angle" 
Cells(2, 16) = cosgc 
Cells(1, 17) = "SlopeExt" 
Cells(1, 18) = "SlopeFlex" 
 
Select Case Speed 
    Case 5 
        th = 0.5 
    Case Else 
        th = 1.1 
End Select 
Speed = Speed - th 
 
'read in numbers 
ReDim dat(4, 13000) 
For I = 1 To 13000 
    If Cells(I + 6, 1) = "" Then Exit For 
    dat(1, I) = Cells(I + 6, 1) 'Time (ms) 
    dat(2, I) = Cells(I + 6, 2) 'Torque (Nm) 
    dat(3, I) = Cells(I + 6, 4) 'Position (Anatonical, degree) 
    dat(4, I) = Cells(I + 6, 5) 'Velocity (deg/sec) 
Next I 
ttlpnt = I - 1 
'find the three extension trials 
ReDim est(3)    'starting of the extension phase 
ReDim eend(3)   'end of the extension phase 
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'first extension 
For I = 1 To ttlpnt 
    If dat(4, I) > Speed And dat(4, I + 1) > Speed And dat(4, I + 2) > Speed Then 
        est(1) = I 
        Exit For 
    End If 
Next I 
For I = est(1) To ttlpnt 
    If dat(4, I) < Speed And dat(4, I + 1) < Speed And dat(4, I + 2) < Speed Then 
        eend(1) = I - 1 
        Exit For 
    End If 
Next I 
'second extension 
'**************find the beginning of the next extension phase 
For I = eend(1) To ttlpnt 
    If dat(4, I) < 0 Then Exit For 
Next I 
nst = I 'new starting point 
For I = nst To ttlpnt 
    If dat(4, I) > 0 Then Exit For 
Next I 
nst = I 
'******************************************************** 
For I = nst To ttlpnt 
    If dat(4, I) > Speed And dat(4, I + 1) > Speed And dat(4, I + 2) > Speed Then 
        est(2) = I 
        Exit For 
    End If 
Next I 
For I = est(2) To ttlpnt 
    If dat(4, I) < Speed And dat(4, I + 1) < Speed And dat(4, I + 2) < Speed Then 
        eend(2) = I - 1 
        Exit For 
    End If 
Next I 
'Third extension 
'**************find the beginning of the next extension phase 
For I = eend(2) To ttlpnt 
    If dat(4, I) < 0 Then Exit For 
Next I 
nst = I 'new starting point 
For I = nst To ttlpnt 
    If dat(4, I) > 0 Then Exit For 
Next I 
nst = I 
'******************************************************** 
For I = nst To ttlpnt 
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    If dat(4, I) > Speed And dat(4, I + 1) > Speed And dat(4, I + 2) > Speed Then 
        est(3) = I 
        Exit For 
    End If 
Next I 
For I = est(3) To ttlpnt 
    If dat(4, I) < Speed And dat(4, I + 1) < Speed And dat(4, I + 2) < Speed Then 
        eend(3) = I - 1 
        Exit For 
    End If 
Next I 
'+++++++++++++++++++++++++++++++++++++++++ 
'find the three flexion trials 
ReDim fst(3)    'starting of the flexion phase 
ReDim fend(3)   'end of the flexion phase 
'first flexion 
For I = eend(1) To ttlpnt 
    If dat(4, I) < -Speed And dat(4, I + 1) < -Speed And dat(4, I + 2) < -Speed Then 
        fst(1) = I 
        Exit For 
    End If 
Next I 
For I = fst(1) To ttlpnt 
    If dat(4, I) > -Speed And dat(4, I + 1) > -Speed And dat(4, I + 2) > -Speed Then 
        fend(1) = I - 1 
        Exit For 
    End If 
Next I 
'second flexion 
For I = eend(2) To ttlpnt 
    If dat(4, I) < -Speed And dat(4, I + 1) < -Speed And dat(4, I + 2) < -Speed Then 
        fst(2) = I 
        Exit For 
    End If 
Next I 
For I = fst(2) To ttlpnt 
    If dat(4, I) > -Speed And dat(4, I + 1) > -Speed And dat(4, I + 2) > -Speed Then 
        fend(2) = I - 1 
        Exit For 
    End If 
Next I 
'Third flexion 
For I = eend(3) To ttlpnt 
    If dat(4, I) < -Speed And dat(4, I + 1) < -Speed And dat(4, I + 2) < -Speed Then 
        fst(3) = I 
        Exit For 
    End If 
Next I 
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For I = fst(3) To ttlpnt 
    If dat(4, I) > -Speed And dat(4, I + 1) > -Speed And dat(4, I + 2) > -Speed Then 
        fend(3) = I - 1 
        Exit For 
    End If 
Next I 
'Export trials into new array 
'find max number of data points in all six trials 
maxp = 0 
For I = 1 To 3 
    If maxp < eend(I) - est(I) + 1 Then maxp = eend(I) - est(I) + 1 
    If maxp < fend(I) - fst(I) + 1 Then maxp = fend(I) - fst(I) + 1 
Next I 
ReDim newdat(2, 2, 3, maxp) '2-exten(1)/flex(2); 2-angle(1)/torque(2); 3-three trials; and maxp - 
maxnumber in all trials 
For J = 1 To 3 
    For I = est(J) To eend(J) 
        newdat(1, 1, J, I - est(J) + 1) = dat(3, I) 
    'without gravity correction 
        'newdat(1, 2, J, I - est(J) + 1) = dat(2, I) 
    'with gravity correction 
        newdat(1, 2, J, I - est(J) + 1) = dat(2, I) + GC * Cos((dat(3, I) - 0) * 3.14 / 180) / Cos(cosgc 
* 3.14 / 180) 
    'gravity correction by itself 
        'newdat(1, 2, J, I - est(J) + 1) = gc * Cos(dat(3, I) * 3.14 / 180) / Cos(cosgc * 3.14 / 180) 
    Next I 
Next J 
For J = 1 To 3 
    For I = fst(J) To fend(J) 
        newdat(2, 1, J, I - fst(J) + 1) = dat(3, I) 
    'without gravity correction 
        'newdat(2, 2, J, I - fst(J) + 1) = dat(2, I) 
    'with gravity correction 
        newdat(2, 2, J, I - fst(J) + 1) = dat(2, I) + GC * Cos((dat(3, I) - 0) * 3.14 / 180) / Cos(cosgc 
* 3.14 / 180) 
    'gravity correction by itself 
        'newdat(2, 2, J, I - fst(J) + 1) = gc * Cos(dat(3, I) * 3.14 / 180) / Cos(cosgc * 3.14 / 180) 
    Next I 
Next J 
'find minimum torque (@angle) during extension motion 
ReDim minT(2, 3)    '2- angle(1)/torque(2); 3- three trials 
For J = 1 To 3 
    minT(2, J) = 1000 
    For I = 1 To eend(J) - est(J) + 1 
        If minT(2, J) > newdat(1, 2, J, I) Then 
            minT(2, J) = newdat(1, 2, J, I) 'find the minimum torque 
            minT(1, J) = newdat(1, 1, J, I) 'find the angle with it 
        End If 
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    Next I 
Next J 
'find maximum torque (@angle) during flexion motion 
ReDim maxT(2, 3) 
For J = 1 To 3 
    maxT(2, J) = -1000 
    For I = 1 To fend(J) - fst(J) + 1 
        If maxT(2, J) < newdat(2, 2, J, I) Then 
            maxT(2, J) = newdat(2, 2, J, I) 'find the maximum torque 
            maxT(1, J) = newdat(2, 1, J, I) 'find the angle with it 
        End If 
    Next I 
Next J 
'find torque associated with the minimum angle during extension motion 
ReDim minA(2, 3)    '2- angle(1)/torque(2); 3- three trials 
For J = 1 To 3 
    For I = 1 To eend(J) - est(J) + 1 
        If newdat(1, 1, J, I) = minAext Then 
            minA(1, J) = newdat(1, 1, J, I) 
            minA(2, J) = newdat(1, 2, J, I) 
        End If 
    Next I 
Next J 
'find torque associated with the maximum angle during flexion motion 
ReDim maxA(2, 3) 
For J = 1 To 3 
    For I = 1 To fend(J) - fst(J) + 1 
        If newdat(2, 1, J, I) = maxAflx Then 
            maxA(1, J) = newdat(2, 1, J, I) 
            maxA(2, J) = newdat(2, 2, J, I) 
        End If 
    Next I 
Next J 
'Print data to spread sheet 
For J = 1 To 3 
    For I = 1 To eend(J) - est(J) + 1 
        Cells(I + 6, 7 + (J - 1) * 2) = newdat(1, 1, J, I) 
        Cells(I + 6, 8 + (J - 1) * 2) = newdat(1, 2, J, I) 
    Next I 
Next J 
For J = 1 To 3 
    For I = 1 To fend(J) - fst(J) + 1 
        Cells(I + 6, 14 + (J - 1) * 2) = newdat(2, 1, J, I) 
        Cells(I + 6, 15 + (J - 1) * 2) = newdat(2, 2, J, I) 
    Next I 
Next J 
Cells(1, 7) = ttlpnt 
Cells(1, 8) = est(1) + 6 
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Cells(1, 9) = eend(1) + 6 
Cells(1, 10) = est(2) + 6 
Cells(1, 11) = eend(2) + 6 
Cells(1, 12) = est(3) + 6 
Cells(1, 13) = eend(3) + 6 
Cells(2, 8) = fst(1) + 6 
Cells(2, 9) = fend(1) + 6 
Cells(2, 10) = fst(2) + 6 
Cells(2, 11) = fend(2) + 6 
Cells(2, 12) = fst(3) + 6 
Cells(2, 13) = fend(3) + 6 
For J = 1 To 3 
    Cells(5, 7 + (J - 1) * 2) = minT(1, J) 
    Cells(5, 8 + (J - 1) * 2) = minT(2, J) 
    Cells(5, 14 + (J - 1) * 2) = maxT(1, J) 
    Cells(5, 15 + (J - 1) * 2) = maxT(2, J) 
    Cells(4, 7 + (J - 1) * 2) = minA(1, J) 
    Cells(4, 8 + (J - 1) * 2) = minA(2, J) 
    Cells(4, 14 + (J - 1) * 2) = maxA(1, J) 
    Cells(4, 15 + (J - 1) * 2) = maxA(2, J) 
Next J 
'End Sub 
'******************************************************** 
'Sub graf2()  'Extension movement 
 
    'sheetname = Group + Num + "_P" + Speed 
    Windows(sheetname + ".xls").Activate 
    Charts.Add 
    ActiveChart.ChartType = xlXYScatterLinesNoMarkers 
    ActiveChart.SetSourceData Source:=Sheets(sheetname).Range("I18") 
    ActiveChart.SeriesCollection.NewSeries 
    ActiveChart.SeriesCollection(1).XValues = Sheets(sheetname).Range("G7:G2863") 
    ActiveChart.SeriesCollection(1).Values = Sheets(sheetname).Range("H7:H2863") 
    ActiveChart.SeriesCollection(2).XValues = Sheets(sheetname).Range("I7:I2863") 
    ActiveChart.SeriesCollection(2).Values = Sheets(sheetname).Range("J7:J2863") 
    ActiveChart.SeriesCollection.NewSeries 
    ActiveChart.SeriesCollection(3).XValues = Sheets(sheetname).Range("K7:K2863") 
    ActiveChart.SeriesCollection(3).Values = Sheets(sheetname).Range("L7:L2863") 
    ActiveChart.Location Where:=xlLocationAsObject, Name:=sheetname 
    With ActiveChart 
        .HasTitle = True 
        .ChartTitle.Characters.Text = "Knee extension movement" 
        .Axes(xlCategory, xlPrimary).HasTitle = False 
        .Axes(xlValue, xlPrimary).HasTitle = False 
    End With 
    With ActiveChart.Axes(xlCategory) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
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    End With 
    With ActiveChart.Axes(xlValue) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlCategory) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlValue) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    ActiveChart.HasLegend = False 
    ActiveChart.PlotArea.Select 
    Selection.ClearFormats 
    'End Sub 
     
    'Sub graf3()  'Flexion movement 
    'sheetname = "P5" 
    Windows(sheetname + ".xls").Activate 
    
    Charts.Add 
    ActiveChart.ChartType = xlXYScatterLinesNoMarkers 
    ActiveChart.SetSourceData Source:=Sheets(sheetname).Range("Q18") 
    ActiveChart.SeriesCollection.NewSeries 
    ActiveChart.SeriesCollection(1).XValues = Sheets(sheetname).Range("N7:N2863") 
    ActiveChart.SeriesCollection(1).Values = Sheets(sheetname).Range("O7:O2863") 
    ActiveChart.SeriesCollection.NewSeries 
    ActiveChart.SeriesCollection(2).XValues = Sheets(sheetname).Range("P7:P2863") 
    ActiveChart.SeriesCollection(2).Values = Sheets(sheetname).Range("Q7:Q2863") 
    ActiveChart.SeriesCollection.NewSeries 
    ActiveChart.SeriesCollection(3).XValues = Sheets(sheetname).Range("R7:R2863") 
    ActiveChart.SeriesCollection(3).Values = Sheets(sheetname).Range("S7:S2863") 
    ActiveChart.Location Where:=xlLocationAsObject, Name:=sheetname 
    With ActiveChart 
        .HasTitle = True 
        .ChartTitle.Characters.Text = "Knee flexion movement" 
        .Axes(xlCategory, xlPrimary).HasTitle = False 
        .Axes(xlValue, xlPrimary).HasTitle = False 
    End With 
    With ActiveChart.Axes(xlCategory) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlValue) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
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    End With 
    With ActiveChart.Axes(xlCategory) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    With ActiveChart.Axes(xlValue) 
        .HasMajorGridlines = False 
        .HasMinorGridlines = False 
    End With 
    ActiveChart.HasLegend = False 
    ActiveChart.PlotArea.Select 
    Selection.ClearFormats 
    End Sub 
 
Sub openfiles()  '***********Program to Place Slope data in one spreadsheet 
 
Group = "CP"    'CP or N   **********Change for each group 
For J = 1 To 17 'Number of subjects 
    For I = 1 To 6 
        Select Case I 
            Case 1 
                Speed = "5" 
            Case 2 
                Speed = "10" 
            Case 3 
                Speed = "30" 
            Case 4 
                Speed = "60" 
            Case 5 
                Speed = "90" 
            Case 6 
                Speed = "120" 
        End Select 
         
Workbooks.OpenText Filename:= _ 
        "C:\TestData\Process\Passive_Log to\" + Group + "\" + Group + Trim(Str(J)) + "\" + Group 
+ Trim(Str(J)) + "_P" + Speed + ".xls" 
         
   slopeext = Cells(2, 17) 
   slopeflex = Cells(2, 18) 
   ActiveWindow.Close 
   'Place data in data spreadsheet 
   Windows(Group + "_SlopeData.xls").Activate 
   Cells(J + 1, I + 1) = slopeext 
   Cells(J + 1, 7 + I + 1) = slopeflex 
   Cells(J + 1, 1) = J 
         
    Next I 
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Next J 
End Sub 
 
Sub openfiles()  '***********Program to Place Peak Resistance Torque data in one spreadsheet 
Group = "CP"    'CP or N   **********Change for each group 
For J = 1 To 17 'Number of subjects 
    For I = 1 To 6 
        Select Case I 
            Case 1 
                Speed = "5" 
            Case 2 
                Speed = "10" 
            Case 3 
                Speed = "30" 
            Case 4 
                Speed = "60" 
            Case 5 
                Speed = "90" 
            Case 6 
                Speed = "120" 
        End Select 
      
Workbooks.OpenText Filename:= _ 
        "C:\TestData\Process\Passive_Log to\" + Group + "\" + Group + Trim(Str(J)) + "\" + Group 
+ Trim(Str(J)) + "_P" + Speed + ".xls" 
    'Find Minimum Resistive torque over the 3 trials for Extension because negative numbers 
    Minext = 1000 
         For K = 1 To 3 
         If Minext > Cells(5, 6 + K * 2) Then 
             Minext = Cells(5, 6 + K * 2) 
         End If 
    Next K 
    'Find Maximum Resistive torque over the 3 trials for Flexion 
    Maxflx = 0.0005 
         For K = 1 To 3 
         If Cells(5, 13 + K * 2) > Maxflx Then 
             Maxflx = Cells(5, 13 + K * 2) 
         End If 
    Next K 
        ActiveWindow.Close 
        'Place data in data spreadsheet 
        Windows(Group + "_ResistanceTorqueData.xls").Activate 
        'place max in appropriate column 
        Cells(J + 1, I + 1) = Minext 
        Cells(J + 1, I + 8) = Maxflx 
   Next I 
Next J 
End Sub
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